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Abstract
This thesis covers three research projects in addition to a literature sur-
vey on solid-phase organic synthesis and photolabile linkers.
Synthesis of Doxorubicin Derivatives on Photolabile Solid
Support. The synthesis of doxorubicin derivatives on photolabile solid
support, compatible with bead-based screening, was investigated. Two
different strategies for the synthesis of doxorubicin derivatives were de-
veloped leading to the synthesis of doxorubicin derivatives with both
amino acids and peptide fragments attached in good to excellent crude
purities.
Total Synthesis of Trioxacarcin DC-45-A2. In efforts towards
the total synthesis of trioxacarcin DC-45-A2 by the Nicolaou group a
new and efficient route for a key fragment was optimized. The new
route featured distinct and high yielding steps and thus provided superior
access to this key building block in terms of overall yield, step count
and scalability. Furthermore a route to another key building block was
developed featuring a Stille cross-coupling.
Synthesis of Poly-fused Heterocycles. In the search for new
biologically active compounds a methodology for the synthesis of poly-
fused heterocycles was investigated. This led to the development and
optimization of a key aldol condensation/conjugate addition sequence
for the synthesis of poly-fused heterocycles.

Resumé
Denne afhandling dækker tre forskningsprojekter udover et litteraturstu-
die omhandlende fast-fase syntese i organisk kemi og fotolabile linkere.
Syntese af doxorubicin derivater på fotolabil fast-fase. Synte-
sen af doxorubicin derivater på fotolabil fast-fase, kompatibelt med bead-
baseret screening, er blevet undersøgt. To forskellige strategier for syntese
af doxorubicin derivater blev udviklet og førte til syntesen af doxorubicin
derivater med både aminosyrer og peptidfragmenter fastgjort, i gode til
fremragende renheder uden oprensning.
Totalsyntese af trioxacarcin DC-45-A2. En ny og effektiv rute
til en central byggeblok til brug i totalsyntesen af trioxacarcin DC-45-
A2 i Nicolaou gruppen er blevet optimeret. Den nye rute indeholder trin
med højt udbytte og giver forbedret adgang til denne byggeblok hvad
angår overordnet udbytte, antal af trin og skalérbarhed. Ydermere er en
rute til en anden central byggeblok blevet udviklet indeholdende en Stille
krydskobling.
Syntese af poly-forbundne heterocykler. I jagten på nye bio-
logisk aktive kemiske stoffer er en metode til syntese af poly-forbundne
heterocykler blevet undersøgt. Dette førte til udvikling og optimering
af en central aldolkondensation/konjugeret additions sekvens til brug i
syntesen af poly-forbundne heterocykler.
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Chapter 1
Solid-Phase Synthesis and
Photolabile Linkers
1.1 Solid-Phase Organic Synthesis
Originally developed by Nobel Prize winning chemist Robert Bruce Merrifield
for the synthesis of peptides [1], solid-phase organic synthesis is an attractive
synthetic technique that offers unique advantages over conventional solution
phase chemistry, both in terms of purification and experimental simplicity.
The technique introduced by Merrifield revolutionized the field of peptide
synthesis and greatly increased the effectiveness and ease with which peptides
can be synthesized. Merrifield’s method relies on the anchoring of the growing
peptide onto a functionalized solid support, cf. scheme 1.1. Firstly, a linker,
linking the substrate to the solid support is attached leading to construct 1.2,
cf. scheme 1.1. Then the first Nα-protected amino acid is attached followed by
deprotection of the temporary Nα-protection group furnishing construct 1.4.
From this point on iterative cycles of amino acid coupling and deprotection
builds the desired peptide from C - to N -terminus. Finally, any amino acid
side-chain protection groups (positioned to mask the reactivity of side-chain
functional groups during the synthesis) are deprotected and the substrate is
released from the solid support by cleavage of the linker providing the desired
peptide 1.6.
Since its introduction half a century ago, many laboratories have focused
on the development of technologies and chemistry suitable for solid-phase or-
ganic synthesis, which has resulted in a remarkable outburst of chemical trans-
formations that can be applied for the routine synthesis of organic molecules
on solid support [2–6]. This has led to the application of solid phase synthesis
in the generation of combinatorial libraries both in academia and industry,
ultimately leading to the identification of new drugs and catalysts [7, 8].
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1.1
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= solid support, X = functional group, Y = O or N, PG = protection group
Scheme 1.1: Illustration of the principles of solid-phase peptide synthesis.
Below follows a brief introduction to the supports, linkers, coupling reagents
and protection group strategies used in solid-phase synthesis.
1.1.1 Supports
The solid support used in solid-phase synthesis must be chemically inert and
mechanically stable under the conditions used and furthermore completely
insoluble in the chosen solvents. Additionally it is important that the solid
supports exhibit good swelling characteristics in the used solvents thus allow-
ing for diffusion of reagents and solvent molecules into the beads. A variety
of resins are available for use in solid-phase synthesis, and a few selected ex-
amples are provided below.
The first resin used by Merrifield for peptide synthesis, a chloromethylated
polystyrene resin cross-linked with divinylbenzene known as the Merrifield
resin (1.7), is still used today [9], cf. figure 1.1. Polystyrene resins show
good swelling properties in DMF and CH2Cl2 but they, however, display low
compatibility with polar solvents, such as water and alcohols, commonly used
in the handling of peptides.
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Figure 1.1: Selected resins for solid-phase synthesis.
Sheppard later introduced a polydimethylacrylamide (PDMA) resin (1.9),
cf. figure 1.1, that overcame the low compatibility with polar solvents and
displayed excellent swelling properties in solvents such as DMF, AcOH and
water [10, 11]. The resin however displayed decreased swelling in apolar sol-
vents such as CH2Cl2, thus possessing reverse properties compared to those
of the Merrifield resin.
A graft copolymer of polystyrene and polyethylene glycol (PEG) was later
developed independently by Barany and Bayer [12, 13]. This resin exhibited
good swelling properties in polar solvents such as MeCN, MeOH and water,
improved mechanical stability as well as lower glass adherence. A typical ex-
ample of this type of resin is the TentaGel resin (1.8), cf. figure 1.1, with PEG
chains grafted to a matrix of polystyrene through ether bonds [9]. Further-
more TentaGel resin shows stability at high pressures which, combined with
its high mechanical stability, makes it ideal for continuous flow synthesis [13].
Meldal introduced a copolymer of polyacrylamide and PEG, the PEGA
resin (1.10), cf. figure 1.1 [14, 15]. With the good hydrophilic properties of
the PEG-grafted polymers in mind Meldal developed a resin mainly consisting
3
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of PEG. This resin displayed a high degree of swelling under standard peptide
synthesis conditions in a broad range of solvents [16] and was furthermore
stable under continuous flow conditions thus allowing for automated synthesis
[15]. The resin furthermore had the ability to allow large proteins to enter the
polymeric matrix thus making the resin highly interesting for use in the area
of chemical biology [16]. The PEGA resin, however, has a drawback in that it
is unsuitable for harsh reaction conditions due to the amide backbone in the
polymer matrix [17,18].
More recently, Albericio introduced an entirely PEG-based resin, termed
ChemMatrix (1.11) [19], cf. figure 1.1. The resin showed good swelling prop-
erties in most common solvents (e.g. MeCN, DMF, CH2Cl2, DMSO, MeOH
and water) and was even compatible with aqueous buffers [19]. The Chem-
Matrix resin additionally displayed good chemical stability being compatible
with strong acids and bases, with the exception of strong Lewis acids [19]. The
resin furthermore had good mechanical stability and allowed for relatively high
loading levels.
1.1.2 Linkers
The use of solid supports in organic synthesis relies on the ability to link the
substrate to the resin while retaining the ability to selectively cleave off some
or all of the product from the solid support during synthesis for the analysis
of reactions, and ultimately to release the target molecule of interest. Thus,
the linker used in solid-phase synthesis serve as temporary immobilization
of the substrate and as protection group for the attached functional group.
The linkers must be stable to all chemical transformations used during the
synthesis, and the final cleavage of the substrate from the resin has to be high
yielding under conditions where the substrate is stable.
Two types of linkers are used in solid-phase synthesis, integral linkers and
non-integral linkers [20]. Integral linkers where developed first and are syn-
thesized directly on the resin, an example is the chloromethylated linker 1.7
used by Merrifield, cf. figure 1.1, where the first amino acid is attached via a
benzyl ester linkage. Other examples of integral linkers are the BHA (1.12)
and MBHA (1.13) linkers, which are cleaved by HF [21, 22], the trityl linker
1.14 (cleaved by dilute HCl) [23–25] and the oxime linker 1.15 (cleaved by
nucleophiles) [26,27], cf. figure 1.2.
The integral linkers however give rise to several disadvantages due the fact
that they are synthesized directly on the resin which can lead to uncontrollable
loading and functionalization [20]. Thus the majority of linkers used in solid-
phase synthesis are non-integral linkers where the linker is attached to the resin
after being prepared in solution. A wide variety of non-integral linkers have
been developed and many are inspired by classical protection group strategies.
Examples of this are the base-labile HMBA linker 1.16 [11] and the acid labile
Rink-amide linker 1.17 [28], cf. figure 1.3, which are still widely used today.
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BHA (1.12): R = H
MBHA (1.13): R = Me
: polystyrene resin
R
NH2
1.14
OH
1.15
N
O2N
OH
Figure 1.2: Selected integral linkers for solid-phase synthesis.
Other examples of linkers include safety-catch linkers 1.18 [29] and pho-
tolabile linkers1 1.19 [30], cf. figure 1.3.
HO
OH
O
NH2
OMeMeO OH
O
O
OH
OMeO
NO2
NH2
OH
O
S
H2N
OO
1.18
HMBA (1.16) Rink-amide (1.17)
1.19
Figure 1.3: Selected non-integral linkers for solid-phase synthesis.
1.1.3 Coupling reagents
Solid-phase peptide synthesis requires repetitive and efficient amide bond for-
mation by the coupling of protected amino acid building blocks to an amino
functionalized resin. For this to proceed in a quantitative manner without
detrimental side reactions a coupling reagent or an activated amino acid is
used to drive the reaction to completion. One of the first coupling reagents
used was the carbodiimide DCC (1.20) [31], cf. figure 1.4. However, DCC is
not compatible with peptide synthesis using the Fmoc protection group strat-
egy due to solubility issues and has thus been replaced by the carbodiimides
1For a brief account of the photolabile linkers available for solid-phase synthesis cf. §1.2.
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N C N
R2
R1
DCC (1.20): R1, R2 = Cy
DIC (1.21): R1, R2 = iPr
EDCI (1.22): R1 = Et, R2 = (CH2)NMe2
X N
N
N
OH
HOBt (1.23): X = CH
HOAt (1.24): X = N
N
N
N
O
P
NMe2
Me2N
NMe2
PF6-
N
N
O
P
N
N
NPF6
-
P NN
N
Br
PF6-
BOP (1.25) PyBOP (1.26) PyBrOP (1.27)
X N
N
N
HBTU (1.28): X = CH, Z = PF6
TBTU (1.29): X = CH, Z = BF4
HATU (1.30): X = N, Z = PF6
O
N
NMe2Z
-
O O
Cl3C
O
CCl3
BTC (1.31)
S
N
N
N
NO2
O O
MSNT (1.32)
Figure 1.4: Selected coupling reagents used in solid-phase synthesis.
DIC (1.21) and EDCI (1.22) [31], cf. figure 1.4. A drawback with the use of
the carbodiimides is however that they are prone to cause racemization of the
amino acid stereogenic center. Racemization can occur by direct enolization,
cf. scheme 1.2. However, another important contributor to racemization is
R2 = amino acid side-chain
R1 N
H
O
X
O
R2H
R1 N
H
O
X
O
R2
R1 N
H
O
X
O
R2HH
+
1.33 1.34 1.35
Scheme 1.2: Epimerization by direct enolization.
the formation of oxazolones 1.36 [32–34], cf. scheme 1.3.
Using carbodiimides in combination with the benzotriazole-based additives
HOBt (1.23) and HOAt (1.24), cf. figure 1.4, has been shown to suppress
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H
O
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O
R2H
O
NR1
O
H
R2 O
NR1
O
R2
H+
1.33 1.36 1.37
R2 = amino acid side-chain
O
NR1
O
H
R2
1.38
Nu
H+
R1 N
H
O
Nu
O
R2H
1.39
Scheme 1.3: Epimerization by oxazolone formation.
racemization and accelerate the reactions of the activated esters [35].
Another coupling reagent is the phosphonium salt BOP (1.25) [36], cf.
figure 1.4. BOP is based on the HOBt structure and is a very efficient cou-
pling reagent, however, the very toxic byproduct hexamethylphosphoramide
(HMPA) is generated when BOP is used. To avoid this detrimental side
product the equally effective reagent PyBOP (1.26), cf. figure 1.4, was intro-
duced [37]. Later the more reactive reagent PyBrOP (1.27), cf. figure 1.4, was
introduced, which has been shown to be very effective in sterically demanding
situations [38,39].
Another type of HOBt-based coupling reagents are the aminium salts
HBTU (1.28) [40] and TBTU (1.29) [41], cf. figure 1.4. These coupling
reagents were shown to be very efficient and resulted in practically no racem-
ization. A more reactive variant, termed HATU (1.30), cf. figure 1.4, based
on the structure of HOAt was later introduced by Carpino [35]. These salts
were originally assigned a uronium-type structure based on the correspond-
ing phosphonium salts. It was, however, later shown that the salts have an
aminium-type structure [42].
Later Gilon used BTC (1.31) as an even more reactive peptide coupling
reagent, generating acid chlorides in situ [43], cf. figure 1.4. BTC was proven
to be very efficient for difficult couplings and in most cases caused no racem-
ization.
Another approach is the use of activated amino acids. Thus, the use of
the corresponding pentafluorophenyl esters of the commonly used amino acids
removes the necessity of adding a coupling reagent [44, 45]. These ester are
furthermore shelf stable.
Finally, the coupling reagent MSNT (1.32), cf. figure 1.4, can be used for
coupling of amino acids to hydroxyl functionalized resins or linkers [46].
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1.1.4 Protection group strategies
With every cycle of deprotection of the Nα-protection group and subsequent
amino acid coupling it is vital that the conditions used for deprotection do
not in any way cause premature cleavage from the resin or removal of side-
chain protection groups. Two protection group strategies are widely used, the
Boc/Bn- [47] and Fmoc/tBu-protection group schemes [48, 49]. Both rely on
orthogonal removal of the Nα-protection group without affecting side-chain
protection groups.
The Boc/Bn-protection group scheme utilizes the acid labile Boc protec-
tion group (1.40), cf. figure 1.5, as the temporary Nα-protection group and
protection groups of the benzyl type 1.41 as side-chain protection groups and
relies on graded acid lability of the temporary protection group and the side-
chain protection groups. Boc can usually be removed with a mixture of TFA
O
O
Fmoc (1.42)
O
O
Boc (1.40)
Trt (1.45)
tBu (1.43)
O
O
Cbz (1.44)
Bn (1.41)
Figure 1.5: Selected acid and base labile protection groups used in solid-phase
synthesis.
and CH2Cl2 whereas the benzyl type side-chain protection groups usually re-
quire more hash acidic conditions such as HF. If a linker that has the same
lability as the side-chain protection groups (e.g. stable to TFA and labile
to HF) is chosen, such as the BHA (1.12) or MBHA (1.13) linker, cf. fig-
ure 1.2, both the linker and the side-chain protection groups can be cleaved
simultaneously on completion of the synthesis.
The Fmoc/tBu-protection group scheme makes use of the base labile Fmoc
protection group (1.42), cf. figure 1.5, as the temporary Nα-protection group
and acid labile protection groups of the tBu type 1.43 as side-chain protection
groups. The Fmoc group is cleaved by 20 (v/v)% piperidine in DMF while the
tBu type side-chain protection groups usually can be removed under relatively
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mild acidic conditions with TFA. The Fmoc/tBu-protection group scheme is
thus an example of a more truly orthogonal protection group strategy relying
on the base lability of the Fmoc group and the acid lability of the tBu group
instead of graded acid lability of the Nα- and side-chain protection groups as
seen with the Boc/Bn-protection group scheme.
Other commonly used protection groups are the Cbz group (1.44) [50],
which can be removed by e.g. HBr, HF and catalytic hydrogenation, and the
Trt group (1.45) [51–53], removable by mild acidic conditions, cf. figure 1.5.
Alternatively, protection groups that offer another dimension of orthogo-
nality exist, relying on deprotection conditions completely orthogonal to com-
mon acid- and base labile protection groups. Among these are the Alloc
(1.46) and All (1.47) protection groups [54], cf. figure 1.6, which can be
cleaved by a Pd catalyst. Other examples are the Dde (1.48) [55–57] and Dts
(1.49) [58–60] groups removable by hydrazinolysis and thiolysis, respectively,
and the photolabile Nvoc protection group (1.50) [61].
O
O
Alloc (1.46) All (1.47)
O
O
Dde (1.48)
S
S
O
O
Dts (1.49)
MeO
MeO NO2
O
O
Nvoc (1.50)
Figure 1.6: Selected protection groups orthogonal to acid and base labile protection
groups.
1.2 Photolabile Linkers
In solid phase organic synthesis the desired molecule is bound through a linker
inserted between the solid support and the molecule in question. Often harsh
cleavage conditions such as strong acids/bases or nucleophiles, are needed,
which can pose compatibility problems with acid- and base-labile compounds
as well as commonly used protecting groups. Furthermore, the range of chem-
ical transformations available for the synthesis of compounds is restricted by
the cleavage conditions of the linker in order to avoid premature cleavage.
Thus, to provide an additional dimension for the introduction of chemical
diversity, linkers relying on alternative cleavage principles are needed.
Photolysis offers a method of cleavage, which is fully orthogonal to conven-
tional chemical methods. Photolabile linkers are particularly interesting since
they do not need acidic, basic or metal-assisted activation for cleavage. In-
deed photochemical substrate release often occurs without additional reagents
and under mild conditions that renders the process environmentally friendly
and especially appealing in the context of green chemistry. The mild condi-
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tions are, furthermore, attractive for direct applications in biological screening
where contamination with cleavage reagents is undesired. Additionally, recent
advances in LED lighting have significantly increased the ease with which
photochemical transformations can be achieved.
Below follows an overview of some of the commonly used photolabile link-
ers in solid phase organic synthesis, with a focus on o-nitrobenzyl and o-
nitroveratryl linkers, and their applications.
1.2.1 Mechanism of photolysis
The mechanism for photochemical cleavage of o-nitrobenzyl and o-nitroveratryl
linkers is a Norrish type II [62] mechanism and a likely path is depicted in
scheme 1.4 [61, 63–66]. An initial hydrogen abstraction leading to the o-
Y
X
O2N
R1
R2
R1 = H or Me, R2 = H or OMe, X = OR or NR3R4, Y = O or CH2
1.51
Y
X
N
R1
R2
O
OH
Y
X
N
R1
R2
O
O
Y
X
N
R1
R2
1.52
O
OH
Y
R2
O
N
HO
X R
1
Y
R2
O
R1
ON
XH +
1.57
1.53
1.561.55
1.54
Scheme 1.4: Mechanism for the photolysis of o-nitrobenzyl and o-nitroveratryl
linkers.
quinonoid intermediate 1.53 followed by cyclization provides the intermediate
1.54. The cyclization leading to 1.54 was originally thought to proceed via
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the anion species 1.55 [66] this was, however, later revised [61, 65]. Finally a
rearrangement results in the formation of o-nitroso species 1.57 and release
of the attached molecule 1.56.
1.2.2 o-nitrobenzyl linkers
The first account of a photolabile linker was the o-nitrobenzyloxy based linker
pioneered by Rich and Gurwara in 1973 [67]. The linker (in this case an
integral linker) 1.58 was set up for attachment of the first amino acid at
the C -terminus via substitution affording the construct 1.59, cf. scheme 1.5.
After standard SPPS and photolysis the first peptide ever constructed on a
Cl
O2N
Boc-Gly-OH, Et3N
O
O2N
Boc-Gly
SPPS
O
O2N
Boc-Ser(Bn)-Tyr(Bn)-Gly
hν (350 nm)
O
ON
1.62
62%
Boc-Ser(Bn)-Tyr(Bn)-Gly-OH
: polystyrene resin
EtOAc
MeOH
1.58 1.59
1.61
1.60
+
Scheme 1.5: The first photolabile linker based on the o-nitrobenzyloxy moiety.
photolabile linker was released in an overall yield of 62%.
However, due to over-nitration during the synthesis of the integral linker
1.58, which made it unsuitable for peptides longer than four amino acids due
to reduced swelling capacity [68], Rich and Gurwara developed a new non-
integral linker 1.63, cf. scheme 1.6. The linker 1.63 was prepared in solution
and then coupled to the resin leading to construct 1.64 [68]. Attachment of
the first amino acid followed by standard SPPS and final photolysis led to the
decapeptide 1.66 in a yield of 64%.
The linker has been used by Merrifield for the preparation of multi detach-
able resins [69,70] and by Barany and co-workers to achieve three dimensional
orthogonal protection in solid-phase organic synthesis [59]. Different varia-
tions of the connection of the linker unit to the resin have been explored, e.g.
adding a phenyl group in the benzylic position [71, 72] or inserting a glycine
unit acting as an internal standard [73].
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1.66
64%
H2N
Br
O2N
O
OH
DCC
DMF
H
N
O
O2N
Br
H
N
O
O2N
O
GlyBocBoc-Gly-OH,
Et3N
pGlu-His(Bn)-Trp-Ser(Bn)-Tyr(Bn)-Gly-Leu-Arg(Ts)-Pro-Gly-OH
1. SPPS
,
EtOAc 2.  hν (350 nm),
   MeOH
1.63
: polystyrene resin
1.64
1.65
Scheme 1.6: Non-integral o-nitrobenzyloxy photolabile linker used for the synthesis
of a decapeptide.
In a study focusing on the synthesis of combinatorial libraries Ohlmeyer
used the o-nitrobenzyloxy linker, which facilitated easy release of the syn-
thesized ligands under conditions optimal for subsequent use in biological as-
says [74].
The linker has furthermore been used for oligonucleotide synthesis by
Green [75–77] and oligosaccharide synthesis by Zehavi [78], Nicolaou [79, 80]
and Parquette [81].
To take into account the fact that many biologically active peptides possess
a terminal primary amide, Rich and Gurwara also developed an o-nitrobenzyl-
amino variation of the o-nitrobenzyl-based linker that upon photolysis releases
an amide [82]. Pillai and co-workers documented the possibility of releasing
secondary amides using this linker [83–85]. An o-nitrobenzylamino linker
was used by Gerace and Auer in their on-bead screening of a one-bead one-
compound library in the search for nuclear import inhibitors [86]. Recently
Seeberger developed an approach for automated oligosaccharide synthesis us-
ing this type of linker [87–89].
1.2.3 α-substituted o-nitrobenzyl linkers
The o-nitrobenzyl-based linkers presented so far have the disadvantage that
the side product of their photolysis is an o-nitrosobenzaldehyde, cf. construct
1.61, scheme 1.5. This is a very reactive species that is prone to polymeriza-
tion, generating a highly colored side product, which acts as an internal light
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filter. This has a detrimental effect on the photolytic cleavage of the desired
compounds due to limited access of light to the reaction site [90].
To solve this issue Pillai prepared the integral linker 1.67, featuring a
methyl group in the α-position [90], cf. scheme 1.7. Using this linker the
O
O2N
Boc-Asp(OBn)-Val-Tyr(Bn)-Val-Glu(OBn)
hν (320 nm)
1.70
40%
: polystyrene resin
EtOH:CH2Cl2 (1:1)
1.69
Br
O2N
1.67
Boc-Glu(OBn)-OH, DIPEA
EtOAc
O
O2N
Boc-Glu(OBn)
1.68
SPPS
Boc-Asp(OBn)-Val-Tyr(Bn)-Val-Glu(OBn)-OH
Scheme 1.7: Integral α-substituted nitrobenzyl-derived photolabile linker used for
the synthesis of pentapeptide 1.70.
pentapeptide 1.70 was synthesized in a yield of 40%.
This resin however suffered from the same problems as seen with Rich
and Gurwara’s original o-nitrobenzyloxy linker, cf. scheme 1.5, in that over-
nitration degraded the swelling properties of the resin and prevented the syn-
thesis of longer peptides.
A solution to this issue was to introduce the nitrated moiety in a more
controlled manner via a nitrated building block instead of performing a nitra-
tion directly on the resin [91], cf. scheme 1.8. Thus, the resin 1.71 underwent
Friedel-Crafts acylation followed by reduction leading to o-nitrobenzhydryl
resin 1.72. With this resin in hand Pillai synthesized both peptides 1.76 [91]
and, after transformation to the amine-functionalized resin 1.74 [92], ami-
dopeptides 1.75. Peptides with up to 10 amino acids were synthesized in
good yields.
Geysen used a related non-integral linker, the 3-amino-3-(2-nitrophenyl)pro-
pionyl (ANP) linker 1.77, for the synthesis of amidopeptides [93], cf. scheme 1.9.
A more acid stable variant was proposed by Schreiber with two methyl groups
in the α-position of the amide [94]. An alcohol-based variant of linker 1.77
was used for oligosaccharide synthesis by Geysen [95]. It also incorporated
a longer spacer between the support and the photosensitive part to avoid
problems with β-elimination and lactonization of the alcohol [95].
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ONO2 OHNO2
AlCl3
Cl
O
NO2, NaBH4
1. HBr
2. NH3
NH2NO2
peptide OH
1. SPPS
2. hν (350 nm),
    EtOH
1. SPPS
1.76
56–60%1.7561–78%peptide NH22. hν (350 nm),   DMF:MeOH (1:1)
: polystyrene resin
1,2-DCE diglyme
1.71 1.72 1.73
1.74
Scheme 1.8: Integral photolabile o-nitrobenzhydryl linker providing access to both
peptides and amidopeptides.
NHFmocNO2
OHO
2. 20% pip./DMF
H2N
NH2NO2
: TentaGel resin
1. PyBOP, DIPEA,
    NMP
1.77 1.78
1. SPPS
2. hν (365 nm),
   H2O
O
N
H
Fmoc-Asp-Arg(Ts)-Val-NH2
1.79
Scheme 1.9: Non-integral photolabile ANP linker used for the synthesis of tripeptide
1.79.
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1.2.4 o-nitroveratryl linkers
Initially introduced by Patchornik as a photolabile linker in 1973 [96], the
use of the o-nitroveratryl group (4,5-dimethoxy-2-nitrobenzyl) in photolabile
linkers was popularized in the mid-1990s by Greenberg [97] and Holmes [30].
Greenberg utilized this type of linker to circumvent some of the issues
observed with the original unsubstituted o-nitrobenzyl linkers, namely long
photolysis times and low yields of liberation [97]. It was theorized that the
introduction of the alkoxy substituents would improve the aforementioned
issues.
The linker 1.80 was prepared in solution and then bound to a long chain
alkyl amine controlled pore glass (LCAA-CPG) support leading to construct
1.81 which was then used for the synthesis of oligonucleotides in good yields
[97], cf. scheme 1.10. Later it was shown that a more efficient photolysis
MeO
O O
NO2
O
Cl
Cl
Cl
MeO
O
H
N
NO2
O
LCAA-CPG
DMF
: LCAA-CPG
O
O
DMTO
2
2
O
O
DMTO
5’-TACGCAATCCTAGATCTAAT P
O
O
(CH2)3COOH
1. oligonucleotide synthesis
2. hν (400 nm), MeCN:H2O (9:1)
3. detritylation
1.82
80%
1.80 1.81
Scheme 1.10: Use of photolabile o-nitroveratryl-based linker for the synthesis of
oligonucleotides.
could be achieved by linking the hydroxyl group of the nucleotide directly to
the linker via a carbonate functionality [98]. This modified linker was later
used for oligonucleotide synthesis by other groups [99].
Nearly simultaneously with the work of Greenberg, Holmes introduced an
o-nitroveratryl-based amine linker with a methyl group in the α-position and
used it for the synthesis of a hexapeptide [30], cf. scheme 1.11. This linker,
producing amides upon photolysis, also solved the problem with formation of
a reactive nitroso aldehyde upon photolysis as described earlier.
In 1997, Holmes published a systematic study of the effect of nitroveratryl
substituents on the photolysis efficiency [100]. It was shown that the rate
of cleavage was 7 to 20 times higher when the o-nitrobenzyl ring was sub-
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1.85
70%
: TentaGel resin
H-Met-Gly-Trp-Met-Asp-Phe-NH2
O
OH
OMeO
NO2
NHFmoc
DIPEA, DMF
H2N ,1.
2. 20% pip./DMF
1.83
HATU,
O
N
H
OMeO
NO2
NH2
1.84
1. SPPS
2. hν (365 nm),
   PBS buffer:DMSO (95:5)
Scheme 1.11: Use of photolabile amine-containing α-methylated nitroveratryl linker
for the synthesis of a hexapeptide by Holmes.
stituted with electron-donating alkoxy substituents. It was also shown that
an alkyl group in the α-position to the amine increased the rate of cleavage
by a factor of 3. The length of the spacer chain also had an influence with
a slightly increased rate for longer chains. It was concluded that both the
alkoxy substituents on the aromatic ring and the alkyl group in the α-position
were significantly beneficial for the photochemical reactivity.
Holmes also developed an alcohol-based version of the linker 1.83 [100],
cf. figure 1.7.
O
OH
OMeO
NO2
OH
1.86
Figure 1.7: Photolabile alcohol-containing α-methylated nitroveratryl linker by
Holmes.
The linkers 1.83 and 1.86 have found numerous applications and it has
also been shown that this linker type could be coupled to a hydroxy based
resin without effect on the efficiency of the photolytic cleavage [101]. An o-
nitroveratryl linker was used by McKeown to develop methods for easing the
analysis of solid phase synthesis reactions by mass spectrometric techniques
[102]. Another example is the use of linker 1.83 by Madder for the preparation
of serine protease mimics [103]. Blackwell likewise used this linker for the
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synthesis of a diketopiperazine library using the Ugi multicomponent reaction
[104], cf. scheme 1.12. The linker 1.83 was attached to the solid support and
O
OH
OMeO
NO2
NHFmoc
DIC, HOSu, DIPEA,
NMP, MW
H2N ,
1.
2. 20% pip./DMF
O
N
H
OMeO
NO2
NH2
DIC, HOSu, DIPEA,
NMP, MW
,
1.
2. 20% pip./DMF
O
OH
R1
FmocHN
R3 NC R4 CHO
,
O
OH
R2
FmocHN
,
O
N
H
OMeO
NO2
H
N
O
H2N
R1
O
N
H
OMeO
NO2
H
N
O
N
R1
R4
NH
O
O
R2FmocHN
1. 10% AcCl/MeOH
2. 20% pip./DMF
3. hν (366 nm),
   MeOH
N
NH
R4
R2
O
OH2N
O
R1
1.89
53–91% purity
R1:
O2N
R2: amino acid side chain
R3: R4: Cy, CH3(CH2)5, Ph(CH2)2
:  modified cellulose
H2O
1.841.83
1.87
1.88
R3
Scheme 1.12: o-nitroveratryl linker used in multicomponent reactions by Blackwell.
subsequent coupling of Fmoc-Phe(4-NO2)-OH by standard methods led to the
construct 1.87. Subjection to Ugi conditions and subsequent methanolysis
and photochemical release afforded diketopiperazines 1.89 in moderate to
good purities.
The linker 1.83 was again used by Gennari for the synthesis of combi-
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natorial libraries of vinylogous sulfonamidopeptides [105]. Furthermore, this
study confirmed the trends Holmes had encountered [100], namely that o-
nitroveratryl-based linkers are superior to o-nitrobenzyl linkers due to the
beneficial effects of alkoxy substituents and the presence of α-methyl group.
Another example is the synthesis of 3,4-disubstituted β-lactams proposed
by Gallop [106], cf. scheme 1.13. The construct 1.90 was deprotected and
condensed with an aldehyde producing imine 1.91 which then underwent a
[2 + 2] cycloaddition with a ketene providing 1.92. Final photolysis led to
: TentaGel resin
O
MeO
NO2
NHFmoc
1. 30% pip./NMP
2. R1CHO,
   (MeO)3CH:CH2Cl2 (1:1)
O
MeO
NO2
N
O
MeO
NO2
N
O
R1
R1
R2CH2COCl, Et3N
CH2Cl2
N
H
O
R2
R1
hν (365 nm)
1.93
71–90%
R1 = COOtBu, 2-pyridyl, Ph2CCH R2 = N
O
O
N
H
O
N
H
O
N
H
O
DMSO
1.90
1.91
1.92
Scheme 1.13: α-methylated nitroveratryl linker used in the synthesis of β-lactams.
β-lactams 1.93 in good yields [106], cf. scheme 1.13.
Meldal used an aldehyde linker closely related to 1.86, for the synthesis
of a small library of arylpiperazine melanocortin subtype-4 agonists [107].
18
o-nitroveratryl linkers
Recently, a new azido-linker based on the o-nitroveratryl group was intro-
duced by Nielsen for the synthesis of 1,2,3-trizoles [108], cf. scheme 1.14. The
O
MeO
OH
OEt
O
SOCl2
CH2Cl2
O
MeO
Cl
OEt
O
O
MeO
N3
OH
O
2. LiOH,
   THF:H2O (3:7)
NO2
NO2
NO2
1. NaN3, DMF
1. TBTU, NEM,
    DMF
H2N
2. CuI, 2,6-lutidine, 
    sodium ascorbate,
    NMP:H2O (1:1)
R,
O
MeO
N
N
H
O
NO2
N
N
R
hν (365 nm)
MeOH:H2O (1:4)
N
N
HN
R
1.98
51–77%
: PEGA800
1.94 1.95
1.97
1.96
Scheme 1.14: Photolabile nitroveratryl-based azido-linker for the synthesis of 1,2,3-
triazoles.
alcohol 1.94 was subjected to SOCl2 followed by substitution with NaN3 and
ester hydrolysis with LiOH leading to the azido linker 1.96. Attachment to
the solid support and subsequent copper(I)-catalyzed azide-alkyne cycload-
dition led to the construct 1.97, which after photolytic cleavage provided
1,2,3-triazoles 1.98 in good yields.
Later Nielsen introduced a hydrazine linker also based on the alcohol 1.94
used in the synthesis of peptide hydrazides in yields of 21–83% [109]. This
methodology also allowed for the solid-phase synthesis of dihydropyrano[2,3-
c]pyrazoles [109].
Another recent example is the linker developed by Lee [110]. This linker
has the tether to the solid support positioned in the α-position, cf. scheme 1.15.
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After attachment to the solid support, standard SPPS and photolytic cleavage,
Leu-enkephalin (1.100) was liberated as an amide in a yield of 50%.
: HiCore resin
2. SPPS
3. hν (365 nm), MeOH
H-Tyr-Gly-Gly-Phe-Leu-NH2
1.100
50%
1. H2N , BOP, HOBt,
DIPEA, DMF
FmocHN
OMe
OMe
OH
OO2N
1.99
Scheme 1.15: Synthesis of Leu-enkephalin as an amide using the photolabile linker
1.99 developed by Lee.
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Screening of chemical compounds is an essential part of identifying leads for
drug development. However, much HTS-based chemical biology research is
a time-consuming and costly process, and as such preserved for very few re-
searchers. Thus efficient and less costly screening-technologies of compound
libraries are sought to complement current drug discovery approaches.
Bead-based screening assays where compounds are synthesized on solid
support and screened while still attached to the resin (so-called on-bead screen-
ing) or after cleavage from the resin (off-bead screening) provides an efficient
and rapid method for the synthesis and biological evaluation of libraries of
thousands of compounds [111–113]. On-bead assays are however not always
predictive of the activity of a compound as a free molecule in solution e.g. be-
cause of interference from the bead matrix [114–116]. Off-bead assays are not
hampered by this limitation and thus provide a method more akin to classic
solution based assays. Off-bead screening furthermore provides the advantage
of being able to screen targets where it is of importance that the compounds
are in solution e.g. enzymes with binding sites that are not readily accessible
and cells [117,118]. Such methods include the use of microtiter plates to keep
beads spatially separated [119,120] and the immobilization of beads in a thin
layer of soft agar to reduce compound diffusion [118, 121]. However, the use
of microtiter plates is hampered by the difficulties of homogenous filling of
wells with beads, while the use of gels is limited by the fact that the assay
environment is determined by the nature of the gel.
Two major challenges are given when establishing a bead-based platform
for the synthesis and off-bead screening of compounds. Firstly, the library
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compounds must be synthesized and released under conditions that are com-
patible with the structural complexity and sensitivity of a given compound to
reaction conditions often employed in automated and parallel synthesis efforts,
including common bases and acids. Secondly, the library compounds must be
released under neutral, biocompatible conditions into an aqueous buffer.
The aim of this study was to develop a methodology for the synthesis
of biologically interesting compounds compatible with a bead-based platform
integrating solid-phase synthesis and cell-based screening (cf. figure 2.1 for
principle). It was envisioned that a library of biologically interesting drug
Add cells Photolytic 
release of 
molecules
Uptake and 
measurement
of biological 
response
= bioactive DOX analog = photocleavable linker
= mammalian cell = PEGA bead
= non-active DOX analogs,
Figure 2.1: Illustration of bead-based platform integrating solid-phase synthesis and
cell-based screening.
analogs prepared on solid support upon mixing with cells and subsequent
photolytic release of the prepared analogs [114,115,118,119,122] would interact
with the cells and thus lead to identification of bioactive drug analogs by
measurement of the biological response, cf. figure 2.1.
To serve as a model substrate for the methodology, doxorubicin (DOX,
2.1), cf. figure 2.2, a renowned cytotoxic agent, was chosen. DOX is a highly
potent anticancer agent and was isolated from cultures of a mutant of Strep-
tomyces peucetius for the first time in 1969 [123]. DOX is an anthracycline
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and among the most utilized antitumor drugs in the world. The mechanism of
action of DOX and other anthracyclines remains a matter of controversy but
intercalation of DNA and inhibition of topoisomerase II are likely to be events
of importance for the antitumor activity of DOX [124–126]. Most patients
receiving systemic cancer treatment receive DOX or another anthracycline at
some time during treatment [127]. DOX is the most commonly used anthracy-
cline and is widely used against a wide range of malignancies, especially solid
tumors [126,128]. DOX is commonly used as part of combination chemother-
apy regimens for the treatment of lymphomas and is one of the most active
drugs in the treatment of breast cancer and soft tissue sarcomas where it is
used both by itself as the primary treatment and in combination with other
drugs as adjuvant chemotherapy [129].
However, its application is limited by significant side effects, the most
serious being severe cardiotoxicity [130]. Considerable work has therefore been
undertaken to chemically modify DOX with the goal of reducing its systemic
toxicity. More than five DOX analogs are marketed in other countries, and
two, daunorubicin (2.2) and idarubicin (2.4), are available in the United
States [131], cf. figure 2.2.
Daunorubicine (2.2) was the first anthracycline found to have antineoplas-
tic activity [129], cf. figure 2.2. It is marketed worldwide [131] and is only
used in leukemia treatment being an important drug in the treatment of acute
lymphocytic leukemia. It exhibits similar side effects to those associated with
DOX [129].
Epirubicin (2.3) is marketed worldwide (except the United States) [131]
and differs from DOX only in the the orientation of a single hydroxyl group
(changing from an axial to an equatorial orientation) [125], cf. figure 2.2.
It has similar antitumor activity to DOX, however, it is less potent. Even
though it causes slightly less cardiac toxicity it has no major advantage over
DOX [129].
Idarubicin (2.4) is marketed worldwide [131] and is structurally similar
to daunorubicin (2.2) differing only in the removal of a methoxy group, cf.
figure 2.2. Idarubicin is used for the treatment of myelogenous leukemia [129]
and also shows activity against multiple myeloma, non-Hodgkins’s lymphoma
and breast cancer and can furthermore be administered orally [125]. It is
not agreed upon whether idarubicin (2.4) offers advantages over DOX and
daunorubicin (2.2) (also with regard to cardiac toxicity) [125].
Pirarubicin (2.5), a 4-tetrahydropyranyl doxorubicin analog, and Aclaru-
bicin (2.6), a trisaccharide anthracycline, cf. figure 2.2, are both marketed
in Japan and France [131]. They show no real advantage over either DOX or
daunorubicin (2.2) [125,129].
In an effort to either expand the antitumor spectrum of DOX or reduce
cardiotoxicity a wide range of newer DOX analogs have been prepared. Below
follows a few selected examples.
Van der Vijgh tested a new DOX prodrug with the aim of lowering the
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Figure 2.2: DOX analogs marketed around the world.
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cardiotoxicity and improving the therapeutic index produced by DOX [132].
The prodrug was a leucine-doxorubicin analog (Leu-DOX, 2.7) , originally de-
veloped by Trouet (but as a daunorubicin analog) in 1980 [133], cf. figure 2.3.
Leu-DOX (2.7) rapidly formed DOX upon intravenous administration and
showed diminished cardiotoxicity [132].
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Figure 2.3: New DOX analogs.
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Schally introduced the DOX analogs 2-pyrrolinodoxorubicin 2.8 and 1,3-
tetrahydropyridinodoxorubicin 2.9 in 1996 [134], cf. figure 2.3, obtained
from DOX by reaction with 4-iodobutyraldehyde and 5-iodovaleraldehyde. 2-
pyrrolinodoxorubicin 2.8 was 500–1000 times more potent than DOX and 30–
50 times more potent than 1,3-tetrahydropyridinodoxorubicin 2.9 [134]. This
was explained by an increased steric hindrance caused by the 6-membered ring
in 2.9 as compared to the 5-membered ring of 2.8, which is more planar [134].
Carditoxicity of the analogs was not commented upon in the study.
Koch developed a DOX-formaldehyde conjugate 2.10, cf. figure 2.3, tar-
geted against breast cancer cells in 2004 [130]. The conjugate, also called
doxsaliform, was 4–10-fold more cytotoxic than DOX. The aromatic ring can
be functionalized as seen with DOX-5-formylsaliform 2.11, cf. figure 2.3,
which may be utilized for the attachment to a targeting molecule [130]. A
year later, Koch introduced the new DOX-formaldehyde conjugate Doxaz
2.12 [135], cf. figure 2.3. This cyclic conjugate is more reactive than 2.11
and shows a reduced cytotoxicity [135].
Kratz developed a peptide prodrug of DOX 2.13 in 2007 [136], cf. fig-
ure 2.3. A peptide sequence which can be specifically cleaved by the cysteine
protease cathepsin B, which has been observed overexpressed in malignant
tumors, was incorporated into the prodrug thus making specific drug delivery
to the tumor possible [136].
Methods have been fashioned to keep the plasma level of DOX muted to
minimize cardiotoxicity, but the only apparently effective methods available so
far are slow infusion and the use of iron chelators [125]. Continuous infusion of
DOX over 96 h has been shown to maintain therapeutic efficacy while reduc-
ing cardiotoxicity compared to bolus administration [131]. This technique is
however cumbersome and costly and requires prolonged hospitalization of the
patients every three weeks [131]. Infusion of dexrazoxane, an iron chelator, be-
fore DOX has been shown to reduce cardiotoxicity [125]. However, there have
been reports showing reduced response rates in women receiving DOX for the
treatment of breast cancer when used in combination with dexrazoxane [125].
Synthetic efforts in the context of preparing DOX analogs are hampered by
the structural complexity and sensitivity of DOX to the often harsh reaction
conditions used in solid-phase synthesis for the deprotection of protection
groups or linker cleavage such as strong acids and bases [137–141]. At acidic
pH (pH < 4) the major degradation product is the aglycone 2.14 resulting
from hydrolysis and loss of the amino sugar [139], cf. scheme 2.1. At higher
pH (pH > 4) the major degradation product is the aromatized aglycone 2.15
[139], cf. scheme 2.1. For the structurally related daunorubicin (2.2) the
main degradation product at alkaline pH (pH 8) is the aromatized aglycone
2.16 [138, 139], cf. scheme 2.2. The corresponding degradation product is,
however, not observed for DOX (it can however be obtained upon subjecting
DOX to severe acidic conditions) [139]. At highly alkaline conditions both
DOX and daunorubicin (2.2) degrade in to a complex mixture of degradation
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products [138,140].
DOX would thus provide a challenging case study showcasing the mild
conditions of the aforementioned methodology and its applicability in the
synthesis and release of structurally complex compound derivatives, conditions
that would furthermore be ideal for direct screening efforts.
2.1 Synthetic Strategy
The goal was thus to develop a synthetic methodology compatible with the
aforementioned screening platform. Two different strategies for the synthesis
of DOX derivatives were envisioned, utilizing either the primary amine or
the primary alcohol in DOX as the functional handle for derivatization, cf.
scheme 2.3. In both cases, the photolabile linker will initially be attached
H2N
coupling of
photolabile linker
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doxorubicin
photolytic
release
R
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MeO
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Scheme 2.3: Synthetic strategy for the synthesis of DOX derivatives.
to the solid support followed by amino acid coupling. DOX is then attached
either via its primary amine (N -functionalization) or its primary alcohol (O-
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functionalization) leading to DOX amino acid/peptide derivatives. Finally,
the DOX derivative will be photolytically released from the resin.
2.2 Acid- and Base Stability of Doxorubicin
Aware of the limited stability of DOX towards acidic and basic conditions
[137], chemical investigations were initiated with studying the stability of DOX
towards some of the standard reaction conditions used in SPPS, TFA in H2O
and piperidine in DMF.1 The results showed that DOX is stable in 10% TFA
for an extended period of time, while a concentration of 5% piperidine is
allowed for 20 min, cf. figure 2.4.
2.3 Photolabile Linker Synthesis
The photolabile linker intermediates 2.20, 1.94 and 1.95, cf. scheme 2.4
(originally prepared by Nielsen for the synthesis of azido linker 1.96, cf.
scheme 1.14), were thought to be a good starting point for the development
of the photolabile handle needed. Thus, large scale synthesis of chloride 1.95
was initiated. The first step leading to ketone 2.19 was performed in approx.
the same scale as originally reported with a comparable yield. The following
nitration could easily be scaled to a 40 g scale (four times what was originally
reported) without any effect on the yield. Likewise, the reduction affording
alcohol 1.94 proved to be very scalable and provided in a 40 g scale (10 times
what was originally reported) a yield only slightly lower than reported by
Nielsen (87% vs. quant.). Scale-up of the last step leading to chloride 1.95
was however associated with a drop in yield (from 79% to 52%) in a 35g scale
(nine times what was originally reported) due to elimination leading to alkene
formation.
Furthermore, the o-nitroveratryl linker 1.83, cf. figure 2.5, was prepared
according to the original procedure by Holmes [30], as this linker was needed
for the O-functionalization approach, cf. scheme 2.3.
2.4 N -functionalization of Doxorubicin
After the successful synthesis of linker intermediates 2.20, 1.94 and 1.95, the
development of a method for N -functionalization of DOX was initiated.
1These experiments were done in collaboration with former Senior Scientist Sebastian
T. Le Quement during my Master’s project.
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(b) Stability of DOX in piperidine.
Figure 2.4: Investigation of the acid and base stability of DOX in (a) TFA (aq) and
(b) piperidine in DMF. Determined by LCMS.
30
N -functionalization of Doxorubicin
O
MeO
OH
O
MeO
O
OEt
O
2.19
92%
O
MeO
O
OEt
O
OH
MeO
O
OEt
O
NO2
NO2
Cl
MeO
O
OEt
O
SOCl2:CH2Cl2 (1:2)
NO2
2.17
Br
O
OEt
K2CO3 (2 equiv)
2.18
(1 equiv)
DMF, rt to 60 °C, 23 h
40 g scale
+
0 °C, 2.5 h
40 g scale
HNO3:Ac2O (3:8)
2.20
89%
MeOH, 0 °C to rt, 2 h
40 g scale
1.94
87%
NaBH4 (3 equiv)
0 °C to rt, 3 h
35 g scale
1.95
52%
Scheme 2.4: Large scale synthesis of photolabile linker intermediate 1.95.
NHFmoc
MeO
O
OH
O
NO2
1.83
Figure 2.5: Photolabile o-nitroveratryl linker 1.83.
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2.4.1 Solid-phase approach for the synthesis of
N -functionalized DOX derivatives
To investigate2 the use of the primary amine in DOX as the functional handle
for derivatization and attachment to the solid support the linker intermedi-
ates 2.20 and 1.94 were, after ester hydrolysis, coupled to the solid support
already functionalized with a HMBA linker to ease analysis, cf. scheme 2.5.
Following attachment of H-Ala-OtBu · HCl either via reductive amination or
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Scheme 2.5: Attempts at installation of H-Ala-OtBu or BnNH2 on constructs 2.21
and 2.24.
Mitsunobu/substitution conditions would then, after tBu deprotection pro-
2The experiments described in this section were performed during my Master’s project.
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vide the carboxylic acid handle needed for attachment of DOX via its primary
amine. Thus construct 2.21 was subjected to reductive amination conditions,
cf. scheme 2.5. However, even though a wide variety of reductive amination
conditions were tested, both with H-Ala-OtBu · HCl and with the more nu-
cleophilic model substrate BnNH2, the photolinker substrates 2.22 and 2.23
were not observed after HMBA linker cleavage in any of the performed exper-
iments.
Construct 2.24 was likewise subjected to either Mitsunobu conditions with
BnNH2 or several different methods for chloride formation followed by substi-
tution with BnNH2, however, this did not lead to the wanted substrate 2.23
after HMBA linker cleavage either, cf. scheme 2.5.
As no successful method for the attachment of neither H-Ala-OtBu · HCl
nor BnNH2 had been found the pure solid-phase approach was abandoned.
2.4.2 Combined solution and solid-phase approach for the
synthesis of N -functionalized DOX derivatives
Instead it was rationalized that an amino acid could be attached to one of
the photolabile linker intermediates in solution, before being coupled to the
solid support, thus leading to photolabile linker building blocks of the general
structure 2.26, cf. figure 2.6. This would thus eliminate the need to perform
O
OH
O
NO2
NPG
MeO
OPG
O
R
2.26
Figure 2.6: General structure of proposed amino acid photolabile linker building
block.
the difficult coupling of the first amino acid on solid-phase.
Initially, a reductive amination approach utilizing photolabile linker in-
termediate 2.20 was attempted, cf. table 2.1. The use of NaCNBH3 and
Na(OAc)3BH in different solvents (MeOH, THF and CH2Cl2) did not lead to
any formation of the product or the corresponding imine (table 2.1, entry 1–3).
The addition of a Lewis acid to aid imine formation (this time without adding
any reducing agent) did not improve the outcome and these conditions did not
lead to any imine formation either. As no successful conditions leading to the
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Table 2.1: Attempts at synthesis of photolabile Gly linker intermediate 2.27 via
reductive amination.
O
OEt
O
NO2
O
MeO
O
OEt
O
NO2
NH
MeO
OtBu
O
2.272.20
H-Gly-OtBu·HCl (1 equiv),
reducing agent, additive
solvent, rt
Entry Reducing agent (equiv) Additive (equiv) Solvent
1 NaCNBH3 (1) AcOH (1) MeOH
2a Na(OAc)3BH (1.5) Et3N (1) THF
3a Na(OAc)3BH (1.5) Et3N (1) CH2Cl2
4 - TiCl4 (0.5), Et3N (1) CH2Cl2
5 - TiCl4 (0.5), Et3N (3) CH2Cl2
a 4Å molecular sieves added.
desired photolabile Gly linker intermediate 2.27 (or even the corresponding
imine) had been found the reductive amination approach was abandoned.
A new strategy was devised relying on the chloride photolabile linker inter-
mediate 1.95, cf. scheme 2.4. It was thus envisioned that subjecting chloride
1.95 to substitution conditions with H-Gly-OtBu would lead to the desired
photolabile Gly linker intermediate 2.27. Initial attempts suffered from low
yields and severe side product formation (mainly the alcohol 1.94). Thorough
optimization3 varying base (K2CO3, DBU, Et3N, DIPEA, DMAP), additives
(Ag2O, KI) and reaction mixture concentration identified the conditions shown
in scheme 2.6 as the most optimal. It was furthermore discovered that dry
conditions and extensive degassing were essential for obtaining a high yield
and that running the reaction relatively concentrated (∼ 0.5M) was beneficial.
Thus the subjection of chloride 1.95 to H-Gly-OtBu · HCl, Et3N and KI led
to the formation of the wanted photolabile Gly linker intermediate 2.27 in a
yield of 74%, cf. scheme 2.6.
Fmoc protection of 2.27 followed. The secondary amine of photolabile
Gly linker intermediate 2.27 proved to be quite unreactive (likely due to
steric factors) and extended reaction time under standard Fmoc protection
conditions furnished photolabile Fmoc-Gly intermediate 2.28 in a yield of 67%,
cf. scheme 2.7. To avoid deprotection of the base-labile Fmoc group, 2.28 was
then subjected to enzymatic ester hydrolysis, instead of more conventional
3Some of these experiments were performed during my Master’s project.
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methods (e.g. LiOH or NaOH), affording the photolabile Gly linker 2.29 in a
quantitative yield (up to a 5 g scale), cf. scheme 2.7.
With linker 2.29 in hand the investigation into using it as a linker for
the synthesis of DOX derivatives was commenced. HATU-mediated cou-
pling of 2.29 to an Ala-HMBA functionalized PEGA resin provided the tBu-
protected Gly-functionalized photolabile support 2.30, cf. scheme 2.8. The
tBu-protection group was then removed with TFA:CH2Cl2 (1:1) to expose
a carboxylic acid handle, which was then reacted with DOX under standard
HATU-mediated coupling conditions to afford the Fmoc-protected photolabile
construct 2.31, cf. scheme 2.8.
In order to establish the conditions that accomplished removal of the Fmoc-
protection group without affecting the DOX moiety the Fmoc-Gly-DOX con-
struct 2.31 was subjected to piperidine in DMF4 at different concentrations,
cf. figure 2.7. These results indicated that 0.5% piperidine in DMF would be
the optimal conditions to remove the Fmoc group without causing unwanted
decomposition. Construct 2.31 was thus exposed to these conditions. Grati-
fyingly, subsequent photolytic release led to the release of Gly-DOX 2.32 in
a high crude purity of 87%.
Expanding on the successful initial synthesis of Gly-DOX the next step
was the synthesis of other photolabile amino acid linkers. Thus chloride
1.95 was subjected to the earlier developed conditions together with either
H-Leu-OtBu ·HCl, H-Ala-OtBu ·HCl or H-Phe-OtBu ·HCl, cf. table 2.2. How-
Table 2.2: Synthesis of photolabile amino acid linker intermediates 2.33a–c.
O
OEt
O
NO2
NH
MeO
OtBu
O
2.33a–c1.95
H2NCHRCO2tBu·HCl (1 equiv),
Et3N (5 equiv), KI (0.1 equiv)
DMF, 60 °C
O
OEt
O
NO2
Cl
MeO
R
Entry R Reaction time (days) Product, yield (%)a
1 CH2CH(CH3)2 7 2.33a, 42
2 Me 6 2.33b, 50
3 CH2Ph 6 2.33c, 34
a Isolated yield after flash column chromatography
ever, these amino acids proved to be less reactive than H-Gly-OtBu ·HCl and
4These experiments were performed by Senior Research Scientist Katrine Qvortrup.
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Scheme 2.8: Attachment of photolabile Gly linker 2.29 to the solid support followed
by coupling of DOX and photolytic release of Gly-DOX 2.32.
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(a) Stability of Fmoc-Gly-DOX construct 2.31.
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(b) Deprotection of Fmoc-Gly-DOX construct 2.31.
Figure 2.7: Investigation of (a) the stability of and (b) the deprotection rate of
Fmoc-Gly-DOX photolabile construct 2.31 in piperidine in DMF. Determined by
LCMS.
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furthermore the products 2.33a–c were very difficult to purify leading to the
desired photolabile amino acid linker intermediates in yields of 34–50%, cf.
table 2.2.
With photolabile amino acid linker intermediates 2.33a–c in hand the
next step was Fmoc protection of the secondary amine moieties, cf. table 2.3.
However, in none of the performed experiments were the desired photolabile
Table 2.3: Attempts at Fmoc protection of photolabile amino acid linker interme-
diates 2.33a–c.
O
OEt
O
NO2
NH
MeO
OtBu
O
conditions
R
O
OEt
O
NO2
NFmoc
MeO
OtBu
O
R
2.33a–c 2.34a–c
Entry R Fmoc reagent base Solvent
1 CH2CH(CH3)2 FmocCl - dioxane:10% NaHCO3 (aq) (1:1)
2 CH2CH(CH3)2 FmocOSu Et3N MeCN:H2O (1:1)
3 Me FmocCl - dioxane:10% NaHCO3 (aq) (1:1)
4 Me FmocOSu Et3N MeCN:H2O (1:1)
5 CH2Ph FmocCl - dioxane:10% NaHCO3 (aq) (1:1)
6 CH2Ph FmocOSu Et3N MeCN:H2O (1:1)
Fmoc-amino acid intermediates 2.34a–c observed.
With the very low reactivity of the secondary amines 2.33a–c in mind it
was theorized that these photolabile amino acid linker intermediates could,
after ester hydrolysis, be coupled to the solid support without any polymer-
ization occurring if a less reactive coupling reagent was used. To test the
hypothesis intermediates 2.33a–c were subjected to ester hydrolysis, cf. ta-
ble 2.4. As the Fmoc group present on the original photolabile Gly linker was
not present this time, a more conventional ester hydrolysis method was used.
Thus linker intermediates 2.33a–c were exposed to LiOH affording photola-
bile amino acid linkers 2.35a–c in excellent yields (85% to quant.) with the
non-quantitative yield in the hydrolysis of 2.33b being due to slight hydrolysis
of the tBu-ester, cf. table 2.4.
The photolabile amino acid linkers 2.35a–c were now attached to the solid
support, cf. scheme 2.9. The Gly-DOX linker was attached using a HATU
mediated protocol, cf. scheme 2.8, but the linkers 2.35a–c were coupled with
the less reactive coupling reagent TBTU instead to avoid polymerization due
to the free, but very unreactive, secondary amine. Gratifyingly, the linkers
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2.36a–c
O
OH
O
NO2
NFmoc
MeO
OtBu
O
H2N
O
N
H
O
NO2
NFmoc
MeO
OtBu
O
TBTU (2.9 equiv),
NEM (4 equiv)
,
1. TFA:CH2Cl2 (1:1)
2. DOX·HCl (3 equiv),
   HATU (2.9 equiv),
   DIPEA (5 equiv),
   DMF, rt, 2 h
O
N
H
O
NO2
NFmoc
MeO
O
DOX OH
NH
2.38a–c
93 to >95%  crude purity
hν (365 nm)
OMe
O OH
OHO
O
OH
OH
O
H
O
OH
NH
O
H2N
DMF, rt, 2 h
2.35a–c
(3 equiv)
2.37a–c
: Ala-HMBA-PEGA800
R
R R
R
DMF
Scheme 2.9: Attachment of photolabile amino acid linkers 2.35a–c to the solid
support followed by coupling of DOX and photolytic release of Leu-DOX 2.38a, Ala-
DOX 2.38b and Phe-DOX 2.38c.
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Table 2.4: Ester hydrolysis of 2.33a–c leading to photolabile amino acid linkers
2.35a–c.
O
OEt
O
NO2
NH
MeO
OtBu
O
THF:H2O (3:1)
R
LiOH (2 equiv)
O
OH
O
NO2
NH
MeO
OtBu
O
R
2.33a–c 2.35a–c
Entry R Reaction time (h) Product, yield (%)a
1 CH2CH(CH3)2 25 2.35a, quant.
2 Me 26 2.35b, 85
3 CH2Ph 26 2.35c, quant.
a Isolated yield after aqueous work-up.
were coupled to the solid support without any indication of polymerization
taking place leading to constructs 2.36a–c, cf. scheme 2.9. Deprotection of
the tBu-protection group, attachment of DOX and photolytic release then fur-
nished, in excellent crude purities, Leu-DOX 2.38a (>95%), Ala-DOX 2.38b
(94%) and Phe-DOX 2.38c (93%).
After the successful synthesis of four amino acid DOX derivatives the next
goal was the construction of more elaborate DOX derivatives. In the attempt
to attach small peptides to DOX, the photolabile construct 2.30 was subjected
to Fmoc deprotection and subsequent coupling of Fmoc-Gly-OH using either
HATU or PyBrOP as coupling reagent, cf. table 2.5.
However, in both cases 2.39 was isolated after HMBA linker cleavage in-
dicating that the coupling procedure had not been successful, likely due to
the very low reactivity of the secondary amine as seen earlier. These results
turned the focus to finding an even more reactive coupling reagent. BTC
had been reported by Gilon to be very effective for the use in difficult pep-
tide couplings [43]. The use of these conditions led to successful coupling
of Fmoc-Gly-OH and a subsequent Fmoc deprotection and HATU-mediated
coupling of Fmoc-Ala-OH provided the photolabile peptide construct 2.41,
cf. scheme 2.10. Finally, tBu deprotection, HATU-mediated coupling of DOX
and photolysis provided Ala-Gly-Gly-DOX tripeptide 2.43 in a remarkable
crude purity of >95%.
In an attempt to expand on this satisfying result, amino acid coupling
was likewise attempted on the photolabile amino acid constructs 2.36a–c,
cf. table 2.6. As seen with the photolabile Gly construct 2.30, HATU and
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Table 2.5: Attempts at amino acid coupling onto photolabile Gly construct 2.30.
O
N
H
O
NO2
NFmoc
MeO
OtBu
O
1. 20% pip./DMF
2. Fmoc-Gly-OH,
   coupling conditions,
   rt, 2 h
3. 20% pip./DMF 
4. NaOH (aq)
2.30 2.39
: Ala-HMBA-PEGA800
O
N
H
O
NO2
NH
MeO
OtBu
O
OH
O
Entry Equiv of Fmoc-Gly-OH Coupling reagent (equiv) Base (equiv)
1 3 HATU (2.9) DIPEA (5)
2 3 PyBrOP (4) DIPEA (6)
Table 2.6: Attempts at amino acid coupling onto the secondary amines 2.36a–c.
O
N
H
O
NO2
NH
MeO
OtBu
O
1. Fmoc-Gly-OH,
   coupling conditions
2. 20% pip./DMF 
3. NaOH (aq)
2.36a–c 2.44a–c
: Ala-HMBA-PEGA800
O
N
H
O
NO2
NH
MeO
OtBu
O
OH
O
R R
Entry R Coupling reagent Base Temp. (◦C)
1 CH2CH(CH3)2 HATU DIPEA rt
2a CH2CH(CH3)2 BTC 2,4,6-collidine rt
3 CH2CH(CH3)2 BTC 2,4,6-collidine 50
4 Me HATU DIPEA rt
5 Me BTC 2,4,6-collidine 50
6 CH2Ph PyBroP DIPEA rt
a Beads preswelled in THF:DIPEA (1:1).
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O
N
H
O
NO2
NFmoc
MeO
OtBu
O
1. 20% pip./DMF
2. Fmoc-Gly-OH (5 equiv), 
   BTC (1.65 equiv), 
   2,4,6-collidine (14 equiv), 
   THF, 50 °C, 1 h
1. 20% pip./DMF
O
N
H
O
NO2
N
MeO
O
O
OtBu
FmocHN
O
N
H
O
NO2
N
MeO
O
O
OtBu
N
H
O
FmocHN
O
N
H
O
NO2
N
MeO
O
N
H
O
FmocHN
DOX OH
NH
O
OMe
O OH
OHO
O
OH
OH
O
H
O
OH
NH
O
N
H
O
H
N
H2N
O
2.30 2.40
2. Fmoc-Ala-OH (3 equiv),
   HATU (2.9 equiv),
   DIPEA (5 equiv),
   DMF, rt, 2 h
1. TFA:CH2Cl2 (1:1)
2. DOX·HCl (3 equiv),
   HATU (2.9 equiv),
   DIPEA (5 equiv),
   DMF, rt, 2 h
2.41
2.42
2.43
>95% crude purity
2. hν (365 nm), DMF
1. 0.5% pip./DMF
: Ala-HMBA-PEGA800
Scheme 2.10: Synthesis of N -functionalized Ala-Gly-Gly-DOX tripeptide 2.43.
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PyBrOP were unable to effect the coupling of Fmoc-Gly-OH, only leading to
2.44a–c (entries 1, 4 and 6). However, with the photolabile constructs 2.36a–
c not even the use of BTC as a coupling reagent furnished the desired products
and again only 2.44a and 2.44b were observed, (entries 3 and 5). Another
procedure for amino acid coupling using BTC [142], relying on pretreatment
of the resin with DIPEA, was also investigated but did not accomplish the
coupling either (entry 2). The secondary amine in the constructs 2.36a–c thus
proved to be very unreactive, likely due to steric factors, and in fact not even
acetylation of this moiety could be accomplished using common acetylating
reagents (e.g. AcCl, Ac2O).
2.5 O- and N -functionalization of Doxorubicin
To explore different sites of structural modification with regard to the synthesis
of DOX derivatives focus was turned towards the primary alcohol of DOX as
this would be an obvious site for modification, cf. figure 2.11. It was further-
2.1
OMe
O OH
OHO
O
OH
OH
O
H
O
OH
NH2
O-functionalization
N-functionalization
Scheme 2.11: Sites for structural modification of DOX.
more envisioned that this site, after modification, could serve as a handle for
attachment to the solid support thus also allowing for N -functionalization via
standard SPPS methods, which had proved to be difficult with the methods
developed in §2.4.
To fuel these investigations the DOX ester building block 2.48, known
from the literature [143], was deemed essential and its synthesis thus became
a starting point, cf. scheme 2.12. The original procedure was reported to
provide 2.48 in an overall yield of 70%. This procedure however performed
poorly in our laboratory and gave rise to complex reaction mixtures with only
small amounts of product formed.5 With the high price of DOX in mind a new
5These initial experiments were performed by former Senior Scientist Sebastian T. Le
Quement.
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and improved route to DOX ester building block 2.48 was thus developed, cf.
scheme 2.12. DOX was Fmoc protected with FmocCl providing Fmoc-DOX
2.45
methyl glutaryl chloride (8.2 equiv),
2,4,6-collidine (11.8 equiv)
OMe
O OH
OHO
O
O
OH
O
H
O
OH
NHFmoc
FmocCl (1 equiv), 
NaHCO3 (4 equiv)
dioxane:H2O (1:1),
rt, 22 h
DOX OH
NH3
DOX OH
NHFmoc
DOX O
NHFmoc
O
OMe
O
Cl-
CH2Cl2, −78 °C, 1.5 h
2.46
quant.
2.47
quant.
2.48
quant.
Novozyme 435
acetone:K3PO4 buffer (4:1),
rt, 9 days
O
OH
O
Scheme 2.12: Synthesis of DOX ester building block 2.48.
2.46 in quantitative yield. Then Fmoc-DOX 2.46 was reacted with methyl
glutaryl chloride with 2,4,6-collidine as base furnishing the DOX diester 2.47
again in a quantitative yield, cf. scheme 2.12. Both steps proceeded without
the need for any chromatographic purification. Finally, enzymatic ester hy-
drolysis with Novozyme 435 selectively hydrolyzed the methyl ester, without
affecting the internal ester, affording the DOX ester building block 2.48 in a
quantitative yield (in up to a 1 g-scale).
With DOX ester building block 2.48 in hand an initial experiment were
performed where 2.48 was coupled to the solid support in a HATU-mediated
coupling, this time functionalized with the o-nitroveratryl linker 1.83 [30],
cf. scheme 2.13. Rewardingly, the resulting DOX construct 2.50 was readily
Fmoc-deprotected (using the previously established conditions, cf. §2.4.2) and
released by photolysis providing DOX amide derivative 2.51 in a crude purity
of 64%.
The release of 2.51 confirmed the possibility of anchoring DOX to the
solid support via its primary alcohol and then functionalizing the primary
amine (N -functionalization) via standard SPPS. Thus Fmoc deprotection of
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H2N
NO2
MeO
O
N
H
O
DMF, rt, 2 h
OMe
O OH
OHO
O
O
OH
O
H
O
OH
NH2
O
NH2
O
2.48 (3 equiv),
HATU (2.9 equiv),
DIPEA (5 equiv)
2. hν (365 nm), DMF
1. 0.5% pip./DMF
2.51
64% crude purity
2.49
NO2
MeO
O
N
H
O
2.50
O
DOXO
NHFmocHN
O
: Ala-HMBA-PEGA800
Scheme 2.13: Synthesis of O-functionalized DOX amide derivative 2.51.
the primary amine on DOX construct 2.50 and subsequent HATU-mediated
coupling of Fmoc-Ala-OH was attempted. This however led to unclean cou-
pling and the generation of an unidentified side product. It was speculated
that the use of a less reactive coupling reagent such as TBTU would suppress
side product formation. Gratifyingly, Fmoc deprotection of construct 2.50
followed by a TBTU-mediated coupling of Fmoc-Ala-OH provided a clean
coupling and led to the release of Ala-Dox amide 2.52 in a good crude purity
of 70%, cf. scheme 2.14.
After the successful release of 2.52 a test of the developed methodology
in a more complex setting was attempted. Thus a tripeptide (Gly-Lys-Ala)
was synthesized on the o-nitroveratryl linker using HATU-mediated couplings
followed by attachment of DOX ester building block 2.48 leading to the photo-
labile DOX construct 2.54 cf. scheme 2.15. Fmoc deprotection of the primary
amine on DOX and subsequent TBTU-mediated coupling of Fmoc-Ala-OH fol-
lowed by further HATU-mediated SPPS afforded, after photolysis, the DOX
dipeptide derivative 2.55 in a crude purity of 48%.
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OMe
O OH
OHO
O
O
OH
O
H
O
OH
NH
O
NH2
O
1. 0.5% pip./DMF
2.52
70% crude purity
: Ala-HMBA-PEGA800
2. Fmoc-Ala-OH (3 equiv),
   TBTU (2.9 equiv),
   NEM (4 equiv),  
   DMF, rt, 2 h
3. hν (365 nm), DMF
O
FmocHN
NO2
MeO
O
N
H
O
2.50
H
N
O
DOX O
NHFmoc O
Scheme 2.14: N -functionalization of construct 2.50 and subsequent photolytic re-
lease.
2.6 Conclusion
In the present project the synthesis of DOX derivatives on photolabile solid
support, compatible with bead-based screening, has been investigated. Two
different strategies for the synthesis of DOX derivatives have been explored
where both the primary amine and the primary alcohol of DOX were utilized
as sites for structural modification.
Four amino acid photolabile linkers have been synthesized allowing for
the photolytic release of DOX amino acid derivatives (N -functionalization)
in excellent crude purities (87 to >95%). Furthermore, the photolabile Gly
linker 2.29 has been used to construct Ala-Gly-Gly-DOX tripeptide 2.43 in a
remarkable crude purity of >95%. This methodology was however not compat-
ible with the other amino acid photolabile linkers likely due to steric factors.
Another methodology allowing for both N - and O-functionalization was
also developed. The DOX ester building block 2.48 was synthesized in three
steps, all of which proceeded with a quantitative yield. This allowed for the
tethering of DOX to the solid support through its primary alcohol and sub-
sequent N -functionalization via standard SPPS methods. It was furthermore
possible to construct peptides on the solid support before the attachment
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2.54
MeO
O
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O
H
N
NO2
Gly-Lys(Boc)-Ala
O O
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MeO
O
N
H
O
H
N
NO2
Fmoc-Gly-Lys(Boc)-Ala
1. 20% pip./DMF
MeO
O
N
H
O
H2N
NO2
2.49 2.53
2. 2.48 (3 equiv),
   HATU (2.9 equiv),
   DIPEA (5 equiv),
   DMF, rt, 2 h
HATU-mediated
SPPS
2. HATU-mediated SPPS
3. hν (365 nm), DMF
1. Fmoc-Ala-OH (3 equiv),
   TBTU (2.9 equiv),
   NEM (4 equiv),
   DMF, rt, 2 h
: Ala-HMBA-PEGA800
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Scheme 2.15: Synthesis of DOX dipeptide derivative 2.55.
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of DOX ester building block 2.48 thus allowing for O-functionalized DOX
peptide derivatives. This culminated in the synthesis of the O- and N -
functionalized DOX dipeptide 2.55 in a crude purity of 48% thus leaving
room for further optimization.
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2.7 Experimental
2.7.1 General methods
Reagents were purchased at the highest commercial quality and used without
further purification, unless otherwise noted. All reactions were carried out un-
der an argon atmosphere with dry solvent under anhydrous conditions, unless
otherwise noted. Dry solvents were obtained by passing commercially avail-
able pre-dried, oxygen-free formulations through activated alumina columns.
Yields refer to chromatographically and spectroscopically (1H NMR) homo-
geneous material, unless otherwise stated.
Reactions were monitored by thin-layer chromatography (TLC) carried
out on Merck aluminium sheets covered with silica (C60) using UV light as
visualizing agent or an aqueous solution of phosphomolybdic acid and cerium
sulfate or a basic aqueous solution of potassium permanganate and heat as
developing agents. Matrex silica gel (60, particle size 0.035–0.070 mm) was
used for flash column chromatography.
Solid-phase synthesis was carried out using plastic-syringe techniques. Flat-
bottomed polyethylene syringes were fitted with polypropylene filters and were
attached to Teflon R© tubing and valves, allowing vacuum to be applied to the
syringes.
NMR spectra were recorded on a Bruker Ascend 400 MHz instrument
equipped with a Prodigy cryoprobe, a Varian Unity Inova 500MHz instrument
or a Bruker Avance 800MHz instrument equipped with a TCI cryoprobe.The
chemical shifts (δ) are reported in parts per million (ppm) and the coupling
constants (J) in Hz. For spectra recorded in DMSO-d6, signal positions were
measured relative to the signal for DMSO (δ 2.50 ppm for 1H NMR and δ
39.43 ppm for 13C NMR). For spectra recorded in CDCl3, signal positions
were measured relative to the signal for CHCl3 (δ 7.26 ppm for
1H NMR and
δ 77.0 ppm for 13C NMR).
Infrared (IR) spectra were recorded on a Bruker Alpha FT-IR spectrom-
eter. Analytical RP-UPLC-MS (ESI) analysis was performed on a Waters
AQUITY RP-UPLC system equipped with a diode array detector using an
AQUITY UPLC BEH C18 column (d 1.7 mm, 2.1 × 50 mm; column temp:
65 ◦C; flow: 0.6 mL/min.). Eluents A (0.1% HCO2H in H2O) and B (0.1%
HCO2H in MeCN) were used in a linear gradient (5% B to 100% B) in a total
run time of 2.6min. The LC system was coupled to a SQD mass spectrometer.
Analytical LC-HRMS (ESI) analysis was performed on an Agilent 1100 RP-
LC system equipped with a diode array detector using a Phenomenex Luna
C18 column (d 3mm, 2.1× 50mm; column temp: 40 ◦C; flow: 0.4mL/min.).
Eluents A (0.1% HCO2H in H2O) and B (0.1% HCO2H in MeCN) were used
in a linear gradient (20% B to 100% B) in a total run time of 15min. The LC
system was coupled to a Micromass LCT orthogonal time-of-flight mass spec-
trometer equipped with a Lock Mass probe operating in positive electrospray
mode.
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2.7.2 Synthesis of photolabile linkers
Ketone 2.19. Acetovanillone 2.17 (36.00g, 216.6mmol), ethyl 4-bromobutyrate
2.18 (43.04 g, 220.7mmol) and K2CO3 (62.38 g, 451.4mmol) were dissolved
in DMF (200mL). The reaction mixture was stirred at rt for 20 h. The reac-
tion mixture was then heated to 60 ◦C for 3 h whereupon water (500mL) was
added. The resulting mixture was extracted with EtOAc (3 × 250 mL) and
the combined organic phases were washed with water (7× 500mL) and brine
(4 × 500 mL), dried over Na2SO4 and the solvent was removed in vacuo to
give the title compound as an off-white solid (56.09g, 92%). 1H NMR (CDCl3,
400MHz) δ 7.56–7.50 (m, 2H), 6.89 (d, J = 8.3 Hz, 1H), 4.18–4.10 (m, 4H),
3.90 (s, 3H), 2.55 (s, 3H), 2.52 (d, J = 7.2 Hz, 2H), 2.18 (p, J = 6.8 Hz, 2H),
1.25 (t, J = 7.1 Hz, 3H). 1H NMR spectroscopic data were consistent with
those in the literature [108].
Nitro ketone 2.20. Solutions of ketone 2.19 (2×20.00g, 2×71.35mmol)
in Ac2O (2×70mL) were added to solutions of HNO3 (2×400mL) and Ac2O
(2×80mL) at 0◦C in two flasks. The reaction mixtures were stirred at 0◦C for
2h 30 min. and were then poured into ice water (6L). The solution was filtered
and the solid was dissolved in EtOAc (1L) and washed with sat. K2CO3 (aq)
(1 L), water (2× 1 L) and brine (1 L), dried over MgSO4 and the solvent was
removed in vacuo to give the title compound as a yellow solid (41.47 g, 89%).
1H NMR (CDCl3, 400MHz) δ 7.60 (s, 1H), 6.74 (s, 1H), 4.19–4.12 (m, 4H),
3.95 (s, 3H), 2.54 (t, J = 7.2 Hz, 2H), 2.49 (s, 3H), 2.19 (p, J = 6.7 Hz, 2H),
1.26 (t, J = 7.1 Hz, 3H). 1H NMR spectroscopic data were consistent with
those in the literature [108].
Nitro alcohol 1.94. Nitro ketone 2.20 (2× 19.50 g, 2× 59.94mmol) was
dispersed in MeOH (2× 1.2 L) in two flasks and the solutions were cooled to
0 ◦C. NaBH4 (2× 6.850 g, 2× 181.1mmol) was added in portions whereupon
the solutions were allowed to reach rt. The reaction mixtures were stirred
for 2 h and then sat. NH4Cl (aq) (2 × 600 mL) was added. The solutions
were concentrated in vacuo to 2 × 600 mL, combined and extracted with
EtOAc (4 × 500mL). The combined organic phases were washed with water
(2 × 500 mL) and brine (500 mL), dried over MgSO4 and the solvent was
removed in vacuo to give the title compound as a yellow solid (33.98 g, 87%).
1H NMR (CDCl3, 400MHz) δ 7.55 (s, 1H), 7.29 (s, 1H), 5.55 (q, J = 6.3Hz,
1H), 4.17–4.08 (m, 4H), 3.96 (s, 3H), 2.53 (t, J = 7.2 Hz, 2H), 2.22–2.13 (m,
2H), 1.54 (d, J = 6.3Hz, 3H), 1.26 (t, J = 7.1Hz, 3H). 1H NMR spectroscopic
data were consistent with those in the literature [108].
Chloride 1.95. Nitro alcohol 1.94 (33.99 g, 103.8 mmol) was dissolved
in CH2Cl2 (680mL) and the resulting solution was cooled to 0
◦C whereupon
SOCl2 (340 mL) was added. The reaction mixture was allowed to reach rt
and was then stirred for 3 h. The reaction mixture was concentrated in vacuo
and then co-evaporated with toluene (6 × 300 mL). The residue was then
purified by flash column chromatography on silica gel (EtOAc:heptane (2:3))
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to give the title compound as a yellow solid (18.59g, 52%). 1H NMR (CDCl3,
400MHz) δ 7.48 (s, 1H), 7.27 (s, 1H), 5.91 (q, J = 6.6Hz, 1H), 4.18–4.06 (m,
4H), 3.97 (s, 3H), 2.52 (t, J = 7.2 Hz, 2H), 2.17 (p, J = 6.7 Hz, 2H), 1.86 (d,
J = 6.7 Hz, 3H), 1.24 (t, J = 7.1 Hz, 3H). 1H NMR spectroscopic data were
consistent with those in the literature [108].
Gly photolabile linker intermediate 2.27. Chloride 1.95 (5.000 g,
14.46mmol), H-Gly-Ot-Bu·HCl (2.908g, 17.35mmol) and KI (0.288g, 1.73mmol)
were dissolved in DMF (29mL). Et3N (10.09mL, 72.34mmol) was added and
then the reaction mixture was heated to 60 ◦C. The reaction mixture was
stirred at 60 ◦C for 3 days whereupon water (100mL) was added. The result-
ing mixture was extracted with EtOAc (3×100mL) and the combined organic
phases were washed with water (2 × 200mL) and brine (200mL), dried over
Na2SO4 and the solvent was removed in vacuo. The residue was then purified
by flash column chromatography on silica gel (EtOAc:heptane:Et3N (40:59:1))
to give the title compound as a yellow amorphous solid (4.717 g, 74%). Rf =
0.11 (EtOAc:heptane:Et3N (30:69:1));
1H NMR (CDCl3, 400MHz) δ 7.45 (s,
1H), 7.40 (s, 1H), 4.54 (q, J = 6.4 Hz, 1H), 4.14 (q, J = 7.1 Hz, 2H), 4.09 (t,
J = 6.3 Hz, 2H), 3.95 (s, 3H), 3.19–3.04 (m, 2H), 2.52 (t, J = 7.3 Hz, 2H),
2.21–2.13 (m, 2H), 1.46 (d, J = 6.4Hz, 3H), 1.42 (s, 9H), 1.25 (t, J = 7.1Hz,
3H); 13C NMR (CDCl3, 101MHz) δ 173.0, 170.9, 154.1, 147.1, 141.7, 134.2,
109.7, 109.1, 82.0, 68.4, 60.7, 56.7, 52.7, 49.5, 30.7, 28.2, 24.4, 23.7, 14.3;
IR (neat) cm−1: 2977, 2935, 1729, 1578, 1515, 1368, 1335, 1269, 1212, 1150,
1056, 1031, 846; HRMS (ESI) calcd for C21H33N2O8
+ [M+H]+ 441.2231,
found 441.2266.
Fmoc-Gly photolabile linker intermediate 2.28. Gly photolabile
linker intermediate 2.27 (4.539g, 10.30mmol) was dissolved in dioxane (16mL)
and then sat. NaHCO3 (aq) (26mL) was added. A solution of FmocCl (3.199g,
12.37 mmol) in dioxane (10 mL) was then added and the reaction mixture
was stirred at rt for 19 h whereupon water (400 mL) was added. The re-
sulting mixture was extracted with EtOAc (3 × 400 mL) and the combined
organic phases were washed with water (2 × 400 mL) and brine (400 mL),
dried over MgSO4 and the solvent was removed in vacuo. The residue was
then purified by flash column chromatography on silica gel (EtOAc:heptane
(1:3)) to give the title compound as a yellow amorphous solid (4.598 g, 67%).
Rf = 0.46 (EtOAc:heptane (1:1)); 1H NMR (CDCl3, 400MHz)
6 δ 7.80–7.69
(m, 1H), 7.69–7.60 (m, 1H), 7.59–7.48 (m, 2H), 7.43–6.89 (m, 6H), 6.06–5.73
(m, 1H), 4.55–4.23 (m, 2H), 4.23–4.00 (m, 6H), 3.95–3.84 (m, 4H), 2.59–2.48
(m, 2H), 2.26–2.12 (m, 2H), 1.73–1.55 (m, 2H), 1.50–1.36 (m, 10H), 1.26 (t,
J = 7.1 Hz, 3H); 13C NMR (CDCl3, 101MHz)
7 δ 173.0, 169.2, 156.6/155.8,
153.9/153.4, 147.1/146.9, 143.9/143.7, 141.3/141.2, 139.9, 134.7/132.7, 127.7,
127.1, 125.2/124.8, 120.0/119.9, 110.4/109.0, 110.0/109.5, 82.02, 68.3, 67.8,
6Due to the presence of rotamers the NMR data was difficult to analyze.
7Due to the presence of rotamers some carbon signals were present twice.
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60.7, 56.5, 52.9/51.9, 48.0/46.9, 47.3, 30.7, 28.1, 24.4, 19.5/18.9, 14.4; IR
(neat) cm−1: 2978, 2940, 1731, 1703, 1579, 1520, 1450, 1333, 1270, 1152,
1040, 740; HRMS (ESI) calcd for C36H42N2NaO10
+ [M+H]+ 685.2732, found
685.2734.
Gly photolabile linker 2.29. Fmoc-Gly photolabile linker intermediate
2.28 (4.255g, 6.420mmol) was dissolved in acetone (96mL) and buffer (0.1M
KH2PO4/0.1M NaOH, 24mL) was added. Novozyme 435 beads were added
and the resulting mixture was shaken gently at rt for 6 days. The reaction
mixture was filtered through a plug of Celite and the solvent was removed
in vacuo. The residue was dissolved in CH2Cl2 and filtered and the solution
was then concentrated and co-evaporated with MeCN several times to give
the title compound as a yellow amorphous solid (4.723 g, quant). 1H NMR
(CDCl3, 799 MHz)
8 δ 7.79–7.69 (m, 1H), 7.67–7.58 (m, 1H), 7.58–7.49 (m,
2H), 7.48–6.89 (m, 6H), 6.03–5.77 (m, 1H), 4.57–4.27 (m, 2H), 4.21–3.97 (m,
4H), 3.95–3.85 (m, 4H), 2.70–2.53 (m, 2H), 2.26–2.11 (m, 2H), 1.67–1.59 (m,
2H), 1.48–1.39 (m, 10H); 13C NMR (CDCl3, 201MHz)
9 δ 178.5, 169.2/169.1,
156.6/155.8, 153.8/153.3, 147.0/146.8, 143.8, 141.2, 139.8, 134.5/132.6, 127.6,
127.0, 125.1/124.7, 120.0/119.8, 110.3/108.9, 109.9/109.5, 82.1/82.0, 68.0,
67.9/67.8, 56.4, 52.7/51.8, 47.8/46.8, 47.3/47.11, 30.4, 28.0, 24.1, 19.4/18.7; IR
(neat) cm−1: 3290, 2940, 1702, 1521, 1450, 1332, 1270, 1215, 1151, 1040, 740;
HRMS (ESI) calcd for C34H39N2O10
+ [M+H]+ 635.2599, found 635.2598.
Leu photolabile linker intermediate 2.33a. Chloride 1.95 (1.00 g,
2.89mmol), H-Leu-OtBu·HCl (0.776g, 3.47mmol) and KI (0.058g, 0.35mmol)
were dissolved in DMF (5.8mL). Et3N (2.02mL, 14.5mmol) was added and
then the reaction mixture was heated to 60 ◦C. The reaction mixture was
stirred at 60 ◦C for 7days whereupon water (20mL) was added. The resulting
mixture was extracted with EtOAc (3 × 20 mL) and the combined organic
phases were washed with water (2 × 40 mL) and brine (2 × 40 mL), dried
over Na2SO4 and the solvent was removed in vacuo. The residue was then
purified by flash column chromatography on silica gel (EtOAc:heptane:Et3N
(20:78:2)) to give the title compound as a yellow amorphous solid (0.610 g,
42%). Rf = 0.42 (EtOAc:heptane (2:3)); 1H NMR (CDCl3, 400MHz) δ 7.75–
7.42 (m, 2H), 4.75–4.52 (m, 1H), 4.19–4.05 (m, 4H), 3.97 (s, 3H), 3.30–2.76
(m, 1H), 2.53 (dd, J = 13.4, 7.1 Hz, 2H), 2.22–2.12 (m, 2H), 1.84–1.65 (m,
1H), 1.65–1.37 (m, 11H), 1.36 (s, 3H), 1.25 (t, J = 7.1Hz, 3H), 0.92–0.70 (m,
6H); 13C NMR (CDCl3, 101MHz)
10 δ 173.1, 173.0, 154.0, 147.1, 141.8/141.0,
134.2, 110.1, 109.0/109.0, 82.3, 68.4/68.3, 60.7, 58.6/58.5, 56.7, 51.6, 42.4,
30.7, 28.1, 28.1, 25.2/25.0, 24.4/24.4, 22.9/22.5, 14.4; IR (neat) cm−1: 2958,
2871, 1726, 1515, 1469, 1368, 1336, 1269, 1211, 1147, 1058, 1028; HRMS (ESI)
calcd for C25H41N2O8
+ [M+H]+ 497.2857, found 497.2862.
8Due to the presence of rotamers the NMR data was difficult to analyze.
9Due to the presence of rotamers some carbon signals were present twice.
10Due to the presence of diastereomers some carbon signals were present twice.
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Ala photolabile linker intermediate 2.33b. Chloride 1.95 (1.009 g,
2.918mmol), H-Ala-OtBu·HCl (0.636g, 3.50mmol) and KI (0.058g, 0.35mmol)
were dissolved in DMF (5.8mL). Et3N (2.03mL, 14.6mmol) was added and
then the reaction mixture was heated to 60 ◦C. The reaction mixture was
stirred at 60 ◦C for 6days whereupon water (20mL) was added. The resulting
mixture was extracted with EtOAc (3 × 20 mL) and the combined organic
phases were washed with water (2 × 50 mL) and brine (2 × 50 mL), dried
over Na2SO4 and the solvent was removed in vacuo. The residue was then
purified by flash column chromatography on silica gel (EtOAc:heptane:Et3N
(25:73:2)) to give the title compound as a yellow amorphous solid (0.660 g,
50%). Rf = 0.28 (EtOAc:heptane (2:3)); 1H NMR (CDCl3, 400MHz) δ 7.92–
7.34 (m, 2H), 4.95–4.59 (m, 1H), 4.19–4.05 (m, 4H), 4.04–3.91 (m, 3H), 3.33–
2.89 (m, 1H), 2.58–2.45 (m, 2H), 2.24–2.10 (m, 2H), 1.91–1.30 (m, 15H), 1.26
(t, J = 7.1 Hz, 3H); 13C NMR (CDCl3, 101 MHz)
11 δ 173.1, 169.2, 154.2,
147.3, 141.9/141.2, 133.8, 110.1, 109.1/109.0, 82.4/81.8, 68.4, 60.7, 57.1/56.6,
55.2, 51.6/50.9, 30.7, 28.0, 24.4, 23.5/23.3, 18.5, 14.4; IR (neat) cm−1: 2977,
2935, 1726, 1514, 1368, 1335, 1267, 1212, 1147, 1054, 1034; HRMS (ESI) calcd
for C22H35N2O8
+ [M+H]+ 455.2388, found 455.2394.
Phe photolabile linker intermediate 2.33c. Chloride 1.95 (0.721 g,
2.09mmol), H-Phe-OtBu·HCl (0.653g, 2.53mmol) and KI (0.042g, 0.25mmol)
were dissolved in DMF (4.2mL). Et3N (1.47mL, 10.5mmol) was added and
then the reaction mixture was heated to 60 ◦C. The reaction mixture was
stirred at 60 ◦C for 6days whereupon water (20mL) was added. The resulting
mixture was extracted with EtOAc (3 × 20 mL) and the combined organic
phases were washed with water (2 × 50 mL) and brine (2 × 50 mL), dried
over Na2SO4 and the solvent was removed in vacuo. The residue was then
purified by flash column chromatography on silica gel (acetone:toluene:Et3N
(1.5:97.5:1)) to give the title compound as a yellow amorphous solid (0.372 g,
74%). Rf = 0.42 (EtOAc:heptane (2:3)); 1H NMR (CDCl3, 400MHz) δ 7.46–
7.06 (m, 7H), 4.51–4.41 (m, 1H), 4.15 (q, J = 7.1 Hz, 2H), 4.11–4.03 (m,
2H), 3.93–3.50 (m, 3H), 3.35–2.95 (m, 1H), 2.94–2.65 (m, 2H), 2.52 (t, J =
7.3Hz, 2H), 2.17 (p, J = 6.7Hz, 2H), 1.43–1.23 (m, 15H); 13C NMR (CDCl3,
101MHz)12 δ 174.7/173.5, 173.1/173.1, 153.9/153.8, 146.7/146.7, 141.6/141.1,
138.1/137.5, 136.4/135.7, 129.7/129.5, 128.4/128.3, 126.7/126.6, 109.9/109.6,
109.1/108.9, 81.8/81.4, 68.4/68.3, 61.6/61.0, 60.7, 56.4/56.1, 51.1/51.0, 40.2/39.6,
30.8/30.8, 28.1/28.0, 24.8/23.6, 24.5/24.4, 14.36; IR (neat) cm−1: 2977, 2933,
1726, 1514, 1368, 1335, 1268, 1211, 1149, 1057, 1029; HRMS (ESI) calcd for
C28H39N2O8
+ [M+H]+ 531.2701, found 531.2706.
Leu photolabile linker 2.35a. Leu photolabile linker intermediate 2.33a
(0.572g, 1.15mmol) was dissolved in THF (11.5mL) and water (1.5mL). Then
1M LiOH (aq) (2.30mL, 2.30mmol) was added and the reaction mixture was
11Due to the presence of diastereomers some carbon signals were present twice.
12Due to the presence of diastereomers most carbon signals were present twice.
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stirred at rt for 25h whereupon 1MHCl (aq) (3.15mL) and water (40mL) were
added. The resulting mixture was extracted with EtOAc (3 × 50 mL). The
combined organic phases were washed with brine (50mL), dried over Na2SO4
and the solvent was removed in vacuo to give the title compound as a yellow
amorphous solid (0.543 g, quant.). 1H NMR (CDCl3, 400MHz) δ 7.53–7.34
(m, 2H), 4.60–4.42 (m, 1H), 4.16–4.06 (m, 2H), 3.94 (d, J = 7.6Hz, 3H), 3.20–
2.72 (m, 1H), 2.61 (q, J = 7.0Hz, 2H), 2.24–2.13 (m, 2H), 1.87–1.65 (m, 1H),
1.53–1.32 (m, 14H), 0.92–0.73 (m, 6H); 13C NMR (CDCl3, 101MHz)
13 δ 178.1,
178.1, 153.9/153.8, 146.8, 141.8/141.0, 135.6, 110.2/109.8, 109.1/109.0, 81.7,
68.2/68.1, 58.5, 56.5/56.3, 51.1, 43.1/42.8, 30.4/30.4, 28.2, 28.1, 25.2/24.9,
24.2/24.2, 23.2/22.9, 22.5/22.4; IR (neat) cm−1: 2975, 2933, 2874, 1722, 1514,
1334, 1268, 1212, 1147, 1052; HRMS (ESI) calcd for C23H37N2O8
+ [M+H]+
469.2544, found 469.2548.
Ala photolabile linker 2.35b. Ala photolabile linker intermediate 2.33b
(0.627 g, 1.38mmol) was dissolved in THF (13.8mL) and water (2mL). Then
1M LiOH (aq) (2.75mL, 2.75mmol) was added and the reaction mixture was
stirred at rt for 26 h whereupon 1M HCl (aq) (3.81mL) and water (40mL)
were added. The resulting mixture was extracted with EtOAc (3 × 50 mL).
The combined organic phases were washed with brine (50 mL), dried over
Na2SO4 and the solvent was removed in vacuo to give the title compound
as a yellow amorphous solid (0.497 g, 85%). 1H NMR (CDCl3, 400MHz) δ
7.53–7.29 (m, 2H), 4.66–4.46 (m, 1H), 4.17–4.04 (m, 2H), 3.95 (s, 3H), 3.21–
2.81 (m, 1H), 2.64–2.57 (m, 2H), 2.24–2.13 (m, 2H), 1.55–1.28 (m, 12H),
1.28–1.16 (m, 3H); 13C NMR (CDCl3, 101 MHz)
14 δ 178.1, 178.1, 154.0,
146.8, 141.8/141.2, 135.3, 109.8, 109.2/109.1, 81.8/81.6, 68.2, 56.5, 55.3/55.0,
51.4/50.7, 30.4/30.4, 28.1/28.1, 24.3/23.4, 24.2, 19.5/18.6; IR (neat) cm−1:
2975, 2932, 2873, 1722, 1514, 1368, 1334, 1212, 1147, 1052; HRMS (ESI)
calcd for C20H31N2O8
+ [M+H]+ 427.2075, found 427.2071.
Phe photolabile linker 2.35c. Phe photolabile linker intermediate
2.33c (0.353 g, 0.665mmol) was dissolved in THF (6.7mL) and water (1mL).
Then 1M LiOH (aq) (1.35mL, 1.35mmol) was added and the reaction mixture
was stirred at rt for 26h whereupon 1M HCl (aq) (1.93mL) and water (20mL)
were added. The resulting mixture was extracted with EtOAc (3×20mL). The
combined organic phases were washed with brine (20mL), dried over Na2SO4
and the solvent was removed in vacuo to give the title compound as a yellow
amorphous solid (0.333 g, quant.). 1H NMR (CDCl3, 400MHz) δ 7.47–7.10
(m, 7H), 4.60–4.44 (m, 1H), 4.21–4.00 (m, 2H), 3.95–3.52 (m, 3H), 3.46–2.99
(m, 1H), 2.99–2.65 (m, 2H), 2.61 (t, J = 7.2Hz, 2H), 2.18 (p, J = 6.7Hz, 2H),
1.42–1.24 (m, 12H); 13C NMR (CDCl3, 101MHz)
15 δ 178.1, 178.0, 154.0/153.9,
146.8/146.7, 141.6/141.1, 137.9, 135.3, 129.7/129.5, 128.5/128.3, 126.9/126.6,
13Due to the presence of diastereomers some carbon signals were present twice.
14Due to the presence of diastereomers some carbon signals were present twice.
15Due to the presence of diastereomers most carbon signals were present twice.
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110.2/109.7, 109.2/109.0, 82.04, 68.2/68.1, 61.5/61.1, 56.5/56.3, 51.4/51.1,
40.0/39.3, 30.4/30.3, 28.1/28.0, 24.58, 24.16; IR (neat) cm−1: 2973, 2932,
1719, 1514, 1334, 1268, 1211, 1149, 1056; HRMS (ESI) calcd for C26H35N2O8
+
[M+H]+ 503.2388, found 503.2388.
2.7.3 Synthesis of DOX ester building block 2.48
FmocDOX 2.46. DOX · HCl 2.45 (0.101 g, 0.174 mmol) was dissolved in
H2O (1 mL) and dioxane (0.6 mL) and then NaHCO3 (0.058 g, 0.69 mmol)
was added. FmocCl (0.045 g, 0.17mmol) was added dropwise as a solution in
dioxane (0.4mL). The reaction mixture was stirred at rt for 22 h whereupon
0.2% TFA (aq) (20mL) was added and the resulting mixture was put in the
fridge for 10 min. The reaction mixture was then filtered and the solid was
washed with 0.2% TFA and then Et2O to give the title compound as red
amorphous solid (0.131 g, quant.). 1H NMR (DMSO, 500 MHz) δ 14.05 (s,
1H), 13.28 (s, 1H), 7.94–7.89 (m, 2H), 7.88–7.83 (m, 2H), 7.70–7.63 (m, 3H),
7.42–7.34 (m, 2H), 7.33–7.26 (m, 3H), 6.97 (d, J = 7.9 Hz, 1H), 5.45 (s, 1H),
5.25–5.20 (m, 1H), 4.99–4.91 (m, 1H), 4.75–4.68 (m, 1H), 4.63–4.59 (m, 1H),
4.56 (s, 2H), 4.28–4.20 (m, 2H), 4.19–4.12 (m, 3H), 3.99 (s, 3H), 3.77–3.67
(m, 1H), 3.48–3.40 (m, 1H), 3.03–2.93 (m, 2H), 2.23–2.11 (m, 2H), 1.91–1.81
(m, 1H), 1.53–1.45 (m, 1H), 1.13 (d, J = 6.4 Hz, 3H); 13C NMR (DMSO,
125MHz) δ 212.3, 186.7, 186.6, 159.4, 154.8, 154.0, 153.1, 142.4, 139.3, 135.0,
134.1, 133.2, 132.5, 126.2, 125.6, 123.9, 118.9, 118.6, 118.4, 117.7, 109.4, 109.2,
99.2, 73.5, 68.7, 66.7, 64.5, 64.0, 62.0, 55.1, 45.8, 44.9, 35.2, 30.7, 28.3, 15.5; IR
(neat) cm−1: 3435, 2935, 1716, 1615, 1578, 1409, 1283, 1207, 1118, 1075, 1015,
983, 760, 739; HRMS (ESI) calcd for C42H39NNaO13
+ [M+Na]+ 788.2314,
found 788.2313.
DOX ester building block intermediate 2.47. FmocDOX 2.46 (0.822g,
1.07mmol) was dissolved in CH2Cl2 (280mL) and then 2,4,6-collidine (1.66mL,
12.6mmol) was added. The reaction mixture was cooled to −78 ◦C and then a
solution of methyl glutaryl chloride (1.440g, 8.749mmol) in CH2Cl2 (13.9mL)
was added dropwise. The reaction was stirred at −78◦C for 90min whereupon
the reaction mixture was concentrated in vacuo and then co-evaporated with
EtOH (2 × 400 mL). 2% TFA (aq) (280 mL) was added and the resulting
mixture was put in the fridge for 15min. The reaction mixture was then fil-
tered and the solid was washed with cold heptane. The solid was dissolved in
CH2Cl2 (350mL), concentrated in vacuo and then co-evaporated with EtOH
(450mL) to give the title compound as red amorphous solid (0.937 g, quant.).
1H NMR (DMSO, 500MHz) δ 14.03 (s, 1H), 13.26 (s, 1H), 7.94–7.87 (m, 2H),
7.87–7.80 (m, 2H), 7.70–7.62 (m, 3H), 7.42–7.34 (m, 2H), 7.32–7.26 (m, 2H),
6.97 (d, J = 7.8 Hz, 1H), 5.62 (s, 1H), 5.28–5.13 (m, 3H), 4.97–4.91 (m, 1H),
4.71 (s, 1H), 4.26–4.19 (m, 2H), 4.18–4.13 (m, 2H), 3.98 (s, 3H), 3.77–3.71 (m,
1H), 3.59 (s, 3H), 3.47–3.41 (m, 1H), 3.09–2.86 (m, 2H), 2.48–2.38 (m, 4H),
2.36–2.00 (m, 2H), 1.83–1.78 (m, 2H), 1.93–1.46 (m, 2H), 1.14 (d, J = 5.9 Hz,
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3H); 13C NMR (DMSO, 125MHz)16 δ 207.7, 186.3, 172.7, 171.7, 160.5, 155.8,
155.1, 154.2, 143.6, 140.4, 136.5, 135.1, 134.5, 133.5, 127.8, 127.2, 125.5, 120.1,
119.8, 119.1, 118.8, 110.5, 110.4, 100.7, 75.1, 69.9, 68.1, 66.5, 65.9, 65.4, 56.4,
51.0, 47.0, 46.4, 36.1, 32.0, 32.0, 31.5, 29.7, 19.5, 16.6; IR (neat) cm−1: 3434,
2945, 1727, 1615, 1578, 1409, 1283, 1205, 1117, 1068, 1012, 982, 761, 739;
HRMS (ESI) calcd for C48H47NNaO16
+ [M+Na]+ 916.2787, found 916.2784.
DOX ester building block 2.48. DOX ester building block intermediate
2.47 (0.937g, 1.05mmol) was dissolved in acetone (125mL) and buffer (0.1M
KH2PO4/0.1M NaOH, 20mL) was added. Novozyme 435 beads were added
and the resulting mixture was shaken gently at rt for 9 days. Then EtOAc
(1 L) was added and the resulting mixture was filtered. The solution was
then washed with 2% TFA (aq) (500mL) and water (9× 500mL), dried over
MgSO4 and the solvent was removed in vacuo to give the title compound
as a red amorphous solid (0.9407 g, quant). 1H NMR (DMSO, 500 MHz)
δ 14.03 (s, 1H), 13.26 (s, 1H), 12.09 (s, 1H), 7.93–7.88 (m, 2H), 7.88–7.83
(m, 2H), 7.70–7.62 (m, 3H), 7.42–7.35 (m, 2H), 7.33–7.27 (m, 2H), 6.97 (d,
J = 8.0 Hz, 1H), 5.61 (s, 1H), 5.27–5.13 (m, 3H), 4.98–4.91 (m, 1H), 4.71 (d,
J = 5.5Hz, 1H), 4.27–4.19 (m, 2H), 4.18–4.13 (m, 2H), 3.98 (s, 3H), 3.73–3.66
(m, 1H), 3.48–3.43 (m, 1H), 3.09–2.85 (m, 2H), 2.44 (t, J = 7.1 Hz, 2H),
2.31 (t, J = 7.2 Hz, 2H), 2.24–1.96 (m, 2H), 1.83–1.74 (m, 2H), 1.93–1.45
(m, 2H), 1.14 (d, J = 6.2 Hz, 3H); 13C NMR (DMSO, 125MHz)17 δ 207.2,
185.9, 173.4, 171.4, 160.1, 155.4, 154.6, 153.8, 143.2, 140.0, 135.7, 134.8, 134.0,
133.1, 126.7, 126.3, 124.7, 119.5, 119.5, 118.9, 118.3, 110.1, 109.9, 100.1, 74.7,
69.7, 67.7, 65.9, 65.6, 65.2, 56.2, 46.9, 46.3, 35.9, 32.1, 32.0, 31.5, 29.6, 19.6,
16.7; IR (neat) cm−1: 3400, 2935, 1721, 1615, 1578, 1409, 1282, 1206, 1116,
1069, 1014, 982, 760, 739; HRMS (ESI) calcd for C47H45NNaO16
+ [M+Na]+
902.2631, found 902.2622.
2.7.4 Solid-phase synthesis
General solid-phase procedures
Prior to usage, the amino-functionalized PEGA800 resin was washed with H2O
(×6), EtOH (×6), DMF (×6), MeOH (×6) and CH2Cl2 (×6) before being
lyophilized.
MSNT coupling. Acid (3 equiv) was dissolved in CH2Cl2 at rt, then
MeIm (2.25 equiv) and MSNT (3 equiv) were added. After 5min. the mixture
was added to the resin and the mixture was occasionally stirred over the next
1 h. The resin was then washed with CH2Cl2 (×1), DMF (×1) and CH2Cl2
(×1) and the coupling was repeated once whereupon the resin was washed
16Signal from one of the carbonyl carbons in the anthracycline ring system could not be
observed.
17Signal from one of the carbonyl carbons in the anthracycline ring system could not be
observed.
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with CH2Cl2 (×6), DMF (×6), CH2Cl2 (×6), DMF (×6) and CH2Cl2 (×6)
before being lyophilized.
TBTU coupling. Acid (3 equiv) was dissolved in DMF at rt and then
NEM (4 equiv) and TBTU (2.9 equiv) were added. After 5min. the mixture
was added to the resin and the mixture was occasionally stirred over 2h. The
resin was then washed with DMF (×6), CH2Cl2 (×6), DMF (×6) and CH2Cl2
(×6) before being lyophilized.
HATU coupling. Acid (3 equiv) was dissolved in DMF at rt and then
DIPEA (5 equiv) and HATU (2.9 equiv) were added. After 5min. the mixture
was added to the resin and the mixture was occasionally stirred over 2h. The
resin was then washed with DMF (×6), CH2Cl2 (×6), DMF (×6) and CH2Cl2
(×6) before being lyophilized.
BTC coupling. Acid (5 equiv) was dissolved in THF at rt and then BTC
(1.65 equiv) was added followed by slow addition of 2,4,6-collidine (14 equiv).
After 1min. the mixture was added to the resin and the mixture was heated
to 50 ◦C and shaken for 1 h. The resin was the washed with DMF (×6),
CH2Cl2 (×6), DMF (×6) and CH2Cl2 (×6) and the coupling was repeated
once whereupon the resin was washed with THF (×6), DMF (×6), CH2Cl2
(×6), DMF (×6) and CH2Cl2 (×6) before being lyophilized.
20% Fmoc deprotection. The resin was swelled in 20 (v/v)% piperidine
in DMF for 2min. and then washed with DMF (×6). Then the resin was again
swelled in 20 (v/v)% piperidine in DMF for 18min. whereupon the resin was
washed with DMF (×6), CH2Cl2 (×6), DMF (×6) and CH2Cl2 (×6).
0.5% Fmoc deprotection. The resin was swelled in 0.5(v/v)% piperidine
in DMF for 45min.. The resin was then washed with DMF (×6), CH2Cl2 (×6),
DMF (×6) and CH2Cl2 (×6). For difficult deprotections the procedure was
repeated once or twice.
tBu deprotection. The resin was swelled in CH2Cl2:TFA (1:1) and the
mixture was occasionally stirred over 2 h. The resin was then washed with
CH2Cl2 (×6), DMF (×6), CH2Cl2 (×6), DMF (×6) and CH2Cl2 (×6).
Release from HMBA linker. 5–10mg of resin was treated with 0.1M
NaOH (aq) for 2 h followed by neutralization with 0.1M HCl (aq).
Photolytic release. 10–20 mg of resin was swelled in DMF in a petri
dish with a custom-made quartz cover and irradiated at 365 nm for 1–2 h.
DOX derivatives
Cf. appendix A for RP-HPLC-UV chromatograms of these products.
Gly-DOX 2.32. Prepared according to the general solid-phase proce-
dures followed by photolytic release. RP-HPLC purity: 87%, Rt = 5.38min.;
HRMS (ESI) calcd for C29H33N2O12
+ [M+Na]+ 601.2033, found 601.2029.
Leu-DOX 2.38a. Prepared according to the general solid-phase proce-
dures followed by photolytic release. RP-HPLC purity: >95%, Rt = 5.65min.;
HRMS (ESI) calcd for C33H41N2O12
+ [M+Na]+ 657.2659, found 657.2655.
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Ala-DOX 2.38b. Prepared according to the general solid-phase proce-
dures followed by photolytic release. RP-HPLC purity: 94%, Rt = 5.75min.;
HRMS (ESI) calcd for C30H35N2O12
+ [M+Na]+ 615.2190, found 615.2184.
Phe-DOX 2.38c. Prepared according to the general solid-phase proce-
dures followed by photolytic release. RP-HPLC purity: 93%, Rt = 5.78min.;
HRMS (ESI) calcd for C36H39N2O12
+ [M+Na]+ 691.2503, found 691.2499.
Ala-Gly-Gly-DOX tripeptide 2.43. Prepared according to the gen-
eral solid-phase procedures followed by photolytic release. RP-HPLC purity:
>95%, Rt = 5.71 min.; HRMS (ESI) calcd for C34H41N4O14
+ [M+Na]+
729.2619, found 729.2613.
DOX amide 2.51. Prepared according to the general solid-phase proce-
dures followed by photolytic release. RP-HPLC purity: 64%, Rt = 8.12min.;
MS (ESI) calcd for C32H37N2O13
+ [M+H]+ 657.2, found 657.5.
Ala-Dox amide 2.52. Prepared according to the general solid-phase pro-
cedures followed by photolytic release. RP-HPLC purity: 70%, Rt = 7.80min.;
MS (ESI) calcd for C50H52N3O16
+ [M+H]+ 950.3, found 950.4.
DOX dipeptide 2.55. Prepared according to the general solid-phase pro-
cedures followed by photolytic release. RP-HPLC purity: 48%, Rt = 8.00min.;
MS (ESI) calcd for C79H103N10O25
+ [M+H]+ 1591.7, found 1591.7.
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Chapter 3
Total Synthesis of
Trioxacarcin DC-45-A2
The stereoselective synthesis of biologically active natural products via total
synthesis provides a unique opportunity to access structural analogs and, in
some cases, provides a more efficient access to large quantities of the natural
product, both of which are crucial in drug discovery efforts. It furthermore
serves as the true test of power for existing synthetic methodologies and is thus
the driving force for refinement of existing synthetic methods and the discovery
of new chemical reactivity. It also provides final proof and confirmation of the
structure of complex natural products or, in many cases, results in revision
and discovery of the true structure [144].
In the following the work performed during a research stay in the group
of Professor K.C. Nicolaou at Rice University on the total synthesis of triox-
acarcin DC-45-A2 will be described.1
3.1 The Trioxacarcin Class of Antitumor
Antibiotics
The trioxacarcins are a class of antitumor antibiotics isolated from various
Streptomyces strains in 1981 and 2004 [146–148]. Several members of the class
inhibit different cancer cell lines and furthermore show antibacterial proper-
ties.
Naturally occurring trioxacarcins share the structural core DC-45-A2 3.1
and obtain their structural diversity mainly by glycosylation with various
1The work described in this chapter contributed to the completion and publication of
the total synthesis of trioxacarcin DC-45-A2 [145].
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saccharides on two of the hydroxy functionalities, exemplified by trioxacarcin
A 3.2, cf. figure 3.1.
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Figure 3.1: The molecular structure of trioxacarcin DC-45-A2 3.1, trioxacarcin A
3.2, gutingimycin 3.3 and the monoglycosylated trioxacarcin DC-45-A1 3.4.
The mode of action of the trioxacarcins is believed to be alkylation of DNA
by attack of a guanosine residue on the trioxacarcin spiro epoxide. For triox-
acarcin A 3.2 this has been supported by a crystal structure of the natural
product covalently bound to DNA [149] and furthermore by isolation of the
trioxcarcin A guanine conjugate gutingimycin 3.3 [150]. It is furthermore be-
lieved that the planar trioxacarcin ring system can intercalate DNA analogous
to the anthracycline cancer drugs, e.g. doxorubicin [150], cf. chapter 2.
The first total synthesis of trioxacarcin DC-45-A2 3.1 was published by
Andrew Myers in 2011 [151]. Myers furthermore published routes to the
monosaccharides trioxacarcinoside A [152] and B [153] and these efforts ulti-
mately led to the total synthesis of trioxacarcin A 3.2 [154]. Myers’ synthesis
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commenced with a Hauser-Kraus annulation [155–157] of advanced building
blocks 3.5 and 3.6, cf. scheme 3.1. A few chemical manipulations followed to
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Scheme 3.1: Myers’ total synthesis of trioxacarcin DC-45-A2 3.1.
give aldehyde 3.8 set up for the key step; a rhodium-mediated 1,3-dipolar cy-
cloaddition employing diazo ketone 3.9 leading to the bicyclic polyoxygenated
system present in 3.10 which after a final series of deprotections was trans-
formed to trioxacarcin DC-45-A2 3.1. Even though Myers’ total synthesis
is highly convergent, the key step was hampered by low diastereoselectivity
leading to a mixture of diastereomers comprised of all four possible outcomes
so difficult to separate that it was subjected to the next step without purifi-
cation. This resulted in a low yield of 26% of the wanted diastereomer and
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thus led to the loss of valuable late-stage material.
With room for improvement evident, the group of K. C. Nicolaou com-
menced an effort to develop an enantioselective route to trioxacarcin DC-45-A2
3.1 with an improved strategy for the construction of the tricyclic polyoxy-
genated system based on a stereo- and regioselective epoxide rearrangement,
cf. scheme 3.2. For the synthetic plan to succeed, large amounts of the cyclo-
Me
OMe
O
Si
O
tBu tBu
O
OTBS
OPMB
O
OTES
MeO
OMe
O
Me
OMe
OHO O
OH
OH
O
OH
O
MeO
MeO
O
Me
OMe
O
Si
O
tBu tBu
O
OTBS
OPMB
OH
O
Me
OMe
O
Si
O
tBu tBu
O
OTBS
OPMB
Me
OMe
O
Si
O
tBu tBu
O
OTBS
OPMB
OH
Me
OMe
O
Si
O
tBu tBu
O
OTBS
OPMB
Me
MOMO
O
O
CNO
OTBS
OPMB
+
O
O
MeO
OMe
OTES
Me
OMe
O
Si
O
tBu tBu
O
OTBS
OPMB
O
O
DC-45-A2 (3.1)3.17
3.15 3.16
3.13 3.14
3.6 3.123.5
Scheme 3.2: Synthetic strategy for the synthesis of trioxacarcin DC-45-A2 3.1 by
the Nicolaou group.
hexenone 3.5 were needed. A new route for this building block had just been
developed in the Nicolaou group and one of the goals of the project described
herein was the optimization and scale-up of this route. Furthermore, the al-
lylic oxidation of 3.12 to 3.13 gave low yields due to poor chemoselectivity
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resulting in oxidation of the benzylic methyl group when subjected to com-
mon allylic oxidation methods. Thus another goal was to find an alternative
way of installing the allylic hydroxy group possibly before the Hauser-Kraus
annulation. For this purpose the intermediates on the way to cyanophthalide
3.6 would likely prove interesting and as 3.6 was furthermore needed to fuel
front-line investigations of the key step, large amounts of this building block
was likewise needed.
3.2 Optimization and Scale-up of New Route to
Cyclohexenone 3.5
Before the K. C. Nicolaou group started their investigation into an optimized
route for cyclohexenone 3.5 four routes were already known. Myers’ group had
developed three distinct routes as part of their trioxacarcin program [151,158]
and Ueda had published a fourth route in connection with development of new
fluorescence-labelled probes [159,160].
3.2.1 Literature reports on synthetic routes to
cyclohexenone 3.5
Myers’ first (and preferred) route started from l-malic acid 3.18 [151], cf.
scheme 3.3. A four step procedure, known from the literature [161,162], led to
lactone 3.21, which after Weinreb amide formation, oxidation, chemoselective
vinyl addition and PMB-protection was converted to the Weinreb amide 3.23.
Final addition of another vinyl group and following RCM gave cyclohexenone
3.5 in an overall yield of 19% over 10 steps [151]. 1.3g was produced whereby
the route seemed to be somewhat scalable, but was, with 10 steps, rather
lengthy.
The second route from the Myers group commenced from TBS-protected
resorcinol2 3.25 [151], cf. scheme 3.4, which was transformed into trans-diol
3.27 in three steps by a known procedure [163]. DMP oxidation followed by
elimination led to cyclohexenone 3.28, which after a protection group shuﬄe
comprising a low yielding mono TBS deprotection and a subsequent PMB
protection provided cyclohexenone 3.5 in an overall yield of 12% over seven
steps [151]. However, only 0.3 g of cyclohexenone 3.5 was produced calling
into question the scalability of the route.
The last route published by Myers started from quinic acid 3.30 [158],
cf. scheme 3.5, and was then transformed to PMB-protected cyclohexenone
3.37 in seven steps by a previously reported procedure [164, 165]. Silyl enol
ether formation followed by a Rubottom oxidation [166] led to the hydroxy
2It is not stated in the references cited in Myers’ paper whether TBS-protected resorcinol
3.25 was prepared in their lab or acquired from commercial sources. It appears to be very
expensive to obtain commercially in the amounts used.
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Scheme 3.3: Myers’ route to cyclohexenone 3.5 starting from l-malic acid 3.18.
ketone 3.39, which after a final TBS-protection provided cyclohexenone 3.5
in an overall yield of 6% over 10 steps [158]. In addition to being rather low
yielding and lengthy, the route was only reported in a very small scale (30mg
of product).
The fourth route was published by the group of Minuro Ueda as part of
investigations into new fluorescence-labelled probes [159,160]. The route com-
menced from d-glucose 3.40, which was transformed into iodide 3.44 by an
eight step procedure [159], cf. scheme 3.6. A TBS-protection followed by
an elimination afforded alkene 3.45. A Ferrier carbocyclization [167], with
simultaneous demethylation of the methoxy group, followed by a final elim-
ination step provided cyclohexenone 3.5 in an overall yield of 14% over 12
steps [160]. Even though the overall yield was satisfactory the route was very
lengthy (12 steps) and only a very small amount of product was synthesized
(5.5mg) seriously calling into question the scalability of the route.
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Scheme 3.4: Myers’ route to cyclohexenone 3.5 starting from TBS-protected resor-
cinol 3.25.
As none of the previous routes to cyclohexenone 3.5 seemed optimal and
furthermore had not been reported in a large scale the Nicolaou group set out
to develop an improved, scalable synthetic strategy.
3.2.2 New route to cyclohexenone 3.5
The new route developed in the Nicolaou group3 relied upon access to allylic
alcohol 3.51 as reported by the O’Brien group [168, 169]. The route started
from 1,4-cyclohexadiene 3.46, which was converted into the meso-diol 3.47 by
the Upjohn method (OsO4/NMO) [170,171] in a yield of 50%, cf. scheme 3.7.
The O’Brien group used modified Woodward conditions (KIO3, I2, KOAc)
[172], however, the basic Amberlite resin used for the acetate hydrolysis was
not available in the Nicolaou lab so an alternate method was used. The
next step was a double TBS-protection leading to the bis-TBS ether 3.48 in
an excellent yield of 93%. Bis-TBS ether 3.48 was then diastereoselectively
epoxidized with mCPBA. O’Brien reported that the use of cyclohexane as
solvent was crucial for the facial selectivity [169] and these conditions led to
the formation of the wanted trans-epoxide 3.49 in a good yield of 89%. The
3This route was developed by former visiting PhD student Mette Terp Petersen.
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Scheme 3.5: Myers’ route to cyclohexenone 3.5 starting from quinic acid 3.30.
68
New route to cyclohexenone 3.5
O
OH
OH
HO
OH
OH
1. AcCl
2. PhCH(OMe)2,
   TsOH
O
OH
O
MeO
OH
O Ph
3.41
49% (2 steps)
3.40
1.  N-tosylimidazole,
   NaH
2. NaH
O
O
MeO
O Ph
O
3.42
66% (2 steps)
O
O
MeO
O Ph
OPMB
1. LiAlH4
2. PMBCl,
   NaH
3.43
80% (2 steps)
O
OH
MeO
I
OPMB
1. AcOH⋅H2O
2. I2, PPh3,
   imidazole
3.44
80% (2 steps)
O
OTBS
MeO
OPMB
1. TBSOTf, 
   2,6-lutidine
2. tBuOK
3.45
94% (2 steps)
O
OTBS
OPMB
1. cat. Hg(OCOCF3)2
2. MsCl, Et3N
3.5
70% (2 steps)
12 steps
14% overall
yield
Scheme 3.6: Ueda’s route to cyclohexenone 3.5 starting from d-glucose 3.40.
69
Chapter 3. Total Synthesis of Trioxacarcin DC-45-A2
acetone, rt, 67 h
25 g scale
OsO4 (0.02 equiv),
NMO⋅H2O (1 equiv)
TBSCl (3 equiv),
imidazole (5 equiv)
OH
OH
OTBS
OTBS
CH2Cl2, rt, 2 days
6 g scale
3.47
50%
3.48
93%
3.46
mCPBA (1.7 equiv),
NaHCO3 (2 equiv)
OTBS
OTBS
O
cyclohexane, rt, 17 h
17 g scale
nBuLi (2 equiv),
amine 3.50 (2 equiv)
OTBS
OTBS
OH
THF, −10 °C to rt, 18 h
14 g scale
3.49
89%
3.51
94%, 80% ee
1. PMBTCA (2.5 equiv), 
   TrBF4 (0.05 equiv),
   THF, rt, 1 h
OH
OH
OPMB
TEMPO (3 equiv),
pTsOH⋅H2O (3 equiv)
CH2Cl2, 0 °C, 45 min.
6 g scale
O
OH
OPMB
TBSCl (1.8 equiv), 
imidazole (3 equiv)
O
OPMB
OTBS
CH2Cl2, rt
4 g scale
Ph
N
NHMe
Me
amine 3.50
2. TBAF (7 equiv),
   THF, reflux, 4 h
17 g scale
3.52
84% (2 steps)
3.39
74%
3.5
33%
Scheme 3.7: The new route developed in the K. C. Nicolaou lab for the synthesis
of cyclohexenone 3.5.
following enantioselective epoxide rearrangement was mediated by the (+)-
norephedrine derived chiral amine 3.50 and provided allylic alcohol 3.51 in a
high yield of 94%. The enantioselectivity was however significantly lower than
what was originally reported by O’Brien (80% ee vs. 94% ee) leaving room
for optimization. The next step was a one-pot PMB-protection, effected by
PMBTCA and catalytic TrBF4, and double TBS-deprotection with TBAF.
Initially, a two step procedure was attempted but the intermediate PMB-
protected bis-TBS ether was very difficult to purify due to the presence of
several decomposition products from the PMBTCA. Deprotection of the two
TBS-protected alcohols significantly changed the polarity of the product and
thus greatly eased the purification resulting in isolation of the PMB-protected
diol 3.52 in a good yield of 84%. The PMB-protected diol 3.52 was then
subjected to allylic oxidation effected by TEMPO and pTsOH [173] leading
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to the hydroxy ketone 3.39 in a good yield of 84%. The final TBS-protection
however proceeded in disappointingly low yields and only provided the desired
cyclohexenone 3.5 in a yield of 33% on a 4 g scale again leaving room for
optimization.
The newly developed route to cyclohexenone 3.5 seemed very promising
but the scalability still needed to be tested and the enantioselective epoxide
rearrangement and final TBS-protection to be optimized. The dihydroxylation
of 1,4-cyclohexadiene 3.46 under Upjohn conditions could be run on a 51 g
scale without the yield dropping and actually provided diol 3.47 in a slightly
higher yield of 61% on this scale, cf. scheme 3.8. The double TBS-protection of
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Scheme 3.8: Optimized conditions for the new route developed in the K. C. Nicolaou
lab for the synthesis of cyclohexenone 3.5.
diol 3.47 on a 16g scale (approx. three times the original scale) was associated
with a slightly lower yield of 73%. This could, however, also be caused by a
slightly higher amount of impurities left over from the dihydroxylation step
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as the combined yield over the first two steps was comparable with what
had originally been observed in the Nicolaou group (45% vs. 47%). The
diastereoselective epoxidation effected bymCPBA could be run on a 34g scale,
without decrease of either diastereoselectivity or yield, resulting in formation
of epoxide 3.49 in a yield of 85% and thus confirming the scalability of the
first three steps of the route.
The enantioselectivity of the epoxide rearrangement, leading to allylic al-
cohol 3.51, as reported by O’Brien had been difficult to reproduce, so an
investigation into this step was needed. It was found that a very high purity
of the (+)-norephedrine derived chiral amine 3.50 was paramount for a high
ee and extensive and tedious purification was necessary.4 It was furthermore
found that the scale of the reaction impacted the ee, cf. table 3.1. The yields
Table 3.1: Scale dependence of the enantioselectivity in the epoxide rearrangement
of epoxide 3.49.
OTBS
OTBS
O
nBuLi (2 equiv),
amine 3.50 (2 equiv)
OTBS
OTBS
OH
THF, −10 °C to rt
3.49 3.51
Entry Scale Yield (%)a, b ee (%)b
1 3.8 g 95 89
2 5.4 g 95 88
3 7.0 g 92 85
a Isolated yield after flash column chromatography.
b Average of at least two reactions.
remained consistently high, but the ee decreased as the scale increased with
the highest ee of 89% being obtained on a 3.8 g scale (entry 1). The reaction
could however be run in several flasks simultaneously, and the reaction mix-
tures could be combined and worked-up together thus easing the throughput
of material.
The one-pot PMB-protection/double TBS-deprotection was found to give
a slightly higher yield at a scale a little smaller than originally reported in the
Nicolaou group with reaction on a 13 g scale resulting in a high yield of 96%
of PMB-protected diol 3.52 vs. the original 84% on a 17 g scale. The allylic
oxidation leading to hydroxy ketone 3.39 was found to proceed in slightly
lower yields on a larger scale with reaction on a 15 g scale (approx. three
times the scale originally reported) proceeding with a yield of 64%.
4Usually 4–5 successive distillations of the (+)-norephedrine derived chiral amine 3.50
was necessary.
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The final TBS-protection had been found to proceed in low yields under
the conditions originally used by the Nicolaou group. Reproduction of these
results with CH2Cl2 as the solvent confirmed this and led to yields around
50% at the most. It was however found that a change of solvent to DMF
and performing the chromatographic purification as fast as possible greatly
increased the yield leading to formation of the desired cyclohexenone building
block 3.5 in a yield of 85% on a 9 g scale. Thus the synthesis was completed
in an overall yield of 19% over seven steps and provided 11.6 g of product.
The optimized route to cyclohexenone 3.5, proceeding in an overall yield
of 19% in only seven steps and with 11.6 g of product produced was thus
superior to the existing routes with regard to overall yield, step count and
scalability, cf. table 3.2.
Table 3.2: Comparison of different routes to cyclohexenone 3.5.
Route Starting material No. of steps Scalea Overall yield
Myers 1 l-malic acid 10 1.3 g 19%
Myers 2 TBS-protected resorcinol 7 0.3 g 12%
Myers 3 quinic acid 10 30mg 6%
Ueda d-glucose 12 5.5mg 14%
Nicolaou 1,4-cyclohexadiene 7 11.6 g 19%
a Amount of cyclohexenone 3.5 produced.
3.3 Scale-Up of Cyanophthalide Building Block 3.6
The cyanophthalide building block 3.6 was needed for further investigations
into the key step leading to the bicyclic polyoxygenated system present in
3.17, cf. scheme 3.2. Furthermore, several intermediates on the way to 3.6
could possibly prove useful for later investigations into the installation of the
allylic alcohol in 3.13 before the Hauser-Kraus annulation.
The route to cyanophthalide 3.6 was reproduced in large scale according to
the literature procedure [151]. Thus 4-methylsalicylic acid 3.53 was subjected
to MeI on a 74g scale leading to ester 3.54, cf. scheme 3.9. Substitution with
AllBr and subsequent amidation through activation with Al(Me)3 and reac-
tion with Et2NH provided amide 3.56, which was subjected to a neat Claisen
rearrangement [174] leading to terminal olefin 3.57, which after isomerization
of the double bond provided phenol 3.58 in a yield of 66% over five steps
without purification of intermediates. A MOM-protection on a 65 g scale fol-
lowed affording the MOM ether 3.59 in a quantitative yield. The subsequent
ortho-lithiation was performed on a smaller scale of 23 g due to safety consid-
erations and provided aldehyde 3.60 in a yield of 91% upon quenching with
DMF. Finally, treating the aldehyde 3.60 with TMSCN, catalytic amounts of
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Scheme 3.9: Scale-up of cyanophthalide building block 3.6.
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KCN and 18-crown-6, on a 23g scale, followed by exposure to AcOH provided
cyanophthalide 3.6 in a yield of 76%.
3.4 Development of Route to TBS Ether
Cyanophthalide Building Block 3.61
Due to low yields in the allylic oxidation of 3.12, cf. scheme 3.2, primarily
caused by low chemoselectivity resulting in oxidation of the benzylic methyl
group when subjected to common allylic oxidation methods, investigations
into a new strategy where the allylic alcohol was installed before the Hauser-
Kraus was commenced, cf. scheme 3.10. Thus, a strategy for the synthesis of
TBS ether cyanophthalide 3.61 was needed.
Me
OMe
O
Si
O
tBu tBu
O
OTBS
OPMB
OH Me
MOMO
O
O
CNO
OTBS
OPMB
+
TBSO
3.13 3.5 3.61
Scheme 3.10: Retrosynthetic analysis for the the Hauser-Kraus annulation of allylic
alcohol 3.13.
3.4.1 Attempts at synthesis of TBS ether cyanophthalide
3.61 via an isomerization/oxidation approach
The first attempted strategy relied on a isomerization/oxidation strategy in-
spired by a recent paper by the Jiang group, where they report the palladium-
catalyzed transformation of terminal olefins into allylic aldehydes [175]. Thus
phenol 3.57 was MOM-protected in a yield of 94%, cf. scheme 3.11. With
MOMO
Me
NEt2
OOH
Me
NEt2
O
MOMCl (2.5 equiv),
DIPEA (3.5 equiv)
CH2Cl2, rt, 74 h
3.62
94%
3.57
Scheme 3.11: MOM-protection of phenol 3.57.
MOM ether 3.62 in hand the formation of allylic aldehyde 3.63 with DDQ,
H2O and catalytic amounts of PdCl2, as reported by Jiang, was attempted,
cf. scheme 3.12. However, neither at rt nor at 50 ◦C was the desired al-
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Scheme 3.12: Attempted isomerization/oxidation of MOM ether 3.62.
lylic aldehyde 3.63 observed. When cyanophthalide 3.6 was subjected to the
same conditions complete decomposition of starting material was observed, cf.
scheme 3.13. Upon exposure to the same conditions, MOM ether 3.59 led to
allylic alcohol 3.65, however only in a very low yield (<10%), cf. scheme 3.13.
Another report by the White group detailed the formation of allylic ac-
etates from terminal olefins effected by Pd(OAc)2 and BQ, cf. scheme 3.12.
However, none of the desired allylic acetate 3.64 was isolated. The last at-
tempt at an isomerization/oxidation was a HgO mediated installation of an
allylic alcohol.5 The allylic alcohol 3.65 was however not observed.
As no successful conditions for an oxidative installment of the allylic alco-
hol had been found this strategy was abandoned.
3.4.2 Synthesis of TBS ether cyanophthalide 3.61 via a Stille
cross-coupling approach
A new strategy comprising a Stille cross-coupling [176–178] was outlined, cf.
scheme 3.14. Thus, TBS ether cyanophthalide 3.61 would originate from
stannane 3.67 and iodocyanophthalide 3.68, which could be accessed from
cyanophthalide 3.69 by MOM-protection and iodination. Cyanophthalide
3.69 could ultimately be synthesized from 4-methylsalicylic acid 3.53 by
5These reaction conditions was based on prior experience within the group.
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Scheme 3.13: Attempted allylic oxidation of MOM ethers 3.6 and 3.59.
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Scheme 3.14: Retrosynthetic analysis for TBS ether cyanophthalide 3.61 with a
Stille cross-coupling as the key step.
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a known procedure6 [179]. In connection with an earlier synthetic strat-
egy for the total synthesis of trioxacarcin DC-45-A2 3.1 in the Nicolaou
group, the iodination had been attempted before cyanophthalide formation,
cf. scheme 3.15. However, all attempts at iodination of either ester 3.54 or
OH
Me
NMe2
O
O
OH
Me
NMe2
O
O
OH
Me
NMe2
O
O
I I
I
OH
Me
OMe
O
OH
Me
OMe
O
I
I
+
3.71 3.72 3.73
+
+
3.70 3.54
OH
Me
OMe
O
3.54
OH
Me
NMe2
O
O
3.71iodination
conditions
iodination
conditions
Scheme 3.15: Unsuccessful attempts at monoiodination of ester 3.54 and aldehyde
3.71.
aldehyde 3.71 led to inseparable mixtures of the starting materials, mono-
and diiodinated products. Thus, it was decided to install the iodide moiety
after cyanophthalide formation.
Cyanophthalide 3.69 was MOM-protected in a yield of 86%, cf. scheme 3.16.
With MOM cyanophthalide 3.74 in hand the next step was the iodination
leading to iodocyanophthalide 3.68. The desired iodocyanophthalide was not
observed when MOM cyanophthalide 3.74 was exposed to either NIS or I2,
cf. scheme 3.17. Subjection of non MOM-protected cyanophthalide 3.69 to
I2 with either NMM or DIPEA as base did not provide the desired monoiod-
inated product either, cf. scheme 3.18. Exposure of cyanophthalide 3.69 to
NIS did, however, lead to formation of monoiodinated cyanophthalide 3.75.
The purification of iodocyanophthalide 3.75 proved to be very difficult and
thus a one-pot iodination and MOM-protection procedure was employed re-
sulting in a less difficult purification, cf. scheme 3.19. The iodocyanophthalide
6Cyanophthalide 3.69 was available in the group.
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Scheme 3.16: MOM-protection of cyanophthalide 3.69.
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Scheme 3.17: Attempts at iodination of MOM cyanophthalide 3.74.
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Scheme 3.18: Attempts at iodination of cyanophthalide 3.69 with I2.
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Scheme 3.19: One-pot iodination and MOM-protection of cyanophthalide 3.69.
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3.68 was isolated in a yield of 20% over two steps with the diiodinated prod-
uct being a major side product. Due to time constraints this result was not
optimized any further.
With iodocyanophthalide 3.68 in hand all that remained for the successful
synthesis of TBS ether cyanophthalide 3.61 was the stannane 3.67 and the
final Stille cross-coupling between the two building blocks. Konoike reported
that stannane 3.67 could be accessed from TBS-protected propargyl alcohol
3.76 by hydrostannylation with AIBN and Bu3SnH in refluxing benzene for
20 min. in a yield of 85%. This result was however not reproducible, with
the reported conditions leading to a nearly inseparable mixture of the trans
and cis isomers more akin to what Corey reported when subjecting non TBS-
protected propargyl alcohol to the same conditions [180]. It was found that
prolonged reaction times favored the trans isomer and after 16 h in refluxing
benzene the stannane 3.67 was isolated in a yield of 38% with minor amounts
of the cis isomer present, cf. scheme 3.20.
TBSO SnBu3
3.67
38%, trans:cis (85:15)
HO
3.76
Bu3SnH (1.2 equiv),
AIBN (0.1 equiv)
benzene, reflux, 16 h
Scheme 3.20: Hydrostannylation of TBS-protected propargyl alcohol 3.76.
Everything was now set up for the final Stille cross-coupling leading to TBS
ether cyanophthalide 3.61. Initially, iodocyanophthalide 3.68 and stannane
3.67 was subjected to cross-coupling in toluene at rt catalyzed by Pd(PPh3)4,
cf. scheme 3.21, however, no formation of the desired product 3.61 was ob-
served. Changing the solvent to refluxing benzene did not lead to product
formation either, but the use of refluxing toluene rewardingly led to the for-
mation of the desired TBS ether cyanophthalide 3.61 in a moderate yield of
42%.7
3.5 Total Synthesis
The rest of the total synthesis was finished by the other members of the tri-
oxacarcin team in the Nicolaou lab [145]. Commencing with a Hauser-Kraus
annulation of building blocks 3.5 and 3.68 followed by methylation provided
the core structure 3.77, cf. scheme 3.22. MOM-deprotection followed by bis-
7Due to a hot plate malfunction the reaction was kept running longer than intended
and slight decomposition of the product was observed when the reaction was stopped. Thus
the yield would likely have been higher if the reaction had been stopped earlier. Since the
reaction was performed during the last days of the external stay in the Nicolaou group there
was no time left to run the reaction again.
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Scheme 3.21: Stille cross-coupling of iodocyanophthalide 3.68 and stannane 3.67.
silylation led to iodide 3.78, which was then subjected to Stille cross-coupling8
with stannane 3.68 followed by a TEMPO oxidation leading to allylic alde-
hyde 3.79. An enantioselective Jørgensen epoxidation [181], a Baylis-Hilman
reaction [182,183] and a TMS protection provided the key cyclization precur-
sor 3.82.
Everything was now set for the key epoxide rearrangement leading to the
bicyclic polyoxygenated system. Cyclization precursor 3.82 was exposed to
BF3 ·OEt2 leading to formation of the desired product in a satisfying yield of
54%, cf. scheme 3.23.
TMS deprotection followed by a three step epoxidation sequence, com-
prised of dihydroxylation, tosylation and elimination, afforded epoxide 3.84,
which after TEMPO-mediated oxidation and silyl-deprotection underwent cy-
clization to form the tricyclic polyoxygenated system in 3.11. Final removal
of the PMB and TBS protection groups provided the coveted trioxacarcin
DC-45-A2 3.1.
3.6 Conclusion
The total synthesis of trioxacarcin DC-45-A2 by the Nicolaou group employed
distinct features comprising, among others, a Stille cross-coupling, a Baylis-
8In the final total synthesis the Stille cross-coupling was performed after the Hauser-
Kraus annulation instead of before as outlined in §3.4.2.
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Scheme 3.22: Total synthesis of trioxacarcin DA-45-A2 3.1 by Nicolaou. Synthesis
of key cyclization precursor 3.82
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Scheme 3.23: Total synthesis of trioxacarcin DA-45-A2 3.1 by Nicolaou. Key step
and end game.
83
Chapter 3. Total Synthesis of Trioxacarcin DC-45-A2
Hilman reaction and an improved strategy for the formation of tricyclic poly-
oxygenated system present in trioxacarcin DC-45-A2. Myers’ key step, a
rhodium mediated 1,3-dipolar cycloaddition, featured poor diastereoselectiv-
ity and a low yield of 28% whereas the epoxide rearrangement utilized by the
Nicolaou group showed better diastereoselectivity and afforded 3.83 in a yield
of 54%.
Nicolaou’s synthesis furthermore included a new route for cyclohexenone
3.5 that, upon optimization, featured distinct and high yielding steps and
thus provided superior access to this key building block in terms of overall
yield, step count and scalability.
Overall, the synthetic strategy developed by Nicolaou was an improvement
in terms of diastereoselectivity and yield of the key step and provided improved
access to the key building block cyclohexenone 3.5 thus easing the throughput
of material.
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3.7 Experimental
3.7.1 General methods
Reagents were purchased at the highest commercial quality and used without
further purification, unless otherwise noted. All reactions were carried out un-
der an argon atmosphere with dry solvent under anhydrous conditions, unless
otherwise noted. Dry solvents were obtained by passing commercially avail-
able pre-dried, oxygen-free formulations through activated alumina columns.
Yields refer to chromatographically and spectroscopically (1H NMR) homo-
geneous material, unless otherwise stated.
Reactions were monitored by thin-layer chromatography (TLC) carried out
on 0.25mm E. Merck silica gel plates (60F254) using UV light as visualizing
agent or an aqueous solution of phosphomolybdic acid and cerium sulfate or
a basic aqueous solution of potassium permanganate and heat as developing
agents. Acros Organics silica gel (60, particle size 0.035–0.070mm) was used
for flash column chromatography.
NMR spectra were recorded on a Bruker Avance III HD 600MHz instru-
ment equipped with a 5 mm DCH cryoprobe. The chemical shifts (δ) are
reported in parts per million (ppm) and the coupling constants (J) in Hz. For
spectra recorded in DMSO-d6, signal positions were measured relative to the
signal for DMSO (δ 2.50 ppm for 1H NMR and δ 39.43 ppm for 13C NMR).
For spectra recorded in CDCl3, signal positions were measured relative to the
signal for CHCl3 (δ 7.26 ppm for
1H NMR and δ 77.0 ppm for 13C NMR).
Infrared (IR) spectra were recorded on a Perkinâˆ’Elmer 100 FT-IR spec-
trometer. High-resolution mass spectra (HRMS) were recorded on an Ion
Trap-Time of Flight Mass Spectrometer (Shimadzu, Columbia, MD) operated
with an ESI source interface and a VG ZAB-ZSE mass spectrometer using
MALDI (matrix-assisted laser-desorption ionization) or ESI (electrospray ion-
ization).
Optical rotations were recorded on a Schmidt+Haensch Polartronic M100
polarimeter at 589.44nm using 100mm cells and the solvent and concentration
indicated.
3.7.2 Synthesis of cyclohexenone building block 3.5
Diol 3.47. 1,4-cyclohexadiene 3.46 (51.18 g, 638.7 mmol) was dissolved in
acetone (1.5L) and NMO ·H2O (86.34g, 638.8mmol) and OsO4 (4% (w/v) aq.
solution, 82.0mL, 12.9mmol) were added. The reaction mixture was stirred
at rt for 24 h. Na2SO3 (50 g) and MgSO4 (200 g) was then added and the
mixture was stirred for 1 h at rt whereupon it was filtered through a short
pad of silica gel, rinsed with EtOAc and concentrated in vacuo to give the
title compound as a black solid (44.71 g, 61%). Rf = 0.22 (EtOAc); 1H NMR
(CDCl3, 600MHz) δ 5.58 (t, J = 1.8 Hz, 2H), 3.94 (t, J = 6.0 Hz, 2H), 2.36
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(dd, J = 16.2, 6.0 Hz, 2H), 2.25 (dd, J = 16.2, 6.0 Hz, 2H), 2.20 (br s, 1H),
2.17 (br s, 1H). 1H NMR spectroscopic data were consistent with those in the
literature [171].
Bis-TBS ether 3.48. Diol 3.47 (15.65 g, 137.1 mmol) was dissolved in
CH2Cl2 (350 mL) and imidazole (46.68 g, 685.7 mmol) and TBSCl (62.11 g,
412.1mmol) were added. The reaction mixture was stirred at rt for 40 h and
was then washed with water (2 × 200 mL) whereupon the combined aque-
ous layers were extracted with CH2Cl2 (5 × 200mL). The combined organic
phases were then dried over MgSO4 and the solvent was removed in vacuo.
The residue was then purified by flash column chromatography on silica gel
(hexanes) to give the title compound as a colorless oil (34.09g, 73%). Rf = 0.39
(EtOAc:hexanes (1:100)); 1H NMR (CDCl3, 600MHz) δ 5.50 (t, J = 1.8 Hz,
2H), 3.84 (t, J = 5.4 Hz, 2H), 2.21 (dd, J = 16.2, 6.6 Hz, 2H), 2.13 (dd,
J = 16.2, 5.4 Hz, 2H), 0.88 (s, 18H), 0.06 (s, 6H), 0.05 (s, 6H). 1H NMR
spectroscopic data were consistent with those in the literature [168].
Epoxide 3.49. Bis-TBS ether 3.48 (34.09 g, 99.48mmol) was dissolved
in cyclohexane (1.1 L) and NaHCO3 (16.72 g, 199.0mmol) and then mCPBA
(41.70g, ca. 30% water content, 169.1mmol) in portions. The reaction mixture
was stirred at rt for 24 h. Then the reaction was quenched with 10% Na2SO3
(aq) (800mL) and water (300mL). The layers were separated and the aque-
ous layer was extracted with CH2Cl2 (5 × 200 mL). The combined organic
phases were then dried over MgSO4 and the solvent was removed in vacuo.
The residue was then purified by flash column chromatography on silica gel
(EtOAc:hexanes (1:50)) to give the title compound as a colorless oil (30.43 g,
85%). Rf = 0.34 (EtOAc:hexanes (1:30)); 1H NMR (CDCl3, 600MHz) δ 3.67
(t, J = 5.1 Hz, 2H), 3.15 (s, 2H), 2.07–1.99 (m, 4H), 0.89 (s, 18H), 0.05 (s,
6H), 0.04 (s, 6H). 1H NMR spectroscopic data were consistent with those in
the literature [168].
Allylic alcohol 3.51. Chiral amine 3.50 (3 × 4.568 g, 3 × 20.92 mmol)
was dissolved in THF (3 × 15 mL) in three flasks and the solutions were
cooled to 0 ◦C. nBuLi (2.5M in hexanes, 3 × 8.37 mL, 3 × 20.9 mmol) was
added dropwise over 5 min. After 55 min. the reaction mixtures was cooled
to −10 ◦C and solutions of epoxide 3.49 (3 × 3.752 g, 3 × 10.46 mmol) in
THF (3 × 15mL) were added dropwise over 10 min. The reactions mixtures
were allowed to warm to rt and stirred at this temperature overnight (18 h).
The reaction mixtures were then quenched with sat. NH4Cl (3× 10mL) and
combined. The resulting mixture was extracted with Et2O (3× 120mL) and
the combined organic phases were washed with 2% HCl (aq) (3 × 120 mL),
sat. NaHCO3 (aq) (3 × 120 mL) and brine (80 mL), dried over MgSO4 and
the solvent was removed in vacuo. The residue was then purified by flash
column chromatography on silica gel (EtOAc:hexanes (1.5:8.5)) to give the
title compound as a white solid (10.64g, 95%, 89% ee by Mosher ester analysis
[184]). Rf = 0.31 (EtOAc:hexanes (1:4)); 1H NMR (CDCl3, 600MHz) δ 5.74
(dd, J = 10.1, 2.9Hz, 1H), 5.65 (dd, J = 10.1, 3.3Hz, 1H), 4.47–4.42 (m, 1H),
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4.15–4.12 (m, 1H), 4.09–4.05 (m, 1H), 2.27 (ddd, J = 13.2, 8.0, 5.3 Hz, 1H),
1.57 (ddd, J = 13.2, 6.3, 2.1 Hz, 1H), 1.44 (s, 1H), 0.90 (s, 9H), 0.89 (s, 9H),
0.08 (s, 3H), 0.08 (s, 3H), 0.08 (s, 3H), 0.07 (s, 3H). 1H NMR spectroscopic
data were consistent with those in the literature [168].
PMB-ether diol 3.52. Allylic alcohol 3.51 (12.90 g, 35.97 mmol) and
TrBF4 (0.5946g, 1.801mmol) were dissolved in THF (380mL) and then freshly
prepared PMBTCA (25.41 g, 89.93mmol) was added dropwise. The reaction
mixture was stirred at rt for 2 h 40 min. whereupon TBAF (1 M in THF,
252mL, 252mmol) was added and the reaction mixture was heated to reflux
for 12 h. The reaction mixture was concentrated on silica gel (400 g) in vacuo
and purified by flash column chromatography on silica gel (acetone:pentane
(1:3)→(2:3)) to give the title compound as an orange solid (8.67 g, 96%).
Rf = 0.39 (acetone:pentane (2:3)); 1H NMR (CDCl3, 600 MHz) δ 7.26 (d,
J = 8.2Hz, 2H), 6.87 (d, J = 8.3Hz, 2H), 5.97 (dd, J = 10.2, 2.0Hz, 1H), 5.78
(dd, J = 10.1, 2.7Hz, 1H), 4.53 (d, J = 11.3Hz, 1H), 4.49 (d, J = 11.3Hz, 1H),
4.22–4.11 (m, 3H), 3.80 (s, 3H), 2.26 (s, 2H), 2.19 (ddd, J = 13.3, 8.0, 5.0Hz,
1H), 1.82 (ddd, J = 13.3, 6.0, 2.3Hz, 1H); 13C NMR (CDCl3, 150MHz) δ 159.2,
130.6, 130.4, 129.4, 129.3, 113.8, 70.9, 70.4, 67.4, 66.7, 55.3, 32.7; IR (neat)
cm−1: 3373, 3031, 2931, 2837, 1611, 1512, 1388, 1301, 1244, 1172, 1063, 1031,
823; HRMS (ESI-TOF) calcd for C14H18NaO4
+ [M+Na]+ 273.1097, found
273.1086; [α]25D = −135.3 (c = 1.0, CHCl3); m.p.: 84–85 ◦C.
Hydroxyenone 3.39. PMB-ether diol 3.52 (14.88 g, 59.45 mmol) was
dispersed in CH2Cl2 and the resulting mixture was cooled to 0
◦C whereupon
pTsOH · H2O was added (33.93 g, 178.4mmol). Then a solution of TEMPO
(27.87 g, 178.4mmol) in CH2Cl2 (40mL was added dropwise over 15–20min.
at 0 ◦C. The reaction mixture was stirred at 0 ◦C for 70 min. whereupon
sat. NaHCO3 (aq) (500 mL) was added. The layers were separated and the
organic phase was washed with sat. NaHCO3 (aq) (500mL). The combined
aqueous phases were then extracted with CH2Cl2 (2 × 500 mL), dried over
MgSO4 and the solvent was removed in vacuo. The residue was then purified
by flash column chromatography on silica gel (EtOAc:hexanes (1:3)) to give
the title compound as an orange oil (9.47 g, 64%). Rf = 0.40 (EtOAc:hexanes
(1:1)); 1H NMR (CDCl3, 600MHz) δ 7.28 (d, J = 8.4Hz, 2H), 6.92–6.87 (m,
3H), 6.10 (d, J = 10.0Hz, 1H), 4.68–4.61 (m, 2H), 4.53 (d, J = 11.3Hz, 1H),
4.26–4.22 (m, 1H), 3.81 (s, 3H), 3.38 (s, 1H), 2.71–2.64 (m, 1H), 1.95 (td,
J = 13.0, 3.9Hz, 1H). 1H NMR spectroscopic data were consistent with those
in the literature [158,160].
Cyclohexenone 3.5. Hydroxyenone 3.39 (9.410 g, 37.90mmol) was dis-
solved in DMF (190mL) and the resulting mixture was cooled to 0 ◦C where-
upon imidazole (7.745 g, 113.8mmol) and TBSCl (10.29 g, 68.27mmol) were
added. The reaction mixture was stirred at 0◦C for 1.5h. Brine (300mL), wa-
ter (300mL) and EtOAc (400mL) were added and the layers were separated.
The combined organic phases were washed with water (2 × 400 mL). The
combined aqueous phases were then extracted with EtOAc (2× 400mL). The
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combined organic phases were dried over Na2SO4 and the solvent was removed
in vacuo. The residue was then purified by flash column chromatography on
silica gel (EtOAc:hexanes (1:4)) to give the title compound as a colorless oil
(11.62g, 85%). Rf = 0.55 (EtOAc:hexanes (1:4)); 1H NMR (CDCl3, 600MHz)
δ 7.28 (d, J = 8.5 Hz, 2H), 6.90 (d, J = 8.6 Hz, 2H), 6.88–6.86 (m, 1H), 5.95
(d, J = 10.2 Hz, 1H), 4.60 (d, J = 11.4 Hz, 1H), 4.55 (d, J = 11.4 Hz, 1H),
4.39–4.34 (m, 2H), 3.81 (s, 3H), 2.32–2.19 (m, 2H), 0.88 (s, 9H), 0.10 (s, 3H),
0.09 (s, 3H). 1H NMR spectroscopic data were consistent with those in the
literature [158,160].
3.7.3 Synthesis of cyanophthalide building block 3.6
Ester 3.54. 4-methylsalicylic acid 3.53 (74.09 g, 487.0mmol) was suspended
in DMF (650 mL) at rt and then Li2CO3 (39.58 g, 535.7 mmol) and MeI
(33.36mL, 535.9mmol). The reaction mixture was then heated to 60 ◦C and
stirred for 16h. Then ice water was added (650mL) and the resulting mixture
was extracted with EtOAc (2× 1 L). Then the combined organic phases were
washed with water 2 × 650mL) and brine (650mL), dried over Na2SO4 and
the solvent was removed in vacuo. The residue was then used directly in the
next reaction without purification. Rf = 0.14 (EtOAc:hexanes (2:98)). The
Rf-value was consistent with that in the literature [151].
Allylic ether 3.55. NaH (60% dispersion in mineral oil, 23.41g, 584.3mmol)
was suspended in DMF (500 mL) at 0 ◦C and then allyl bromide (85.0 mL,
982mmol) was added. Then a solution of the crude ester 3.54 (487.0mmol)
in DMF (250mL) was added and the resulting mixture was stirred at 0 ◦C for
10min. whereupon the reaction mixture was allowed to warm to rt. The reac-
tion mixture was stirred at rt for 12h.Then ice water was added (750mL) and
the resulting mixture was extracted with Et2O (3× 750mL). Then the com-
bined organic phases were washed with water (3×500mL) and brine (500mL),
dried over Na2SO4 and the solvent was removed in vacuo. The residue was
then used directly in the next reaction without purification. Rf = 0.17
(EtOAc:hexanes (1:9)). The Rf-value was consistent with that in the liter-
ature [151].
Amide 3.56. Et2NH (192.0 mL, 1857 mmol) was dissolved in benzene
(300mL) and cooled to 0 ◦C whereupon AlMe3 (2.0M in toluene, 399.0mL,
798.0mmol) was added. The resulting mixture was stirred at 0 ◦C for 20min.
and was then allowed to warm to rt. Allylic ether 3.55 (487.0mmol) was then
added dropwise over 25min. and the reaction mixture was heated to 120 ◦C
and stirred for 17 h. The reaction mixture was then allowed to cool to rt and
was then poured into a mixture of ice water (1.5L) and 12M HCl (aq) (30mL)
and the layers were separated. The aqueous phase was then extracted with
EtOAc (3× 1L). The combined organic phases were washed with water (1L),
sat. NH4Cl (aq) (500 mL) and brine (500 mL), dried over Na2SO4 and the
solvent was removed in vacuo. The residue was then used directly in the next
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reaction without purification. Rf = 0.08 (EtOAc:hexanes (1:4)); 1H NMR
(CDCl3, 600MHz) δ 7.08 (d, J = 7.6 Hz, 1H), 6.77 (d, J = 7.6 Hz, 1H), 6.68
(s, 1H), 6.03–5.93 (m, 1H), 5.37 (d, J = 17.3 Hz, 1H), 5.22 (d, J = 10.6 Hz,
1H), 4.52 (s, 2H), 3.71 (s, 1H), 3.38 (s, 1H), 3.21–3.10 (m, 2H), 2.33 (s, 3H),
1.22 (t, J = 7.1Hz, 3H), 1.01 (t, J = 7.1Hz, 3H). 1H NMR spectroscopic data
were consistent with those in the literature [151].
Phenol 3.57. Amide 3.56 (487.0mmol) was heated neat to 220 ◦C and
stirred for 9h whereupon it was allowed to cool to rt. The residue was then used
directly in the next reaction without purification. Rf = 0.40 (EtOAc:hexanes
(4:21)); 1H NMR (CDCl3, 600 MHz) δ 10.14 (s, 1H), 7.06 (d, J = 8.0 Hz,
1H), 6.66 (d, J = 8.0Hz, 1H), 5.97–5.93 (m, 1H), 5.02–4.97 (m, 2H), 3.52 (q,
J = 7.1 Hz, 4H), 3.48–3.45 (m, 2H), 2.29 (s, 3H), 1.27 (t, J = 7.1 Hz, 6H).
1H NMR spectroscopic data were consistent with those in the literature [151].
Phenol 3.58. Phenol 3.57 (487.0mmol) was dissolved in DMSO (500mL)
at rt and then tBuOK (273.4 g, 2437mmol) was added. The reaction mixture
was heated to 120 ◦C and stirred for 2 h 45 min. The reaction mixture was
then allowed to cool to rt, diluted with water (450 mL) and acidified to pH
1 with 6M HCl (aq) (350mL). The mixture was extracted with EtOAc (2×
750mL). The combined organic phases were washed with water (5× 750mL)
and brine (750mL), dried over Na2SO4 and the solvent was removed in vacuo.
The residue was then purified by flash column chromatography on silica gel
(EtOAc:hexanes (1:9)) to give the title compound as a yellow oil (79.28 g,
66% over five steps). Rf = 0.18 (EtOAc:hexanes (1:4)); 1H NMR (CDCl3,
600MHz) δ 9.94 (s, 1H), 7.01 (d, J = 7.9 Hz, 1H), 6.66 (d, J = 8.0 Hz, 1H),
6.44–6.38 (m, 1H), 6.23 (dq, J = 16.0, 6.5 Hz, 1H), 3.49 (q, J = 7.1 Hz, 4H),
2.32 (s, 3H), 1.94 (dd, J = 6.5, 1.7Hz, 3H), 1.25 (t, J = 7.1Hz, 6H). 1H NMR
spectroscopic data were consistent with those in the literature [151].
MOM ether 3.59. Phenol 3.58 (65.13 g, 263.3 mmol) was dissolved in
CH2Cl2 (600mL) and cooled to 0
◦C whereupon DIPEA (150mL, 861mmol)
and MOMCl (50.0mL, 658mmol) were added and the resulting mixture was
stirred at 0◦C for 20min. The reaction mixture was then allowed to warm to rt
and was then stirred for 36 h. Then water (1.1L) was added and mixture was
extracted with CH2Cl2 (3×1.1L). The combined organic phases were washed
with brine (1.1 L), dried over Na2SO4 and the solvent was removed in vacuo.
The residue was then purified by flash column chromatography on silica gel
(EtOAc:hexanes (1:1)) to give the title compound as a yellow oil (76.73 g,
quant.). Rf = 0.20 (EtOAc:hexanes (1:3)); 1H NMR (CDCl3, 600 MHz) δ
6.99–6.93 (m, 2H), 6.40 (d, J = 16.3 Hz, 1H), 6.05 (dq, J = 16.0, 6.5 Hz,
1H), 5.01–4.90 (m, 2H), 3.67 (s, 1H), 3.48 (s, 3H), 3.42 (s, 1H), 3.23 (d,
J = 5.4Hz, 1H), 3.14 (s, 1H), 2.31 (s, 3H), 1.91 (dd, J = 6.6, 1.3Hz, 3H), 1.23
(t, J = 7.1 Hz, 3H), 1.04 (t, J = 7.1 Hz, 3H). 1H NMR spectroscopic data
were consistent with those in the literature [151].
Aldehyde 3.60. TMEDA (23.8 mL, 159 mmol) was dissolved in THF
(200 mL) and cooled to −78 ◦C and then tBuLi (1.7M in pentane, 105 mL,
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179mmol) was added slowly. The reaction mixture was stirred at −78 ◦C for
20 min. whereupon a solution of MOM ether 3.59 (22.99 g, 78.90 mmol) in
THF (250 mL). The reaction mixture was then stirred for 50 min. and then
DMF (73.0 mL, 947 mmol) was added. After 1 h the reaction mixture was
allowed to warm to rt and was then stirred for 2h. Water (200mL) was added
and after 20min. the mixture was partially concentrated in vacuo to remove
volatiles. The aqueous phase was then extracted with EtOAc (2 × 500 mL).
The combined organic phases were washed with water (3×500mL), dried over
Na2SO4 and the solvent was removed in vacuo. The residue was then purified
by flash column chromatography on silica gel (EtOAc:hexanes (3.5:6.5)) to give
the title compound as a yellow oil (22.84 g, 91%). Rf = 0.20 (EtOAc:hexanes
(3.5:6.5)); 1H NMR (CDCl3, 600MHz) δ 9.90 (s, 1H), 7.54 (s, 1H), 6.47–6.41
(m, 1H), 6.23 (dq, J = 16.1, 6.6 Hz, 1H), 5.02 (d, J = 5.1Hz, 1H), 4.96 (d,
J = 5.1 Hz, 1H), 3.70–3.55 (m, 2H), 3.51 (s, 3H), 3.18–3.09 (m, 2H), 2.39
(s, 3H), 1.95 (dd, J = 6.6, 1.7 Hz, 3H), 1.30 (t, J = 7.1 Hz, 3H), 1.04 (t,
J = 7.2 Hz, 3H). 1H NMR spectroscopic data were consistent with those in
the literature [151].
Cyanophthalide 3.6. Aldehyde 3.60 (22.79g, 71.35mmol) was dissolved
in CH2Cl2 and cooled to 0
◦C and then TMSCN (15.0mL, 120mmol) was added.
The reaction mixture was stirred at 0 ◦C for 10min. whereupon it was allowed
to warm to rt. The reaction mixture was then stirred for 1 h and then KCN
(0.012 g, 0.18mmol) and 18-crown-6 (0.012 g, 0.045mmol) were added. The
reaction mixture was then stirred at rt for 5h and the solvent was removed in
vacuo. The residue was dissolved in AcOH (146mL) and stirred at rt for 106h
whereupon the solvent was removed in vacuo. Sat. NaHCO3 (aq) (1 L) was
added and the aqueous phase was then extracted with EtOAc (3 × 500mL).
The combined organic phases were washed with water (1L), dried over Na2SO4
and the solvent was removed in vacuo. The residue was then purified by flash
column chromatography on silica gel (EtOAc:hexanes (1:7)) to give the title
compound as a yellow oil (14.90 g, 76%). Rf = 0.32 (EtOAc:hexanes (1:3)).
The Rf-value was consistent with that in the literature [151].
3.7.4 Synthesis of TBS ether cyanophthalide building block
3.61
MOM ether 3.62. Phenol 3.57 (1.029 g, 4.160 mmol) was dissolved in
CH2Cl2 (15mL) and cooled to 0
◦C whereupon DIPEA (2.50mL, 14.4mmol)
and MOMCl (0.800mL, 10.5mmol) were added and the resulting mixture was
stirred at 0 ◦C for 20min. The reaction mixture was then allowed to warm to
rt and was then stirred for 74 h. Then water (25mL) was added and mixture
was extracted with CH2Cl2 (3 × 25mL). The combined organic phases were
washed with brine (25mL), dried over Na2SO4 and the solvent was removed
in vacuo. The residue was then purified by flash column chromatography
on silica gel (EtOAc:hexanes (3:7)) to give the title compound as a yellow oil
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(1.135g, 94%). Rf = 0.20 (EtOAc:hexanes (3:7)); 1H NMR (CDCl3, 600MHz)
δ 7.02 (d, J = 7.7 Hz, 1H), 6.96 (d, J = 7.7 Hz, 1H), 5.98–5.90 (m, 1H), 5.02
(d, J = 1.7Hz, 1H), 5.00 (s, 2H), 4.87 (dd, J = 17.2, 1.8Hz, 1H), 3.69 (s, 1H),
3.52–3.48 (m, 5H), 3.40 (s, 1H), 3.17 (s, 1H), 3.13 (s, 1H), 2.29 (s, 3H), 1.24
(t, J = 7.1 Hz, 3H), 1.03 (t, J = 7.1 Hz, 3H); 13C NMR (CDCl3, 150MHz)
δ 169.5, 151.5, 136.1, 132.1, 129.5, 126.5, 125.5, 115.2, 100.5, 57.6, 43.2, 39.2,
31.0, 19.7, 14.0, 13.0.
MOM cyanophthalide 3.74. Cyanophthalide 3.69 (0.100g, 0.529mmol)
was dissolved in CH2Cl2:DMF (3:1) (1mL) and then cooled to 0
◦C. A solution
of DIPEA (0.139 mL, 0.798 mmol) and MOMCl (0.049 mL, 0.65 mmol) in
CH2Cl2 (0.250mL) was added dropwise and the resulting mixture was stirred
at 0 ◦C for 1.5 h. Then sat. NH4Cl (aq) (25 mL) was added and mixture
was extracted with CH2Cl2 (3 × 15mL). The combined organic phases were
washed with water (20mL), dried over Na2SO4 and the solvent was removed
in vacuo. The residue was then purified by flash column chromatography on
silica gel (EtOAc:hexanes (3.5:6.5)) to give the title compound as a yellow oil
(0.106g, 86%). Rf = 0.55 (EtOAc:hexanes (1:1)); 1H NMR (CDCl3, 600MHz)
δ 7.14 (s, 1H), 7.06 (s, 1H), 5.93 (s, 1H), 5.36 (s, 2H), 3.54 (s, 3H), 2.51 (s,
3H); 13C NMR (CDCl3, 150MHz) δ 165.3, 156.7, 150.1, 144.3, 117.7, 116.1,
114.3, 110.3, 94.9, 64.8, 56.9, 22.7.
Iodocyanophthalide 3.68. Cyanophthalide 3.69 (0.600 g, 3.17 mmol)
was dissolved in CH2Cl2 (60mL) and cooled to 0
◦C whereupon NIS (0.928 g,
4.12mmol) was added. The reaction mixture was stirred at 0 ◦C for 45min.
and then 10% Na2S2O3 (aq) (50mL) was added. The layers were separated
and the aqueous phase was extracted with CH2Cl2 (2×50mL). The combined
organic phases were washed with water (50mL), dried over Na2SO4 and the
solvent was removed in vacuo. The residue was then dissolved in CH2Cl2
(60 mL) and cooled to 0 ◦C whereupon DIPEA (0.660 mL, 3.79 mmol) and
MOMCl (0.360mL, 4.74mmol) were added and the resulting mixture was then
allowed to warm to rt and was then stirred for 105min. Then sat. NH4Cl (aq)
(50mL) was added and the layers was separated whereupon the aqueous phase
was extracted with CH2Cl2 (2 × 50mL). The combined organic phases were
washed with water (50mL), dried over Na2SO4 and the solvent was removed
in vacuo. The residue was then purified by flash column chromatography on
silica gel (EtOAc:hexanes (1:7)) to give the title compound as a yellow solid
(0.230g, 20%). Rf = 0.20 (EtOAc:hexanes (1:3)); 1H NMR (CDCl3, 600MHz)
δ 7.29 (s, 1H), 5.93 (s, 1H), 5.54 (d, J = 6.2 Hz, 1H), 5.50 (d, J = 6.2 Hz, 1H),
3.68 (s, 3H), 2.67 (s, 3H); 13C NMR (CDCl3, 150MHz) δ 164.3, 156.4, 153.3,
143.4, 118.1, 113.5, 112.2, 102.5, 101.6, 64.7, 59.0, 30.5. HRMS (ESI-TOF)
calcd for C12H9INO4
– [M−H]− 357.9582, found 357.9572; m.p.: 117–118 ◦C.
Stannane 3.67. TBS ether9 3.76 (3.00 g, 17.6 mmol) was dissolved in
benzene (90mL) and then Bu3SnH (4.20mL, 21.5mmol) and AIBN (0.289 g,
9Prepared according to [185].
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1.76mmol) were added. The resulting mixture was heated to reflux and stirred
for 16 h. The solvent was removed in vacuo and the residue was then purified
by flash column chromatography on silica gel (EtOAc:hexanes (0:100)→(1:99))
to give the title compound as a colorless oil (3.11 g, 38%, trans:cis (85:15)).
Rf = 0.15 (hexanes); 1H NMR (CDCl3, 600 MHz) δ 6.17 (d, J = 19.4 Hz,
1H), 6.05 (dt, J = 19.0, 4.1 Hz, 1H), 4.22–4.18 (m, 2H), 1.55–1.46 (m, 6H),
1.34–1.27 (m, 6H), 0.92 (s, 9H), 0.90–0.82 (m, 15H), 0.07 (s, 6H). 1H NMR
spectroscopic data were consistent with those in the literature [185].
Allylic TBS ether 3.61. A flask was charged with iodocyanophthalide
3.68 (0.060 g, 0.17mmol) and Pd(PPh3)4 (0.019 g, 0.016mmol). Then a solu-
tion of stannane 3.67 (0.093g, 0.20mmol) in toluene (3.4mL) and the resulting
mixture was heated to reflux. The reaction mixture was stirred at reflux for
26 h whereupon the solvent was removed in vacuo. The residue was then pu-
rified by flash column chromatography on silica gel (EtOAc:CH2Cl2:hexanes
(1:1:8)) to give the title compound as a colorless oil (0.029 g, 42%). Rf = 0.27
(EtOAc:hexanes (1:3)); 1H NMR (CDCl3, 600MHz) δ 7.21 (s, 1H), 6.63 (d,
J = 16.1 Hz, 1H), 6.30 (dt, J = 16.1, 4.0 Hz, 1H), 5.94 (s, 1H), 5.33–5.28 (m,
2H), 4.40 (d, J = 1.9Hz, 2H), 3.53 (s, 3H), 2.48 (s, 3H), 0.95 (s, 9H), 0.12 (s,
6H); 13C NMR (CDCl3, 150MHz) δ 165.8, 154.8, 144.0, 141.3, 137.8, 134.2,
120.9, 119.3, 114.2, 113.6, 101.1, 64.8, 63.6, 58.2, 26.0, 22.3, 18.5, −5.2; HRMS
(ESI-TOF) calcd for C21H29NNaO5Si
+ [M+Na]+ 426.1707, found 426.1695.
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Synthesis of Poly-fused
Heterocycles
Poly-fused heterocycles are found in a wide variety of natural products and
have rich biological activities [186–191], cf. figure 4.1.
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Figure 4.1: Poly-fused heterocycles with interesting biological activities.
To match the increasing scientific and pharmaceutical demand for biolog-
ically active compounds, efficient synthetic approaches for the construction of
these heterocyclic skeletons are desirable.
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Along these lines, we set out to develop an efficient strategy for the con-
struction of structurally diverse poly-fused heterocycles.
4.1 Synthetic Strategy
To allow for a high degree of diversity, a strategy relying on a tandem aldol
condensation/conjugate addition to form the core scaffold, was chosen. The
strategy furthermore permitted variation around the core poly-fused scaffold,
also called appendage diversity [192, 193], by employing building blocks in a
convergent manner.
Thus, it was envisioned that a β-keto esters with an internal nucleophile
attached (4.7) upon reaction with a hydrazine in a Knorr-like fashion [194]
would lead to pyrazolone 4.8, cf. scheme 4.1. An aldol condensation be-
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Scheme 4.1: Synthetic strategy for the synthesis of poly-fused heterocycles.
tween pyrazolone 4.8 and an aldehyde would then provide the intermediate
α,β-unsaturated carbonyl 4.9 [195, 196], now ready to undergo an internal
conjugate addition leading to poly-fused heterocycle 4.10 [197]. This inter-
mediate would upon final oxidation lead to the desired poly-fused heterocycle
4.11.
4.2 Synthesis of β-Keto Esters
An efficient method for the preparation of β-keto esters with internal nucle-
ophilic moieties was needed as these were not easily available commercially.
Thus the corresponding substituted acetic acid derivatives 4.12a–c were ac-
tivated with CDI and then treated with the magnesium enolate of ethyl hy-
drogen malonate [198], cf. table 4.1. This provided the β-keto esters 4.13a
(R = 2,3-dimethoxyphenyl), 4.13b (R = 2,4-dimethoxyphenyl) and 4.13c
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Table 4.1: Synthesis of β-keto ester building blocks from the corresponding substi-
tuted acetic acid derivatives.
1. CDI (1.2 equiv)
2. ethyl hydrogen malonate (1.5 equiv),
   iPrMgCl (3 equiv)
THF, 0–50 °C, 6 daysR OH
O
R
O
OEt
O
4.12a–c 4.13a–c
Entry Acid R Product, yield (%)a
1 4.12a 2,3-dimethoxyphenyl 4.13a, 83
2 4.12b 2,4-dimethoxyphenyl 4.13b, 72
3 4.12c 3-indole 4.13c, 87
a Isolated yield after flash column chromatography.
(R = 3-indole) in good yields (72–87%). It was furthermore found that in-
creasing the amount of ethyl hydrogen malonate and iPrMgCl (to 2.25 equiv
and 4.5 equiv respectively) sped up the reaction (leading to full conversion
overnight) and that the potassium salt of the β-dicarbonyl (e.g. methyl potas-
sium malonate) could be used instead of the acid, if needed.
4.3 Synthesis of Pyrazolols
With the β-keto esters 4.13a–c in hand, the next step was the pyrazolone
formation leading to 4.8, cf. scheme 4.1. To save the more precious β-keto
esters 4.13a–c a solvent screen was performed1 with a model substrate (ethyl
acetoacetate 4.14) and 4-chlorophenylhydrazine 4.15, cf. table 4.2.
As can be seen from table 4.2, EtOH, AcOH, DMF, EtOAc and MeCN
all led to similar results, with DMF proving slightly superior in terms of
minimizing side products. However when β-keto ester 4.13c was mixed with
4-chlorophenylhydrazine 4.15 in DMF at 60 ◦C a complex reaction mixture
resulted, cf. scheme 4.2. When EtOH was used as solvent a cleaner conversion
was observed but the desired product was only isolated in a unsatisfactory
yield of 16%, cf. scheme 4.3. It was found that the desired pyrazolone was
present as its pyrazolol tautomer 4.17c, which proved to be a general trend
for these compounds [199, 200]. The low yield obtained was also ascribed to
the product being very difficult to purify due to solubility issues. Addition
of Et3N slightly improved the yield to 25% cf. table 4.3. The pyrazolols
4.17a (R = 2,3-dimethoxyphenyl) and 4.17b (R = 2,4-dimethoxyphenyl)
were isolated in somewhat higher yields of 42% and 39% respectively due
to an easier purification process, cf. table 4.3. Due to time constraints the
pyrazolol formation was not optimized further.
1This solvent screen was carried out by PhD student Kim Mortensen.
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Table 4.2: Screen of solvents and reaction temperature for pyrazolone formation.
O
OEt
O
Cl
H
N
NH2
⋅HCl
+
4.15
Cl
N
N
O
4.16
solvent, temp.
4.14
Entry Solvent Temp. (◦C) Ratio 4.16:side productsa
1 EtOH 80 68:32
2 EtOH 60 80:20
3 AcOH 120 81:19
4 DMF 60 90:10
5 EtOAc 60 80:20
6 toluene 60 0:100
7 heptane 60 0:100
8 THF 60 complex mixture
9 MeCN 60 83:17
10 CH2Cl2 40 complex mixture
a As indicated by LCMS.
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Scheme 4.2: Reaction between β-keto ester 4.13c and 4-chlorophenylhydrazine 4.15
in DMF.
Cl
H
N
NH2
⋅HCl
+
4.13c 4.15
Cl
N
N
HO
4.17c
16%
EtOH, 60 °C
N
H
O
O
OEt
NH
Scheme 4.3: Reaction between β-keto ester 4.13c and 4-chlorophenylhydrazine 4.15
in EtOH.
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Table 4.3: Synthesis of pyrazolol building blocks from the corresponding β-keto
esters.
R
O
OEt
O
Cl
H
N
NH2
⋅HCl
+
4.13a–c 4.15
Cl
N
N R
HO
4.17a–c
Et3N (1.15 equiv)
EtOH, 60 °C, 
1–2 days
Entry β-keto ester R Product, yield (%)a
1 4.13a 2,3-dimethoxyphenyl 4.17a, 42
2 4.13b 2,4-dimethoxyphenyl 4.17b, 39
3 4.13c 3-indole 4.17c, 25
a Isolated yield after flash column chromatography.
4.4 Tandem Aldol Condensation/Conjugate
Addition and Oxidation
Everything was now set up to attempt the key tandem aldol condensation/con-
jugate addition. Thus pyrazolol 4.17a was subjected to BF3·OEt2 in EtOH, cf.
table 4.4. However, none of the desired tetrahydroindazolone 4.18 was isolated
Table 4.4: Attempted tandem aldol condensation/conjugate addition of pyrazolol
4.17a.
benzaldehyde (1 equiv),
additive (1–2.5 equiv)
Cl
N
N
HO
4.17a
OMe
Cl N
N
O
OMe
4.18
EtOH, rt
OMe
OMe
Entry Additive Equiv
1 BF3 ·OEt2 1
2 pTsOH ·H2O 2.5
3 TMSTOf 1
and complete conversion to the di-pyrazolone 4.19 was oberserved [201–205],
cf. figure 4.2. The same was observed when subjecting 4.17a to pTsOH ·H2O
or TMSTOf, cf. table 4.4.
As the electronic properties of the internal nucleophile in pyrazolol 4.17b
was considered more optimal due to superior positioning of the two methoxy
groups, the tandem aldol condensation/conjugate addition was attempted on
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Cl
N
N
O
4.19
N
N
O
Cl
MeO
MeO
OMe
OMe
Cl
N
N
O
4.20
N
N
O
Cl
MeO
OMe
OMe
MeO
Figure 4.2: Side products formed in the tandem aldol condensation/conjugate ad-
dition reaction.
this substrate instead, cf. table 4.5. Upon subjection to BF3 ·OEt2 the desired
product 4.21 and the di-pyrazolone 4.20, cf. figure 4.2, were formed in a
ratio of 12:88 (table 4.5, entry 1). The use of pTsOH · H2O further improved
this ratio (table 4.5, entry 2) and increasing the amount of pTsOH · H2O
led to further improvement (table 4.5, entries 4 and 6). The use of sub-
stoichiometric amounts of benzaldehyde slightly improved the ratio (table 4.5,
entry 3) whereas an excess of benzaldehyde led to increased formation of the
side product 4.20 (table 4.5, entry 5). The use of TMSOTf led to even
further improvement of the ratio between the desired product 4.21 and the
side product 4.20 and the same trend was observed when varying the amount
of benzaldehyde as for pTsOH ·H2O (table 4.5, entries 7–9). Again, increasing
the amount of TMSOTf improved the ratio with the use of 8 equiv leading to
a ratio of 93:7 (table 4.5, entries 10–12).
Using the optimized conditions for the tandem aldol condensation/conju-
gate addition, pyrazolol 4.17b was subjected to TMSTOf (8 equiv) furnishing
the tetrahydroindazolone 4.21 in a good yield of 72%, cf. scheme 4.4. When
pyrazolol 4.17c was subjected to the same reaction conditions a mixture of
what appeared to be different tautomeric forms of the desired product, with
4.22 as the major component, was obtained in a yield of 41% cf. scheme 4.4.
Just as for the indole containing pyrazolol 4.17c, cf. §4.3, the product mixture
was very difficult to purify and it was not possible to separate the different tau-
tomeric forms. The tautomeric mixture was furthermore difficult to analyze
by NMR.
The final oxidation could now be attempted. However when tetrahydroin-
dazolones 4.21 and 4.22 were subjected to DDQ, decomposition of starting
materials was observed and none of the desired products were isolated, cf.
scheme 4.5. Due to time constraints, no further attempts towards the oxida-
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Table 4.5: Screen of reaction conditions for the tandem aldol condensa-
tion/conjugate addition of pyrazolol 4.17b.
benzaldehyde (0.5–5 equiv),
additive (1–8 equiv)
Cl
N
N
HO
4.17b
OMe
Cl N
N
O
OMe
4.21
EtOH, rt
MeO
OMe
Entry Additive Additive equiv Benzaldehyde equiv Ratio 4.21:4.20a
1 BF3 ·OEt2 1 1 12:88
2 pTsOH ·H2O 1 1 19:81
3 pTsOH ·H2O 2.5 0.5 56:44
4 pTsOH ·H2O 2.5 1 50:50
5 pTsOH ·H2O 2.5 5 19:81
6 pTsOH ·H2O 5 1 66:34
7 TMSOTf 1 0.5 57:43
8 TMSOTf 1 1 46:54
9 TMSOTf 1 5 21:79
10 TMSOTf 2 1 76:24
11 TMSOTf 4 1 89:11
12 TMSOTf 8 1 93:7
a As indicated by LCMS.
Cl
N
N
HO
4.17b
OMe
Cl N
N
O
OMe
4.21
72%
Cl
N
N
HO
4.17c
Cl N
N
HO
4.22
41% (mixture of tautomers)
NH
H
N
TMSOTf (8 equiv)
EtOH, rt, 12 days
TMSOTf (8 equiv)
EtOH, rt, 12 days
MeO
OMe
Scheme 4.4: Tandem aldol condensation/conjugate addition of pyrazolol 4.17b and
4.17c.
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Cl N
N
O
OMe
4.21
Cl N
N
O
4.22
H
N
OMe
Cl N
N
H
O
OMe
4.23
Cl N
N
H
O
4.24
H
N
OMe
CH2Cl2:MeCN (1:1)
DDQ (1 equiv)
CH2Cl2:MeCN (1:1)
DDQ (1 equiv)
Scheme 4.5: Attempts at oxidation of tetrahydroindazolones 4.21 and 4.22.
tion of 4.21 and 4.22 were made.
4.5 Conclusion
Three β-keto esters were synthesized in good yields. These were furthermore
transformed into the pyrazolols 4.17a–c. This transformation was in all cases
rather low yielding and further optimization would improve the overall syn-
thetic scheme.
The key aldol condensation/conjugate addition was optimized and led to
the synthesis of tetrahydroindazolones 4.21 and 4.22 in yields of 72% and
41%, respectively. Tetrahydroindazolone 4.22 was however present as what
appeared to be a mixture of tautomers, which were difficult to purify, resulting
in a lower yield. One attempt at the final oxidation of tetrahydroindazolones
4.21 and 4.22 was made, which was unsuccessful and further investigation
into this step is needed.
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4.6 Experimental
4.6.1 General methods
Reagents were purchased at the highest commercial quality and used without
further purification, unless otherwise noted. All reactions were carried out un-
der an argon atmosphere with dry solvent under anhydrous conditions, unless
otherwise noted. Dry solvents were obtained by passing commercially avail-
able pre-dried, oxygen-free formulations through activated alumina columns.
Yields refer to chromatographically and spectroscopically (1H NMR) homo-
geneous material, unless otherwise stated.
Reactions were monitored by thin-layer chromatography (TLC) carried
out on Merck aluminium sheets covered with silica (C60) using UV light as
visualizing agent or an aqueous solution of phosphomolybdic acid and cerium
sulfate or a basic aqueous solution of potassium permanganate and heat as
developing agents. Matrex silica gel (60, particle size 0.035–0.070 mm) was
used for flash column chromatography.
NMR spectra were recorded on a Bruker Ascend 400 MHz instrument
equipped with a Prodigy cryoprobe. The chemical shifts (δ) are reported
in parts per million (ppm) and the coupling constants (J) in Hz. For spectra
recorded in DMSO-d6, signal positions were measured relative to the signal for
DMSO (δ 2.50 ppm for 1H NMR and δ 39.43 ppm for 13C NMR). For spectra
recorded in CDCl3, signal positions were measured relative to the signal for
CHCl3 (δ 7.26 ppm for
1H NMR and δ 77.0 ppm for 13C NMR).
Infrared (IR) spectra were recorded on a Bruker Alpha FT-IR spectrom-
eter. Analytical RP-UPLC-MS (ESI) analysis was performed on a Waters
AQUITY RP-UPLC system equipped with a diode array detector using an
AQUITY UPLC BEH C18 column (d 1.7 mm, 2.1 × 50 mm; column temp:
65 ◦C; flow: 0.6 mL/min.). Eluents A (0.1% HCO2H in H2O) and B (0.1%
HCO2H in MeCN) were used in a linear gradient (5% B to 100% B) in a total
run time of 2.6min. The LC system was coupled to a SQD mass spectrometer.
Analytical LC-HRMS (ESI) analysis was performed on an Agilent 1100 RP-
LC system equipped with a diode array detector using a Phenomenex Luna
C18 column (d 3mm, 2.1× 50mm; column temp: 40 ◦C; flow: 0.4mL/min.).
Eluents A (0.1% HCO2H in H2O) and B (0.1% HCO2H in MeCN) were used
in a linear gradient (20% B to 100% B) in a total run time of 15min. The LC
system was coupled to a Micromass LCT orthogonal time-of- flight mass spec-
trometer equipped with a Lock Mass probe operating in positive electrospray
mode.
4.6.2 Synthesis of β-keto esters
β-keto ester 4.13a. Acid 4.12a (1.000 g, 5.097 mmol) was dissolved in
THF (37 mL) at rt. CDI (0.992 g, 6.12 mmol) was added and the resulting
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mixture was stirred overnight (flask A). Ethyl hydrogen malonate (0.905mL,
7.67mmol) was dissolved in THF (27mL) and stirred at 0 ◦C for 30min. (flask
B). Isopropyl magnesium chloride (2.0M in THF, 7.65 mL, 15.3 mmol) was
added and after 30min. the temperature of the reaction mixture was adjusted
to rt. After 1 h the temperature of the reaction mixture was adjusted to
50 ◦C and stirred for 30min. whereupon it was cannulated in to the solution
in flask A. The resulting mixture was stirred at rt for 6 days whereupon cold
1 M HCl (aq) (200 mL) was added. The resulting mixture was extracted
with EtOAc (3 × 200 mL) and the combined organic phases were washed
with water (2 × 300 mL) and brine (600 mL), dried over MgSO4 and the
solvent was removed in vacuo. The residue was then purified by flash column
chromatography on silica gel (EtOAc:hexanes (3:7)) to give the title compound
as a yellow oil (1.126 g, 83%). Rf = 0.41 (EtOAc:hexanes (1:1)); 1H NMR
(DMSO, 400MHz) δ 6.89 (d, J = 8.2 Hz, 1H), 6.79 (d, J = 1.7 Hz, 1H), 6.71
(dd, J = 8.2, 1.7 Hz, 1H), 4.07 (q, J = 7.1 Hz, 2H), 3.76 (s, 2H), 3.73 (s,
6H), 3.62 (s, 2H), 1.17 (t, J = 7.1 Hz, 3H); 13C NMR (DMSO, 101MHz) δ
201.5, 167.2, 148.6, 147.76, 126.3, 121.8, 113.5, 111.8, 60.5, 55.5, 55.40, 48.5,
48.23, 14.0; IR (neat) cm−1: 2969, 2938, 2907, 2837, 1740, 1713, 1514, 1259,
1236, 1140, 1024; HRMS (ESI) calcd for C14H19O5
+ [M+H]+ 267.1227, found
267.1226.
β-keto ester 4.13b. Acid 4.12b (0.250 g, 1.27 mmol) was dissolved in
THF (9 mL) at rt. CDI (0.248 g, 1.53 mmol) was added and the resulting
mixture was stirred overnight (flask A). Ethyl hydrogen malonate (0.225mL,
1.91mmol) was dissolved in THF (7mL) and stirred at 0 ◦C for 30min. (flask
B). Isopropyl magnesium chloride (2.0M in THF, 1.91 mL, 3.82 mmol) was
added and after 30min. the temperature of the reaction mixture was adjusted
to rt. After 1 h the temperature of the reaction mixture was adjusted to
50 ◦C and stirred for 30min. whereupon it was cannulated in to the solution
in flask A. The resulting mixture was stirred at rt for 6 days whereupon cold
1M HCl (aq) (50mL) was added. The resulting mixture was extracted with
EtOAc (3× 50mL) and the combined organic phases were washed with water
(2×75mL) and brine (75mL), dried over MgSO4 and the solvent was removed
in vacuo. The residue was then purified by flash column chromatography on
silica gel (EtOAc:hexanes (3:7)) to give the title compound as a yellow oil
(0.244g, 72%). Rf = 0.51 (EtOAc:hexanes (1:1)); 1H NMR (DMSO, 400MHz)
δ 6.41–6.38 (m, 1H), 6.37–6.35 (m, 2H), 4.08 (q, J = 7.1 Hz, 2H), 3.77 (s,
2H), 3.72 (s, 6H), 3.63 (s, 2H), 1.17 (t, J = 7.1 Hz, 3H); 13C NMR (DMSO,
101MHz) δ 201.0, 167.1, 160.4, 136.1, 107.8, 98.6, 60.5, 55.1, 54.9, 49.1, 48.4,
14.0; IR (neat) cm−1: 2979, 2941, 2906, 2839, 1740, 1716, 1594, 1461, 1430,
1316, 1203, 1148, 1061, 1028, 834; HRMS (ESI) calcd for C14H19O5
+ [M+H]+
267.1227, found 267.1228.
β-keto ester 4.13c. Acid 4.12c (0.500 g, 2.85 mmol) was dissolved in
THF (20 mL) at rt. CDI (0.555 g, 3.42 mmol) was added and the resulting
mixture was stirred overnight (flask A). Ethyl hydrogen malonate (0.505mL,
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4.28mmol) was dissolved in THF (15mL) and stirred at 0 ◦C for 30min. (flask
B). Isopropyl magnesium chloride (2.0M in THF, 4.30 mL, 8.55 mmol) was
added and after 30min. the temperature of the reaction mixture was adjusted
to rt. After 1h the temperature of the reaction mixture was adjusted to 50 ◦C
and stirred for 30min. whereupon it was cannulated in to the solution in flask
A. The resulting mixture was stirred at rt for 6days whereupon cold 1M HCl
(aq) (100mL) was added. The resulting mixture was extracted with EtOAc
(3× 100mL) and the combined organic phases were washed with water (2×
150mL) and brine (150mL), dried over Na2SO4 and the solvent was removed
in vacuo. The residue was then purified by flash column chromatography on
silica gel (EtOAc:hexanes (3.5:6.5)) to give the title compound as a brown oil
(0.611g, 87%). Rf = 0.38 (EtOAc:hexanes (1:1)); 1H NMR (CDCl3, 400MHz)
δ 8.38 (s, 1H), 7.53 (d, J = 7.9 Hz, 1H), 7.36 (d, J = 8.1 Hz, 1H), 7.24–7.17
(m, 1H), 7.16–7.08 (m, 2H), 4.13 (q, J = 7.1 Hz, 2H), 3.94 (s, 2H), 3.48 (s,
2H), 1.22 (t, J = 7.1 Hz, 3H); 13C NMR (CDCl3, 101MHz) δ 201.8, 167.7,
136.3, 127.2, 123.8, 122.5, 120.0, 118.6, 111.5, 107.5, 61.5, 47.8, 40.2, 14.1; IR
(neat) cm−1: 3391, 2982, 1709, 1458, 1409, 1369, 1315, 1195, 1150, 1026, 742;
HRMS (ESI) calcd for C14H16NO3
+ [M+H]+ 246.1125, found 246.1124.
4.6.3 Synthesis of pyrazolols
Pyrazolol 4.17a. β-keto ester 4.13a (0.400 g, 1.50 mmol) was dissolved in
EtOH (7.5mL) and then 4-chlorophenylhydrazine hydrochloride 4.15 (0.269g,
1.50mmol) and Et3N (0.240mL, 1.72mmol) were added. The reaction mixture
was stirred at 60 ◦C for 2 days whereupon water was added (30 mL). The
resulting mixture was extracted with EtOAc (3 × 30 mL) and the combined
organic phases were washed with water (2× 45mL) and brine (45mL), dried
over Na2SO4 and the solvent was removed in vacuo. The residue was then
purified by flash column chromatography on silica gel (acetone:toluene (5:95))
to give the title compound as a yellow amorphous solid (0.217 g, 42%). Rf =
0.39 (EtOAc:hexanes (1:1)); 1H NMR (DMSO, 400 MHz) δ 11.70 (s, 1H),
7.77 (d, J = 8.8 Hz, 2H), 7.48 (d, J = 8.9 Hz, 2H), 6.92–6.83 (m, 2H),
6.77 (d, J = 8.0 Hz, 1H), 5.31 (s, 1H), 3.72 (s, 6H), 3.71 (s, 2H); 13C NMR
(DMSO, 100 MHz) δ 153.3, 152.2, 148.6, 147.2, 137.9, 132.1, 129.0, 128.8,
121.9, 120.5, 112.6, 111.9, 87.2, 55.5, 55.5, 34.5; IR (neat) cm−1: 2929, 1605,
1589, 1488, 1452, 1321, 1198, 1141, 1091, 1050, 825, 695; MS (ESI) calcd for
C18H18ClN2O3
+ [M+H]+ 345.1, found 345.1.
Pyrazolol 4.17b. β-keto ester 4.13b (0.100 g, 0.376 mmol) was dis-
solved in EtOH (2.0mL) and then 4-chlorophenylhydrazine hydrochloride 4.15
(0.067g, 0.37mmol) and Et3N (0.060mL, 0.43mmol) were added. The reaction
mixture was stirred at 60 ◦C for 2 days whereupon water was added (10mL).
The resulting mixture was extracted with EtOAc (3 × 10 mL) and the com-
bined organic phases were washed with water (2× 20mL) and brine (20mL),
dried over Na2SO4 and the solvent was removed in vacuo. The residue was
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then purified by flash column chromatography on silica gel (MeOH:CH2Cl2
(0.4:99.6)) to give the title compound as a yellow amorphous solid (0.050 g,
39%). Rf = 0.56 (MeOH:CH2Cl2 (2:98));
1H NMR (DMSO, 400 MHz) δ
11.71 (s, 1H), 7.77 (d, J = 8.9 Hz, 2H), 7.48 (d, J = 8.9 Hz, 2H), 6.46–
6.43 (m, 2H), 6.34 (s, 1H), 5.35 (s, 1H), 3.72 (s, 2H), 3.71 (s, 6H); 13C NMR
(DMSO, 101 MHz) δ 160.4, 153.2, 151.6, 141.9, 137.8, 129.1, 128.8, 121.9,
106.8, 97.8, 87.3, 55.1, 35.1; IR (neat) cm−1: 2932, 2834, 1588, 1492, 1316,
1291, 1200, 1155, 1139, 1066, 833; HRMS (ESI) calcd for C18H18ClN2O3
+
[M+H]+ 345.1006, found 345.1001.
Pyrazolol 4.17c. β-keto ester 4.13c (1.000g, 4.077mmol) was dissolved in
EtOH (20mL) and then 4-chlorophenylhydrazine hydrochloride 4.15 (0.723g,
4.08mmol) and Et3N (0.655mL, 4.70mmol) were added. The reaction mixture
was stirred at 60◦C for 18h 30min. whereupon water was added (70mL). The
resulting mixture was extracted with EtOAc (3 × 70 mL) and the combined
organic phases were washed with water (2 × 140 mL) and brine (140 mL),
dried over Na2SO4 and the solvent was removed in vacuo. The residue was
then purified by flash column chromatography on silica gel (MeOH:CH2Cl2
(0.5:99.5)) to give the title compound as a brown amorphous solid (0.333 g,
25%). Rf = 0.48 (MeOH:CH2Cl2 (2:98));
1H NMR (DMSO, 400MHz) δ 11.61
(s, 1H), 10.83 (s, 1H), 7.78 (d, J = 8.8 Hz, 2H), 7.53 (d, J = 7.9 Hz, 1H),
7.47 (s, 2H), 7.34 (d, J = 8.1 Hz, 1H), 7.20 (s, 1H), 7.06 (t, J = 7.4 Hz,
1H), 6.96 (t, J = 7.4 Hz, 1H), 5.29 (s, 1H), 3.90 (s, 2H); 13C NMR (DMSO,
101MHz)2 δ 153.1, 152.6, 138.0, 136.3, 128.8, 127.1, 123.1, 121.8, 120.9, 118.6,
118.3, 112.1, 111.4, 87.2, 25.0; IR (neat) cm−1: 3234, 3108, 3057, 1694, 1490,
1355, 1322, 1088, 827, 743; HRMS (ESI) calcd for C18H15ClN3O
+ [M+H]+
324.0898, found 324.0900.
4.6.4 Synthesis of tetrahydroindazolones
Tetrahydroindazolone 4.21. Pyrazolol 4.17b (0.201g, 0.583mmol) was dis-
solved in EtOH (12mL) and then benzaldehyde (0.059mL, 0.58mmol) and TM-
SOTf (0.845mL, 4.67mmol) were added. The reaction mixture was stirred at rt
for 12days whereupon the solvent was removed in vacuo. The residue was then
purified by flash column chromatography on silica gel (EtOAc:CH2Cl2:heptane
(1:1:2)) to give the title compound as a yellow amorphous solid (0.181g, 72%).
Rf = 0.38 (EtOAc:heptane (1:1)); 1H NMR (DMSO, 400 MHz) δ 7.80–7.74
(m, 2H), 7.50–7.44 (m, 2H), 7.20–7.12 (m, 4H), 7.09–7.03 (m, 1H), 6.60 (d,
J = 2.2Hz, 1H), 6.44 (d, J = 2.2Hz, 1H), 5.25 (s, 1H), 4.08 (d, J = 20.2Hz,
1H), 3.84 (d, J = 19.8 Hz, 1H), 3.77 (s, 3H), 3.71 (s, 1H), 3.68 (s, 3H);
13C NMR (DMSO, 101MHz) δ 160.4, 158.9, 157.7, 149.1, 145.5, 137.2, 135.4,
128.8, 128.5, 127.4, 125.6, 120.6, 119.5, 105.2, 97.1, 55.5, 55.2, 35.3, 35.0, 28.3;
IR (neat) cm−1: 2929, 2835, 1605, 1589, 1488, 1452, 1321, 1299, 1198, 1141,
2Signal from the carbon atom directly attached to chlorine could not be observed.
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1091, 825, 695; HRMS (ESI) calcd for C25H22ClN2O3
+ [M+H]+ 433.1313,
found 433.1315.
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Appendix A
RP-HPLC-UV
Chromatograms for
Solid-Phase Products
A.1 RP-HPLC-UV Chromatogram for Gly-DOX
2.32
Openlynx Report - Page 1 
Sample: 162 Vial:1:D,1 ID:
File:rm-6-70c-9 Date:27-Apr-2015 Time:20:50:19
Description:
Printed: Tue Jul 28 01:28:10 2015
Sample Report:
Sample 162  Vial 1:D,1 ID  File rm-6-70c-9 Date 27-Apr-2015 Time 20:50:19 Description 
Time
2.00 4.00 6.00 8.00 10.00 12.00
A
U
0.0
5.0e-1
1.0
1.5
1.605
Range: 1.628
 (1) 2998 Ch1 254nm@1.2nm (86)
87%
5.38
(88)
4%
5.62
(90)
4%
7.81
A
U
 Peak Number  Compound  Time  AreaAbs  Area %Total  Width  Height  Mass Found
 3  1.00  849  0.70  0  30688
 5  1.04  2996  2.49  0  28605
 86  5.38  104738  86.94  0  1585111
 87  5.55  1200  1.00  0  27322
 88  5.62  4347  3.61  0  68162
 89  6.27  1754  1.46  0  28721
 90  7.81  4585  3.81  0  62353
Time
2.00 4.00 6.00 8.00 10.00 12.00
A
U
0.0
1.0
2.0
2.626
Range: 2.635
 (1) 2998 Ch2 215nm@1.2nm 
(4)
1%
1.03
(11);1%;1.19
(82)
1%
2.64
(86)
2%
5.38
A
U
 Peak Number  Compound  Time  AreaAbs  Area %Total  Width  Height  Mass Found
 1  0.98  72399  1.67  0  2513197
 2  0.99  31889  0.73  0  2402788
 3  1.01  49698  1.14  0  2564782
 4  1.03  50647  1.17  0  2617335
 5  1.06  91018  2.10  0  2590530
 6  1.09  60950  1.40  0  2527052
 7  1.11  36276  0.84  0  2461738
 8  1.13  40353  0.93  0  2448307
 9  1.14  65059  1.50  0  2505033
 10  1.17  48737  1.12  0  2505235
 11  1.19  57825  1.33  0  2590981
 12  1.21  35604  0.82  0  2394343
 13  1.24  71613  1.65  0  2442376
 14  1.26  35505  0.82  0  2409754
 15  1.27  35348  0.81  0  2398969
 16  1.28  31491  0.73  0  2387196
 17  1.30  23619  0.54  0  2381395
 18  1.31  43875  1.01  0  2443466
 19  1.33  55297  1.27  0  2400200
 20  1.35  35166  0.81  0  2370028
 21  1.38  77030  1.77  0  2543429
 22  1.40  39785  0.92  0  2431861
 23  1.42  89834  2.07  0  2561341
 24  1.46  72264  1.66  0  2495015
 25  1.49  56085  1.29  0  2473134
 26  1.51  60854  1.40  0  2511054
 27  1.53  27928  0.64  0  2409669
A. RP-HPLC-UV Chromatogram for Leu-DOX
2.38a
Openlynx Report - Page 6 
Sample: 157 Vial:1:C,8 ID:
File:rm-6-69c-8 Date:26-Apr-2015 Time:22:03:07
Description:
Printed: Tue Jul 28 01:23:14 2015
Sample Report (continued):
Sample 157  Vial 1:C,8 ID  File rm-6-69c-8 Date 26-Apr-2015 Time 22:03:07 Description 
Time
2.00 4.00 6.00 8.00 10.00 12.00
A
U
0.0
5.0e-1
1.0
1.5
1.724
Range: 1.749
 (1) 2998 Ch1 254nm@1.2nm (90)
96%
5.65
(91)
4%
5.99
A
U
 Peak Number  Compound  Time  AreaAbs  Area %Total  Width  Height  Mass Found
 90  5.65  109 53  95.91   1707554
 91  5.99  46 9  4.09   909 4
Time
2.00 4.00 6.00 8.00 10.00 12.00
A
U
0.0
1.0
2.0
3.0
3.129
Range: 3.133
 (1) 2998 Ch2 215nm@1.2nm 
(4)
1%
1.07
(21);1%; .37
(67);1%;2.23
A
U
 Peak Number  Compound  Time  AreaAbs  Area %Total  Width  Height  Mass Found
 1  1.00  73448  1.69  0  2686771
 2  1.03  67316  1.54  0  2615405
 3  1.06  46071  1.06  0  3107491
 4  1.07  59532  1.37  0  3120915
 5  1.09  17867  0.41  0  2689883
 6  1.09  17853  0.41  0  2684399
 7  1.11  58772  1.35  0  2856292
 8  1.13  43122  0.99  0  2693403
 9  1.15  60555  1.39  0  2720145
 10  1.17  64408  1.48  0  2661629
 11  1.19  52066  1.19  0  2775224
 12  1.21  29094  0.67  0  2524267
 13  1.23  46526  1.07  0  2597923
 14  1.24  33204  0.76  0  2508848
 15  1.27  72155  1.66  0  2633527
 16  1.28  31372  0.72  0  2764995
 17  1.29  55071  1.26  0  2990699
 18  1.31  54686  1.25  0  2622663
 19  1.36  90385  2.07  0  2986547
 20  1.37  19727  0.45  0  2994330
 21  1.38  29395  0.67  0  2966323
 22  1.38  46977  1.08  0  2960337
 23  1.40  61506  1.41  0  2707612
 24  1.43  44523  1.02  0  2798377
 25  1.44  53977  1.24  0  2898863
 26  1.47  52117  1.20  0  2761666
 27  1.49  59516  1.37  0  2640679
 28  1.51  42944  0.99  0  2614994
 29  1.52  25346  0.58  0  2542446
 30  1.53  38714  0.89  0  2624297
 31  1.56  114695  2.63  0  2809504
 32  1.60  95979  2.20  0  2787553
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A.3 RP-HPLC-UV Chromatogram for Ala-DOX
2.38b
Openlynx Report - Page 1 
Sample: 155 Vial:1:C,6 ID:
File:rm-6-69a-8 Date:26-Apr-2015 Time:21:34:01
Description:
Printed: Tue Jul 28 01:23:14 2015
Sample Report:
Sample 155  Vial 1:C,6 ID  File rm-6-69a-8 Date 26-Apr-2015 Time 21:34:01 Description 
Time
2.00 4.00 6.00 8.00 10.00 12.00
A
U
0.0
5.0e-1
1.0
1.407
Range: 1.428
 (1) 2998 Ch1 254nm@1.2nm (106)
94%
5.75
A
U
 Peak Number  Compound  Time  AreaAbs  Area %Total  Width  Height  Mass Found
 2  0.98  774  0.72  0  28432
 3  1.01  1592  1.49  0  23669
 106  5.75  100118  93.64  0  1380107
 107  6.52  4436  4.15  0  24454
Time
2.00 4.00 6.00 8.00 10.00 12.00
A
U
0.0
1.0
2.0
2.976
Range: 2.977
 (1) 2998 Ch2 215nm@1.2nm 
(13);1%;1.24
(58)
1%
2.12
(71)
0%
2.77 (106)5%
5.75
(91)
1%
4.79AU
 Peak Number  Compound  Time  AreaAbs  Area %Total  Width  Height  Mass Found
 1  0.96  77386  1.13  0  2923410
 2  0.99  72730  1.07  0  2891524
 2  1.00  27217  0.40  0  2827401
 3  1.02  58295  0.85  0  2822099
 3  1.03  17191  0.25  0  2586665
 4  1.04  44390  0.65  0  2735719
 5  1.06  68168  1.00  0  2835048
 6  1.09  51683  0.76  0  2736052
 7  1.11  52475  0.77  0  2801135
 8  1.13  46230  0.68  0  2851720
 9  1.14  36543  0.54  0  2790384
 10  1.15  30501  0.45  0  2689851
 11  1.17  86605  1.27  0  2790901
 12  1.21  81029  1.19  0  2927746
 13  1.24  77771  1.14  0  2961567
 14  1.25  31198  0.46  0  2730004
 15  1.27  89682  1.31  0  2936687
 16  1.31  60909  0.89  0  2733075
 17  1.32  25559  0.37  0  2617536
 18  1.33  33633  0.49  0  2565854
 19  1.36  55410  0.81  0  2600671
 20  1.38  50170  0.74  0  2862947
 21  1.39  59358  0.87  0  2914894
 22  1.41  26493  0.39  0  2736432
 23  1.42  44061  0.65  0  2763439
 24  1.45  69778  1.02  0  2787909
 25  1.46  34253  0.50  0  2652706
 26  1.48  68284  1.00  0  2657527
 27  1.51  78126  1.14  0  2714018
 28  1.54  52266  0.77  0  2729039
A.4 RP-HPLC-UV Chromatogram for Phe-DOX
2. 8c
Openlynx Report - Page 4 
Sample: 156 Vial:1:C,7 ID:
File:rm-6-69b-8 Date:26-Apr-2015 Time:21:48:36
Description:
Printed: Tue Jul 28 01:23:14 2015
Sample Report (continued):
Sample 156  Vial 1:C,7 ID  File rm-6-69b-8 Date 26-Apr-2015 Time 21:48:36 Description 
Time
2.00 4.00 6.00 8.00 10.00 12.00
A
U
0.0
5.0e-1
1.0
1.321
Range: 1.344
 (1) 2998 Ch1 254nm@1.2nm (87)
93%
5.78
(88)
4%
6.04
A
U
 Peak Number  Compound  Time  AreaAbs  Area %Total  Width  Height  Mass Found
 4  1.03  2767  2.72  0  27652
 87  5.78  95182  93.45  0  1308413
 88  6.04  3909  3.84  0  58577
Time
2.00 4.00 6.00 8.00 10.00 12.00
A
U
0.0
1.0
2.0
2.941
Range: 2.951
 (1) 2998 Ch2 215nm@1.2nm 
(12);1%;1.19 (59);1%;2.12
(81)
1%
2.67
(87)
2%
5.78
A
U
 Peak Number  Compound  Time  AreaAbs  Area %Total  Width  Height  Mass Found
  0.98  6 901  1.53   7 0 3
  0.99  34626  .76   664240
  .01  29 5  .94   64 921
  .02  4 529  . 8   862130
  .04  67430  1.47   893640
  .07  34565  0.76   48195
  .08  44954  0.98   80 970
  .09  83 1  1.28   90685
 9  1.12  53588  1.17  0  2880209
 10  1.14  60925  1.33  0  2816476
 11  1.17  77974  1.70  0  2764056
 12  1.19  60065  1.31  0  2923059
 13  1.21  26253  0.57  0  2688325
 14  1.22  34900  0.76  0  2711950
 15  1.23  46426  1.01  0  2660699
 16  1.26  65683  1.44  0  2557731
 17  1.29  45533  1.00  0  2566040
 18  1.29  33497  0.73  0  2558032
 19  1.32  59604  1.30  0  2713409
 20  1.34  54786  1.20  0  2597033
 21  1.36  62477  1.37  0  2859349
 22  1.38  51400  1.12  0  2645733
 23  1.41  46158  1.01  0  2634320
 24  1.42  48500  1.06  0  2728411
 25  1.44  56316  1.23  0  2657533
 26  1.46  46310  1.01  0  2574510
 27  1.48  33844  0.74  0  2585341
 28  1.49  51146  1.12  0  2717695
 29  1.51  58274  1.27  0  2572863
 30  1.53  43172  0.94  0  2694070
 31  1.55  45669  1.00  0  2574048
A.5 RP-HPLC-UV Chromatogram for
Ala-Gly-Gly-DOX tripeptide 2.43
Openlynx Report - Page 3 
Sample: 163 Vial:1:E,12 ID:
File:rm-6-85c-10 Date:19-May-2015 Time:15:02:46
Description:
Printed: Tue Jul 28 01:28:10 2015
Sample Report (continued):
Sample 163  Vial 1:E,12 ID  File rm-6-85c-10 Date 19-May-2015 Time 15:02:46 Description 
Time
2. 0 4.00 6.00 8.00 10.00 12.00
A
U
0.0
2.5e-1
5.0e-1
7.5e-1
8.642e-1
Range: 8.842e-1
 (1) 2998 Ch1 254nm@1.2nm (107)
96%
5.71
A
U
 Peak Number  Compound  Time  AreaAbs  Area %Total  Width  Height  Mass Found
 2  .  6 7  .40   20 44
 107  5.71  44995  96.10   837472
 108  5.8  1168  2.49   21 80
Time
2.00 4.00 6.00 8.00 10.00 12.00
A
U
0.0
1.0
2.0
2.621
Range: 2.622
 (1) 2998 Ch2 215nm@1.2nm 
(29);1%;1.53
(70)
1%
2.69 (107)
5%
5.71
(88)
0%
4.85 (109)
0%
6.49
A
U
 Peak Number  Compound  Time  AreaAbs  Area %Total  Width  Height  Mass Found
 1  1.00  54482  0.92  0  2355223
 2  1.02  57889  0.97  0  2346477
 3  1.05  55895  0.94  0  2502659
 4  1.06  28215  0.47  0  2439226
 5  1.08  20103  0.34  0  2420239
 6  1.09  40740  0.69  0  2476486
 7  1.10  32084  0.54  0  2453470
 8  1.12  47140  0.79  0  2375997
 9  1.13  43090  0.73  0  2371429
 10  1.16  39918  0.67  0  2433003
 11  1.17  40607  0.68  0  2479466
 12  1.18  39808  0.67  0  2409463
 13  1.20  23718  0.40  0  2387414
 14  1.22  56489  0.95  0  2485840
 15  1.25  48378  0.81  0  2481973
 16  1.25  28091  0.47  0  2468476
 17  1.28  64461  1.09  0  2546375
 18  1.30  47179  0.79  0  2399887
 19  1.32  44333  0.75  0  2447014
 20  1.33  56690  0.95  0  2586915
 21  1.36  72326  1.22  0  2469558
 22  1.39  52736  0.89  0  2477137
 23  1.40  36009  0.61  0  2459546
 24  1.43  50921  0.86  0  2408676
 25  1.45  39299  0.66  0  2399206
 26  1.47  59745  1.01  0  2457278
 27  1.49  48877  0.82  0  2505333
 28  1.50  56691  0.95  0  2489512
 29  1.53  45106  0.76  0  2594418
 30  1.55  31772  0.53  0  2414821
 31  1.56  44272  0.75  0  2450832
A.6 RP-HPLC-UV Chromatogram for DOX
amide 2.51
Openlynx Report - Page 1 
Sample: 140 Vial:1:B,8 ID:
File:rm-3-66c-8 Date:23-Aug-2013 Time:15:18:05
Description:
Printed: Tue Jul 28 01:45:45 2015
Sample Report:
Sample 140  Vial 1:B,8 ID  File rm-3-66c-8 Date 23-Aug-2013 Time 15:18:05 Description 
Time
2.00 4.00 6.00 8.00 10.00 12.00
A
U
0.0
5.0e-1
9.667e-1
Range: 9.878e-1
 (1) 2998 Ch1 254nm@1.2nm (93)
64%
8.12
(78)
8%
5.51
(66)
7%
4.09
(67)
3%
4.39
(92)
5%
7.77
(108)
4%
9.67
(113)
2%
10.47
A
U
 Peak Number  Compound  Time  AreaAbs  Area %Total  Width  Height  Mass Found
 5  0.99  4774  5.57  0  34206
 66  4.09  5978  6.98  0  81678
 67  4.39  2900  3.39  0  49376
 78  5.51  6929  8.09  0  77013
 92  7.77  4608  5.38  0  67121
 93  8.12  54923  64.11  0  956406
 108  9.67  3731  4.36  0  77753
 113  10.47  1825  2.13  0  30441
Time
2.00 4.00 6.00 8.00 10.00 12.00
A
U
0.0
1.0
2.
2.733
Range: 2.769
 (1) 2998 Ch2 215nm@1.2nm 
(7)
1%
1.02
(8);1%;1.04
A
U
 Peak Number  Compound  Time  AreaAbs  Area %Total  Width  Height  Mass Found
 1  0.51  4231  0.07  0  73261
 2  0.76  8380  0.14  0  53541
 3  0.86  1622  0.03  0  33254
 4  0.97  115081  1.96  0  2705068
 5  0.99  63595  1.09  0  2750423
 6  1.01  40995  0.70  0  2750517
 7  1.02  54553  0.93  0  2759854
 8  1.04  58662  1.00  0  2735434
 9  1.06  49087  0.84  0  2704075
 10  1.08  26442  0.45  0  2646456
 11  1.09  43911  0.75  0  2648866
 12  1.11  30632  0.52  0  2631649
 13  1.12  48146  0.82  0  2636872
 14  1.14  43412  0.74  0  2624523
 15  1.15  34562  0.59  0  2599420
 16  1.17  51787  0.88  0  2600530
 17  1.19  77200  1.32  0  2595400
 18  1.23  47158  0.80  0  2590685
 19  1.24  73990  1.26  0  2630026
 20  1.29  101319  1.73  0  2666168
 21  1.31  89077  1.52  0  2696034
 22  1.34  44207  0.75  0  2661684
 23  1.36  57446  0.98  0  2661584
 24  1.38  48384  0.83  0  2647976
 25  1.39  52525  0.90  0  2636703
 26  1.41  43452  0.74  0  2614441
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A.7 RP-HPLC-UV Chromatogram for Ala-DOX
amide 2.52
Openlynx Report - Page 1 
Sample: 105 Vial:1:A,10 ID:
File:rm-2-83c-7-SpeedVac Date:17-Oct-2012 Time:10:37:34
Description:
Printed: Tue Jul 28 01:36:04 2015
Sample Report:
Sample 105  Vial 1:A,10 ID  File rm-2-83c-7-SpeedVac Date 17-Oct-2012 Time 10:37:34 Description 
Time
2.00 4.00 6.00 8.00 10.00 12.00
A
U
0.0
2.5e-1
5.0e-1
7.331e-1
Range: 7.588e-1
 (1) 2998 Ch1 254nm@1.2nm (22)
70%
7.80
(21)
6%
7.50
(20)
3%
4.14
(1)
5%
0.150.62
(24)
3%
8.33
A
U
 Peak Number  Compound  Time  AreaAbs  Area %Total  Width  Height  Mass Found
 1  0.15  3927  5.34  0  27154
 2  0.33  3087  4.20  0  25921
 3  0.47  1646  2.24  0  25411
 4  0.54  1211  1.65  0  25234
 5  0.63  2762  3.76  0  25026
 20  4.14  1860  2.53  0  41728
 21  7.50  4375  5.95  0  74857
 22  7.80  51609  70.20  0  723944
 23  8.16  1161  1.58  0  20381
 24  8.33  1881  2.56  0  24974
Time
2.00 4.00 6.00 8.00 10.00 12.00
A
U
0.0
5.0e-1
8.838e-1
Range: 9.339e-1
 (1) 2998 Ch2 215nm@1.2nm (22)
25%
7.80
(8)
10%
1.02 (19)
1%
3.93
(16)
1%
1.58
A
U
 Peak Number  Compound  Time  AreaAbs  Area %Total  Width  Height  Mass Found
 4  0.55  16008  7.38  0  86205
 6  0.75  21243  9.80  0  117684
 7  0.85  2080  0.96  0  78056
 8  1.02  22546  10.40  0  376468
 9  1.28  17898  8.26  0  71413
 10  1.40  515  0.24  0  61626
 11  1.41  716  0.33  0  61161
 12  1.46  3115  1.44  0  59397
 13  1.49  1668  0.77  0  58316
 14  1.51  1541  0.71  0  57264
 15  1.53  760  0.35  0  56648
 16  1.58  3047  1.41  0  54077
 17  1.86  24827  11.45  1  39655
 18  2.66  15190  7.01  1  33457
 19  3.93  2303  1.06  0  48478
 22  7.80  54436  25.11  0  776228
 24  8.33  1834  0.85  0  25829
A.8 RP-HPLC-UV Chromatogram for DOX
dipeptide 2.5
Openlynx Report - Page 1 
Sample: 107 Vial:1:A,12 ID:
File:rm-2-90c-7-SpeedVac Date:17-Oct-2012 Time:11:06:24
Description:
Printed: Tue Jul 28 01:37:35 2015
Sample Report:
Sample 107  Vial 1:A,12 ID  File rm-2-90c-7-SpeedVac Date 17-Oct-2012 Time 11:06:24 Description 
Time
2.00 4.00 6.00 8.00 10.00 12.00
A
U
0.0
2.0e-1
4.0e-1
4.842e-1
Range: 5.078e-1
 (1) 2998 Ch1 254nm@1.2nm (14)
48%
8.00
(12)
9%
7.68
(8)
7%
5.73
(15)
9%
8.20
(17)
11%
9.69
A
U
 Peak Number  Compound  Time  AreaAbs  Area %Total  Width  Height  Mass Found
 2  1.05  911  2.08  0  20127
 8  5.73  3150  7.17  0  69450
 9  7.12  1711  3.90  0  37777
 11  7.56  1779  4.05  0  40910
 12  7.68  4092  9.32  0  88743
 13  7.80  1461  3.33  0  25026
 14  8.00  20978  47.77  0  463059
 15  8.20  4097  9.33  0  97560
 16  8.40  893  2.03  0  21120
 17  9.69  4843  11.03  0  96951
Time
2.00 4.00 6.00 8.00 10.00 12.00
A
U
0.0
2.0e-1
4.0e-1
6.0e-1
6.814e-1
Range: 7.13e-1
 (1) 2998 Ch2 215nm@1.2nm (14)
24%
8.00
(2)
16%
1.03 (7)
3%
5.64
(6)
3%
1.88
(11)
2%
7.56
(9)
2%
7.12
(15)
5%
8.20
(17)
3%
9.69
A
U
 Peak Number  Compound  Time  AreaAbs  Area %Total  Width  Height  Mass Found
 1  0.76  10033  9.13  0  69121
 2  1.03  17158  15.61  0  332298
 3  1.31  8241  7.50  0  41340
 4  1.78  10485  9.54  0  26586
 5  1.88  2291  2.08  0  23488
 6  1.89  3026  2.75  0  23050
 7  5.64  3448  3.14  0  80535
 9  7.12  2584  2.35  0  50824
 10  7.21  1104  1.00  0  20791
 11  7.56  1941  1.77  0  45012
 12  7.68  1259  1.15  0  31088
 13  7.80  1483  1.35  0  25118
 14  8.00  26738  24.32  0  588847
 15  8.20  5030  4.58  0  114017
 16  8.40  999  0.91  0  23556
 17  9.69  3055  2.78  0  60905
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Abstract: An enantioselective total synthesis of trioxacarcin
DC-45-A2 (1) featuring a novel Lewis acid-induced cascade
rearrangement of epoxyketone 6 to forge the polyoxygenated
2,7-dioxabicyclo[2.2.1]heptane core of the molecule is de-
scribed.
Trioxacarcin DC-45-A2 (1, Figure 1)[1] is a naturally occur-
ring antitumor antibiotic that serves as a biosynthetic pre-
cursor to a variety of other biologically active members of the
family, including the highly potent DC-45-A1 (2), trioxacar-
cin A (3), and LL-D49194a1 (4) (Figure 1).[1] Possessing
a highly oxygenated and complex architecture, trioxacarcin
DC-45-A2 (1) presents an appealing synthetic challenge and
provides opportunities for method and strategy development,
chemical biology, and drug discovery efforts.[2] Recent
synthetic studies have culminated in a total synthesis of this
target molecule and a number of its congeners.[3] In this
Communication, we report an enantioselective and distinc-
tively different approach to the total synthesis of the parent
trioxacarcin DC-45-A2 (1) that could be applied to the
synthesis of all other members of the class and their designed
analogues.
The polyoxygenated 2,7-dioxabicyclo[2.2.1]heptane
system of the trioxacarcins is a most intriguing structural
motif requiring special attention with regard to strategy and
experimentation for its construction. Figure 2 presents our
designed strategy toward DC-45-A2 (1) in retrosynthetic
format. Thus, disconnection of the hemiacetal moiety of
1 followed by functional group transformations led to
advanced precursor 5, whose conversion to the target
molecule could be envisioned through sequential and selec-
tive deprotection/oxidations. Dismantling of the bicyclo-
[2.2.1]heptane system within 5 through an epoxyketone
rearrangement[4] revealed epoxyketone 6 as a precursor,
whose origin could be traced back to key building blocks 7–10
through the disconnections indicated in Figure 2 [that is,
a) Hauser–Kraus annulation; b) Stille reaction; c) asymmet-
ric Jørgensen epoxidation; and d) Baylis–Hillman reaction].
The key epoxyketone rearrangement (6!5, Figure 2) was
presumed to be inducible in a stereo- and regioselective
manner through the action of a suitable monodentate Lewis
acid that would involve inversion of configuration at C6, as
indicated in Figure 2 (see arrows on structure 6).
The required cyclohexenone 10 was prepared enantiose-
lectively from cyclohexadiene 11, as summarized in Scheme 1.
Thus, 11 was subjected to Upjohn dihydroxylation (OsO4 cat.,
NMO, 50% yield) and the resulting diol 12 was silylated to
afford bis-TBS ether 13 (TBSCl, 92% yield). Epoxidation of
the latter (mCPBA, 89% yield) led selectively to epoxide 14,
whose regioselective opening with ()-norephedrine-derived
amine 15 in the presence of nBuLi furnished allylic alcohol 16
in 94% yield and 89% ee.[5] Protection of this alcohol with 4-
methoxybenzyl-2,2,2-trichloroacetimidate (PMBTCA) fol-
lowed by TBAF-induced desilylation led to PMB-ether diol
17 in 84% yield. Selective oxidation of the allylic alcohol of
Figure 1. Molecular structures of trioxacarcins DC-45-A2 (1), DC-45-A1
(2), A (3), and LL-D49194a1 (4).
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the latter (TEMPO, pTSA, 74% yield)[6] furnished hydroxy-
enone 18, whose silylation (TBSCl, 99% yield) led to the
targeted key building block enone 10.
Enone 10 was coupled with the easily accessible iodocya-
nophthalide derivative 9 through a Hauser–Kraus annula-
tion,[7] and the product was elaborated to intermediate 21 as
shown in Scheme 2. Thus, iodocyanophthalide 9 [prepared
from the known cyanophthalide 19[8] by sequential iodination
(NIS) and MOM protection (MOMCl, DIPEA, 50% overall
yield)] was reacted with enone 10 in the presence of tBuOLi
(78 8C)[3,8] and the resulting p-dihydroquinone derivative
was selectively methylated with Me2SO4 to afford tricyclic
system 20 in 69% overall yield. Removal of the MOM group
from the latter intermediate with MgBr2·OEt2,
[9] followed by
treatment with tBu2Si(OTf)2 and 2,6-lutidine then gave
silylated product 21 in 85% overall yield.
Intermediate 21 was advanced to the key cyclization
precursor 6, as summarized in Scheme 3. Thus, Stille coupling
of aryl iodide 21 with stannane 8[10] proceeded in the presence
of CuTC and catalytic amounts of Pd(PPh3)4
[11] to afford
allylic alcohol 22 (74% yield), whose oxidation with TEMPO
and PIDA gave aldehyde 23 (89% yield). Jørgensen asym-
metric epoxidation of a,b-unsaturated aldehyde 23 (24 cat.,
urea·H2O2)
[12] led to epoxyaldehyde 25, which was subjected
without purification to Baylis–Hillman reaction with enone
7[13] (DABCO, 4-nitrophenol) to give labile hydroxyepoxide
26. The latter was immediately protected with N-trimethylsi-
lylimidazole (TMS-imid) to furnish the targeted precursor 6
(+C4-epi-6, d.r. ca. 3:1) in 36% yield over the three steps.
With the penultimate bis-cyclization precursor 6 in hand,
the stage was now set for the coveted cascade ring closures to
forge the targeted 2,7-dioxabicyclo[2.2.1]heptane system of
the growing molecule. To this end, and as shown in Scheme 4,
Figure 2. Retrosynthetic analysis of trioxacarcin DC-45-A2 (1). MOM=
methoxymethyl, PMB=para-methoxybenzyl, TBS= tert-butyldimethyl-
silyl, TMS= trimethylsilyl.
Scheme 1. Synthesis of key building block 10. Reagents and condi-
tions: a) OsO4 (4% w/v aq. solution, 0.02 equiv), NMO (1.0 equiv),
acetone, 25 8C, 72 h, 50%; b) TBSCl (2.4 equiv), imidazole (5.0 equiv),
CH2Cl2, 25 8C, 48 h, 92%; c) mCPBA (1.4 equiv), NaHCO3 (2.0 equiv),
cyclohexane, 25 8C, 17 h, 89%; d) 15 (2.0 equiv), nBuLi (2.0 equiv),
THF, 0!25 8C, 18 h, 94%, 89% ee ; e) PMBTCA (2.5 equiv), TrBF4
(0.05 equiv), THF, 25 8C, 1 h; then TBAF (7.0 equiv), THF, 66 8C, 4 h,
84%; f) TEMPO (3.0 equiv), pTSA (3.0 equiv), CH2Cl2, 0 8C, 45 min,
74%; g) TBSCl (1.8 equiv), imidazole (3.0 equiv), CH2Cl2, 25 8C, 1.5 h,
99%. mCPBA=meta-chloroperoxybenzoic acid, NMO=N-methylmor-
pholine-N-oxide, PMBTCA=para-methoxybenzyl-2,2,2-trichloroacetimi-
date, pTSA=para-toluenesulfonic acid, TBAF= tetra-n-butylammonium
fluoride, TEMPO=2,2,6,6-tetramethyl-1-piperidinyloxy, THF= tetrahy-
drofuran, TrBF4= trityltetrafluoroborate.
Scheme 2. Synthesis of key building block 21. Reagents and condi-
tions: a) NIS (1.4 equiv), DCE, 10 8C, 6 h; b) MOMCl (1.3 equiv),
DIPEA (3.0 equiv), CH2Cl2, 25 8C, 6 h, 50% over two steps; c) 9
(1.0 equiv), 10 (1.0 equiv), tBuOLi (3.0 equiv), THF, 78 8C, 0.5 h;
then Me2SO4 (10 equiv), 0 8C, 5 h, 69%; d) MgBr2·OEt2 (3.0 equiv),
THF, 0 8C, 15 min; e) tBu2Si(OTf)2 (1.2 equiv), 2,6-lutidine (2.5 equiv),
DMF, 0 8C, 0.5 h, 85% over two steps. DCE=1,2-dichloroethane,
DIPEA=N,N-diisopropylethylamine, DMF=N,N-dimethylformamide,
NIS=N-iodosuccinimide.
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epoxyketone 6 (ca. 3:1 mixture of C4-diastereoisomers) was
reacted with catalytic amounts of BF3·OEt2 (monodentate
Lewis acid) in CH2Cl2 at 78 8C, furnishing the desired
product as a mixture of C4-diastereoisomers (d.r. ca. 3:1) (5a,
C4-a-diastereoisomer, 54% yield; 5b, C4-b-diastereoisomer,
18% yield). The assignments of the C4 and C6 configurations
of diastereoisomers 5a and 5b were based on their H4, H5,
H6 coupling constants (5a :[14] J4,5= 4.8 Hz, J5,6= 3.0 Hz;
5b :[14] J4,5= 0 Hz, J5,6= 3.6 Hz).
[15] Both compounds were
obtained as single diastereoisomers at C6 (inverted config-
uration). The reaction is presumed to proceed through
transition states TS-6·B and TS’-6·B as shown in Scheme 4.
In contrast, reaction of substrate 6 with catalytic amounts of
bidentate Lewis acid SnCl4 in CH2Cl2 at 78 8C led to the
opposite diastereoisomers at C6 (J5,6= 0 Hz), 27 (+C4-epi-
27) (37% yield, d.r. ca. 13:1). This reaction is presumed to
proceed through transition states TS-6·Sn and TS’-6·Sn, the
latter being favored over its more sterically congested
alternative conformer TS’’-6·Sn that would have led to
inversion of configuration at C6 (see Scheme 4). These results
support our originally proposed monodentate Lewis acid-
catalyzed epoxyketone rearrangement upon which the strat-
egy for the construction of the dioxabicyclo[2.2.1]heptane
structural motif possessing the desired configurations was
based.
Having succeeded in building the most challenging
structural domain of the targeted molecule, we proceeded
to complete the remaining tasks of the synthesis that included
installation of the epoxide moiety, oxidation at C4, and
deprotection. Thus, advanced intermediate 5a (major diaste-
reoisomer) was converted to the targeted natural product (1)
as shown in Scheme 5. Selective cleavage of the TMS-ether of
5a gave allylic alcohol 28 (TFA, 65% yield) and recovered 5a
(24% yield). Due to difficulties in obtaining the desired
epoxide 29 from 28 through mCPBA or tBuOOH/VO(acac)2
epoxidations, we resorted to a three-step process involving
diastereoselective Upjohn dihydroxylation of the olefinic
bond within 28 (OsO4 cat., NMO) followed by selective
monotosylation of the resulting triol (TsCl, Et3N, DMAP cat.)
and epoxide formation (K2CO3, MeOH, 82% overall yield).
TPAP-catalyzed oxidation of hydroxyepoxide 29 led to
ketoepoxide 30 (93% yield), which could be sequentially
and selectively deprotected to afford trioxacarcin derivatives
31 (Et3N·3HF, 3.0 equiv, 15 min, 88% yield) and 32 (DDQ,
93% yield). Finally, trioxacarcin DC-45-A2 (1) was liberated
Scheme 3. Synthesis of bis-cyclization precursor epoxyketone 6.
Reagents and conditions: a) Pd(PPh3)4 (0.2 equiv), 8 (3.0 equiv), CuTC
(1.2 equiv), DMF/THF 1:1, 85 8C, 12 h, 74%; b) TEMPO (0.1 equiv),
PIDA (1.3 equiv), CH2Cl2, 25 8C, 4 h, 89%; c) 24 (0.2 equiv), urea·H2O2
(7.0 equiv), CHCl3/H2O 20:1, 25 8C, 7 h; d) 7 (10 equiv), DABCO
(0.5 equiv), 4-nitrophenol (0.5 equiv), THF, 25 8C, 12 h; e) TMS-imid
(1.0 equiv), CH2Cl2, 25 8C, 0.5 h, 36% over three steps, d.r. ca. 3:1 at
C4. CuTC= copper(I)-thiophene-2-carboxylate, DABCO=1,4-
diazabicyclo[2.2.2]octane, PIDA= iodobenzene diacetate, TMS-
imid=N-trimethylsilylimidazole.
Scheme 4. Bis-cyclization of precursor epoxyketone 6. Reagents and
conditions: a) SnCl4 (0.05 equiv), CH2Cl2, 78 8C, 1 h, d.r. ca. 13:1 at
C4, 37%; b) BF3·OEt2 (0.3 equiv), CH2Cl2, 78 8C, 3 h, 54% (5a), 18%
(5b).
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from its TBS-ether 32 by exposure to Et3N·3HF (excess, 13 h,
86% yield). Synthetic 1 exhibited identical physical proper-
ties (i.e., 1H and 13C NMR and mass spectra) to those
reported in the literature.[1e,3a]
The total synthesis described herein provides rapid access
to the parent trioxacarcin DC-45-A2 (1) and could be
deployed to reach all other members of the trioxacarcin
family of compounds. Furthermore, the developed synthetic
strategy and technologies could be applied to the construction
of designed analogues for structure activity relationship
studies and drug discovery efforts. Of particular interest is
the design and synthesis of potent trioxacarcins equipped with
handles that could be employed to attach them onto specific
antibodies to construct antibody drug conjugates (ADCs) for
targeted chemotherapy purposes. These objectives are cur-
rently being pursued.
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1 Introduction 
Originally developed by Merrifield for the synthesis of peptides [1], solid phase organic 
chemistry is an attractive synthetic technique that offers unique advantages over conventional 
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2 
solution phase chemistry, both in terms of purification and experimental simplicity. Since its 
introduction half a century ago, many laboratories have focused on the development of 
technologies and chemistry suitable for solid phase organic synthesis, which has resulted in a 
remarkable outburst of chemical transformations that can be applied for the routine synthesis of 
organic molecules on solid support [2, 3, 4, 5, 6]. This has led to the application of solid phase 
synthesis in the generation of combinatorial libraries both in academia and industry, ultimately 
leading to the identification of new drugs and catalysts [7, 8]. 
 The use of solid supports in organic synthesis relies on two interconnected requirements. 
One must be able to link the substrate to the solid phase while retaining the ability to selectively 
cleave off  some or all of the product from the solid support during synthesis for the analysis of 
reactions and ultimately to release the target molecule of interest. Furthermore, a strategy must 
exist for the chemical protection of reactive groups, allowing for selective protection and 
deprotection during synthesis. 
 In solid phase organic synthesis the desired molecule is bound through a linker inserted 
between the solid support and the molecule in question. Often harsh cleavage conditions such as 
strong acids/bases or nucleophiles, are needed, which can pose compatibility problems with acid- 
and base-labile compounds as well as commonly used protecting groups. Furthermore, the range 
of chemical transformations available for the synthesis of compounds is restricted by the 
cleavage conditions of the linker so premature cleavage is avoided. Thus, to provide a further 
dimension for the introduction of chemical diversity, linkers relying on other cleavage principles 
are needed. 
 Photolysis offers a method of cleavage, which is fully orthogonal to conventional 
chemical methods. Photolabile linkers are particularly interesting since they do not need acidic, 
basic or metal-assisted activation for cleavage. Indeed photochemical substrate release often 
occurs without additional reagents and under mild conditions that renders the process 
environmentally friendly and especially appealing in the context of green chemistry. The mild 
conditions are, furthermore, attractive for direct applications in biological screening where 
contamination with cleavage reagents is undesired. Additionally, recent advances in LED 
lighting have significantly increased the ease with which photochemical transformations can be 
achieved, a fact we suspect will lead to increased interest in photochemical substrate activation.  
Below follows an overview of the most commonly used photolabile linkers in solid phase 
organic synthesis. 
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2 Photolabile Linkers  
2.1 o-nitrobenzyloxy linkers 
The first account of a photolabile linker was the o-nitrobenzyloxy based linker pioneered by Rich 
and Gurwara in 1973 [9]. The resin was contructed with a Friedel-Crafts-type chloromthylation 
of the aromtaic rings of polymer 1, cf. scheme 1. A nitration, as described by Merrifield [1], set 
up the resin for attachment of the first amino acid at the C-terminus affording 3. After standard 
SPPS and photolysis the first peptide ever constructed on a photolabile linker was released in a 
yield of 62%. 
1. SnCl4,
    ClCH2OMe
2. HNO3
Cl
O2N
Boc-Gly-OH, Et3N O
O2N
Gly
SPPS
Boc
O
O2N
Boc-Ser(Bzl)-Tyr(Bzl)-Gly
hν (350 nm)
O
ON
1 2 3
4
5
6
62%
Boc-Ser(Bzl)-Tyr(Bzl)-Gly-OH
: polystyrene resin
EtOAc
MeOH
 
Scheme 1. Synthesis and use of the first photolabile linker based on the o-nitrobenzyloxy 
functional group. 
However, it eventually became clear to Rich and Gurwara that this strategy was not 
appropriate for the synthesis of peptides incorporating more than four amino acids [10]. Over-
nitration of the resin apparently caused reduced swelling of the resin in organic solvents due to 
enhanced polarity. Thus in attempt to find a solution to this limitation a new strategy was 
developed where the linker was prepared separately and then coupled to the resin [10], cf. 
scheme 2. The linker 8 was prepared and then coupled to the resin. The construct 9 was then set 
up for attachment of the first amino acid and following standard SPPS the decapeptide 11 was 
synthesized in 64% yield. 
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O
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,
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Scheme 2. Synthesis and use of o-nitrobenzyloxy linker prepared separately from resin. 
The linker has been used by Merrifield for the preparation of multi detachable resins [11, 12] and 
by Barany and co-workers to achieve three dimensional orthogonal protection in solid phase 
organic synthesis [13]. The construct 9 was used in the synthesis of photolabile construct 12, 
containing a t-butyl group and a dithiasuccinoyl group, both of which are photochemically inert 
and mutually orthogonal, cf. scheme 3. 
O
N
SS
OO
Gly
O
Gly Phe LeuO H
N
O
O2N
photolabile
acidlabile
thiollabile
: polystyrene resin
12
 
Scheme 3. Three-dimensional and orthogonal protection of a resin-bound peptide. 
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Different variations of the connection of the linker unit to the resin have been explored, e.g. 
adding a phenyl group in the benzyllic position [14, 15] or the use of a glycine unit as an internal 
standard [16]. 
 The o-nitrobenzyloxy linker has also been used by Pillai in experiments combining the 
advantages of both solid-phase and solution-phase synthesis by incorporating a PEG unit in 
between the photolabile linker unit and the solid support [17]. 
  In a study focusing on the synthesis of combinatorial ligand libraries with molecular 
libraries Ohlmeyer used the o-nitrobenzyloxy linker, which facilitated easy release of the 
synthesized ligands under conditions optimal for subsequent use in biological assays [18]. 
In 1993 Greenberg demonstrated the first application of o-nitrobenzyloxy linkers to 
oligonucleotide synthesis [19, 20, 21]. A DCC mediated coupling of succinatothymidine 13 to 
trichlorphenyl ester 14 followed by a coupling to the solid support (long chain alkyl amine 
controlled pore glass, LCAA-CPG) in the presence of HOBt led to the construct 15 which 
allowed for the synthesis of oligonucleotides, cf. scheme 4. 
H
N
O
O
O
O
H
N O
O
HN
O
O
ODMT
O2N
HO
O
O
H
N O
O
HN
O
O
ODMT
O
OH
O2N
O
Cl
Cl
Cl
1. DCC, CH2Cl2
2. HOBt⋅H2O,
    DMF
H2N
13 14
15
: LCAA-CPG  
Scheme 4. Oligonucleotide synthesis on a photolabile linker. 
Alcohol-containing groups can also be attached to a o-nitrobenzyloxy linker either 
through carbonates [22] or as ethers as shown by Merrifield [23] or as seen in the 
oligosaccharide synthesis by Zehavi and coworkers [24], cf. scheme 5. This linker was also used 
for solid-phase oligosaccharide synthesis by Nicolaou [25, 26] and Parquette [27]. 
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 Scheme 5. Oligosaccharide synthesis utilizing a photolabile o-nitrobenzyloxy linker. 
Amines can be attached through a carbamate function as shown by Armstrong in a 
Passerini reaction-based combinatorial library synthesis [28], cf. scheme 6. 
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Scheme 6. Photolabile o-nitrobenzyloxy linker attached to an amine through a carbamate 
function. 
 Damha hypothesized that incorporating a tertiary carbon center would accelerate the 
photolysis times and thus developed a linker incorporating this feature [29]. Starting from 26 the 
linker 28 was synthesized in two steps and subsequently attached to the solid support, cf. scheme 
7. With the construct 29 in hand Damha synthesized oligoribonucleotides and rewardingly found 
that that the target molecule could readily be cleaved from the linker in only 15 minutes at room 
temperature. 
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26
: LCAA-CPG
NO2
HO
pyridine
O
OtBu
FmocCl
27
NO2
FmocO
CH2Cl2
O
OtBu
TFA
28
NO2
FmocO
O
OH
29
NO2
FmocO
O
H
N
H2NHATU, DMAP,
DMF
 
Scheme 7. Photolabile o-nitrobenzyloxy linker incorporating a tertiary carbon center. 
2.2 o-nitrobenzylamino linkers 
To take into account the fact that many biologically active peptides possess a terminal primary 
amide, Rich and Gurwara developed a variation of the o-nitrobenzyl-based linker that upon 
photolysis releases an amide [30], cf. scheme 8. Starting from p-toluic acid, initial bromination 
followed by nitration led to 8. The bromide 8 was then aminated and immediately Boc-protected 
with Boc-azide furnishing 30. After attachment to the resin and deprotection Boc-Val-OH was 
coupled. Photolysis provided Boc-Val-NH2 (33) in quantitative yield. Furthermore it was shown 
that a decapeptide could be prepared and released in a yield of 65%. Other synthetic routes to 30 
was suggested by Barany starting from 4-aminomethylbenzoic acid [31]. Pillai and co-workers 
documented the possibility of releasing secondary amides by substituting the linker precursor 8 
(or the corresponding chloride) with a primary amine instead of ammonia [32, 33, 34]. An o-
nitrobenzylamino linker was used by Gerace and Auer in their on-bead screening of a one-bead 
one-compound library in the search for nuclear import inhibitors [35].  
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          benzene
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Scheme 8. Photolabile o-nitrobenzylamino linker releasing amides upon photolysis. 
Recently Seeberger developed an approach for the automated synthesis of 
glucosaminoglycans utilizing an o-nitrobenzylamino linker [36]. Iterative cycles of coupling of 
carbohydrate building blocks 35 and 36 to the linker construct 34 yielded, in 16 steps, the 
hexasaccharide 38 in 13% yield after photoclevage in a continuous flow photoreactor, cf. scheme 
9.  
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Scheme 9. Automated solid-phase synthesis of glucoseaminoglycans using an o-
nitrobenzylamino linker. 
The same linker was later used for the synthesis of a 30mer mannoside [37] and for the synthesis 
of β-(1,3)-glucans [38]. 
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2.3 α-substituted o-nitrobenzyl linkers 
The o-nitrobenzyl-based linkers presented so far have the disadvantage that the side product of 
their photolysis is an o-nitrosobenzaldehyde, a very reactive species that is prone to 
polymerization, generating a highly colored side product, which acts as an internal light filter. 
This has a detrimental effect on the photolytic cleavage of the desired compounds due to limited 
access of light to the reaction site [39]. 
 To solve this issue Pillai documented the preparation of resin 41, featuring a methyl 
group in the α-position [39], cf. scheme 10.  
1. AcCl, AlCl3,
    nitrobenzene
2. NaBH4,
    diglyme
OH 1. HBr (g),
    CH2Cl2
2. HNO3
Br
O2N
1 40 41
: polystyrene resin
O
O2N
Boc-Asp(OBn)-Val-Tyr(Bn)-Val-Glu(OBn) hν (320 nm)
44
40%
EtOH:CH2Cl2 (1:1)
43
Boc-Glu(OBn)-OH, DIPEA
EtOAc
O
O2N
Boc-Glu(OBn)
42
SPPS
Boc-Asp(OBn)-Val-Tyr(Bn)-Val-Glu(OBn)-OH
 
Scheme 10. Integral α-substituted nitrobenzyl-derived photolabile linker used for the synthesis 
of pentapeptide 44. 
The resin 1 was subjected to Friedel-Crafts acylation followed by reduction leading to the 
alcohol-functionalized resin 40, which after substitution and nitration was transformed into the 
bromide functionalized integral linker 41. This linker was used for the synthesis of pentapeptide 
44 in a yield of 40%. This resin however suffered from the same problems as seen with Rich and 
Gurwara’s original o-nitrobenzyloxy linker, cf. scheme 1, in that over-nitration degraded the 
swelling properties of the resin and prevented the synthesis of longer peptides. 
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 A solution to this issue is to introduce the support itself in the α-position instead of a 
methyl group [40], cf. scheme 11. The resin 1 underwent Friedel-Crafts acylation followed by 
reduction leading to o-nitrobenzhydryl resin 46. With this resin in hand Pillai synthesized both 
peptides 49 [40] and, after transformation to the amine-functionalized resin 47 [41], 
amidopeptides 48. Peptides with up to 10 amino acids were synthesized in good yields. 
ONO2 OHNO2
AlCl3
Cl
O
NO2, NaBH4
1. HBr
2. NH3
NH2NO2
peptide OH
1. SPPS
2. hν (350 nm),
    EtOH
1. SPPS
451 46
49
56–60%47
48
61–78%
peptide NH2
2. hν (350 nm),
    DMF:MeOH (1:1)
: polystyrene resin
1,2-DCE diglyme
 
Scheme 11. o-nitrobenzhydryl resin providing access to both peptides and amidopeptides. 
Another related linker is the 3-amino-3-(2-nitrophenyl)propionyl (ANP) linker 51 
developed by Geysen and used for the synthesis of amidopeptides [42], cf. scheme 12. A more 
acid stable variant was proposed by Schreiber with two methyl groups in the α position of the 
amide [43]. An alcohol-based variant of linker 51 was used for oligosaccharide synthesis by 
Geysen [44]. It also incorporated a longer spacer between the support and the photosensitive part 
to avoid problems with β-elimination and lactonization of the alcohol [44]. 
O
NO2
1. CH2(COOH)2,
    NH4OAc:AcOH
2. FmocOSu, Et3N
    MeCN:H2O (1:1)
NHFmocNO2
OHO
2. 20% piperidine (DMF)
H2N
NH2NO2
N
H
O
50 51 52
: TentaGel resin
1. PyBOP, DIPEA,
    NMP
1. SPPS
2. hν (365 nm),
    H2O
Fmoc-Asp-Arg(Ts)-Val-NH2
53
 
Scheme 12. Synthesis of photolabile ANP resin used for the synthesis of amidopeptide 53. 
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 An alternate route to similar linkers was designed by Harran allowing access to both 
hydroxyl- and amino-containing linker versions, 58 and 59, both from the ketone 54 [45], cf. 
scheme 13. 
O
NO2BF4
O
NO2
1. NaN3, H2SO4,
    toluene
2. (Boc)2O, DMAP,
    THF NO2
O O
NO2
m-CPBA, NaHPO4,
CH2Cl2
LiOH
NO2
R
HO
O
54 55 56
57 58: R = OH
59: R = NHBoc
CH3NO2
LiOH,
THF:H2O (2:1)
THF:H2O (1:1)
Boc
N O
 
Scheme 13. Synthesis of photolabile ANP type linker. 
2.4 o-nitroveratryl linkers 
Initially introduced by Patchornik as a photolabile linker in 1973 [46], use of the o-nitroveratryl 
group (4,5-dimethoxy-2-nitrobenzyl) in photolabile linkers was popularized in the mid-1990s by 
Greenberg [47] and Holmes [48]. 
Greenberg utilized this type of linker to circumvent some of the issues observed with the 
original unsubstituted o-nitrobenzyl linker, namely long photolysis times and low yields of 
liberation [47]. The synthesis of linker 62 commenced from vanillin (60) which after 
etherification and nitration provided the aldehyde 61, cf. scheme 14. After a few functional 
group interconversions the linker 62 was obtained [47]. 
MeO
O
OH
1. Br(CH2)3OH, K2CO3
    MeCN
2. HNO3, AcOH MeO
O
O OAc
NO2 1. K2CO3, MeOH2. TBDMSCl, Im, DMF
60 61
62
MeO
HO
O
NO2
TBDMSO
3. NaBH4, EtOH
 
Scheme 14. Synthesis of photolabile o-nitroveratryl-based linker. 
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The linker 62 was then bound to a LCAA-CPG support in a few steps leading to the 
construct 65 which was then used for the synthesis of oligonucleotides in good yields [47], cf. 
scheme 15. Later it was shown that a more efficient photolysis could be achieved by linking the 
hydroxyl group of the nucleotide directly to the linker via a carbonate functionality [49]. This 
modified linker, also prepared from vanillin, was later used for oligonucleotide synthesis by 
other groups [50]. 
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Scheme 15. Use of photolabile o-nitroveratryl-based linker for the synthesis of oligonucleotides. 
Nearly simultaneously, Holmes introduced an o-nitroveratryl-based amine linker with a 
methyl group in the α-position [48]. This linker, producing amides upon photolysis, also solved 
the problem with formation of a reactive nitroso aldehyde upon photolysis as described earlier. 
The synthesis of the linker started from acetovanillone (67) and was a 7 step sequence providing 
linker 72, which was then used for the synthesis of hexapeptide 74 in a yield of 70%, cf. scheme 
16.  
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Scheme 16. Synthesis of photolabile amine-containing α-methylated nitroveratryl linker and its 
use for the synthesis of a hexapeptide. 
In 1997, Holmes published a systematic study of the effect of nitroveratryl substituents 
on the photolysis efficiency [51]. It was shown that the rate of cleavage was 7 to 20 times higher 
when the o-nitrobenzyl ring was substituted with electron-donating alkoxy substituents. It was 
also shown that an alkyl group in the α-position to the amine increased the rate by a factor of 3. 
The length of the spacer chain also had an influence with a slightly increased rate for longer 
chains. It was concluded that both the alkoxy substituents on the aromatic ring and the alkyl 
group in the α-position were significantly beneficial for the photochemical reactivity. 
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Holmes also developed an alcohol-based version of the linker 72 [51], which was 
synthesized in a manner resembling that of the amine linker, cf. scheme 17.  
OH
MeO
O
75
Br(CH2)3COOMe,
K2CO3
DMF
O
MeO
O
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O
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HNO3, AcOH
O
MeO
O
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O
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NO2 1. NaBH4, THF
2. NaOH, MeOH
O
MeO
OH
OH
O
78
NO2
 
Scheme 17. Synthesis of photolabile alcohol-containing α-methylated nitroveratryl linker. 
Alternate synthetic pathways for the ester 77 were developed by Teague [52]. 
The linkers 72 and 78 have been used for numerous applications and it has also been 
shown that this linker type could be coupled to a hydroxy based resin without effect on the 
efficiency of the photolytic cleavage [53]. An o-nitroveratryl linker was used by McKeown to 
develop methods for easing the analysis of solid phase synthesis reactions by mass spectroscopic 
techniques [54]. Another example is the use of linker 72 by Madder for the preparation of serine 
protease mimics [55]. Blackwell likewise used this linker for the synthesis of a diketopiperazine 
library using the Ugi multicomponent reaction [56], cf. scheme 18. The linker 72 was attached to 
the solid support and subsequent coupling of Fmoc-Phe(4-NO2)-OH by standard methods led to 
the construct 80. Subjection to Ugi conditions and subsequent methanolysis and photochemical 
release afforded diketopiperazines 82 in moderate to good purities.  
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Scheme 18. o-nitroveratryl linker used in multicomponent reactions by Blackwell. 
The linker 72 was again used by Gennari for the synthesis of combinatorial libraries of 
vinylogous sulfonamidopeptides [57]. Furthermore this study confirmed the trends Holmes had 
encountered [51] namely that o-nitroveratryl-based linkers are superior to o-nitrobenzyl linkers 
due to the beneficial effects of alkoxy-substituents and the presence of an α-methyl group. 
Another example is the synthesis of 3,4-disubstituted β-lactams by Gallop [58], cf. 
scheme 19. The construct 83 was deprotected and condensed with an aldehyde producing imine 
84 which then underwent a [2+2] cycloaddition with a ketene providing 85. Final photolysis led 
to β-lactams 86 in good yields [58], cf. scheme 19. 
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Scheme 19. α-methylated nitroveratryl linker used in the synthesis of β-lactams. 
Meldal used an aldehyde linker, set up for reductive amination and closely related to 72, 
for the synthesis of a small library of arylpiperazine melanocortin subtype-4 agonists [59]. Thus, 
the linker 87 was synthesized and attached to the solid support cf. scheme 20. Construct 88 was 
then subjected to reductive amination and subsequent acylation of the formed amine afforded 90. 
Finally, two alkylation steps and photolytic cleavage provided arylpiperazines 93. 
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Scheme 20. Photolabile linker used for the synthesis of melanocortin subtype-4 agonists. 
Recently, a new azido-linker based on the o-nitroveratryl group was introduced by 
Qvortrup and Nielsen for the synthesis of 1,2,3-trizoles [60], cf. scheme 21.  
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Scheme 21. Photolabile nitroveratryl-based azido-linker used for the synthesis of 1,2,3-triazoles. 
The synthesis commenced from acetovanillone (75) and the alcohol 94 was synthesized in 
analogy to Holmes’ alcohol linker, cf. scheme 17. The alcohol 94 was then subjected to SOCl2 
and after substitution with NaN3 and final ester hydrolysis with LiOH the azido linker 96 was 
obtained. Attachment to the solid support and subsequent copper(I)-catalyzed azide–alkyne 
cycloaddition led to the construct 97, which after photoytic cleavage provided 1,2,3-triazoles in 
good yields. 
 Later they introduced a hydrazine linker [61]. Starting from chloride 95 the linker 100 
was synthesized in two steps and after attachment to the solid support, SPPS and photolytic 
cleavage provided peptide hydrazides in yields of 21–83%, cf. scheme 22. 
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Scheme 22. Photolabile nitroveratryl-based linker used for the synthesis of peptide hydrazides. 
The construct 101 could also be utilized for the solid-phase synthesis of dihydropyrano[2,3-
c]pyrazoles [61].  
Another recent example is the linker developed by Lee [62]. This linker has the tether to 
the solid support positioned in the α-position. Starting from veratraldehyde (103) the linker 108 
was synthesized in six steps, cf. scheme 23.  
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Scheme 23. Synthesis of Leu-enkephalin as an amide using photolabilie linker 108. 
After coupling to the solid support, standard SPPS and photolytic cleavage Leu-enkephaline 
(109) was liberated as an amide in a yield of 50%. 
2.5 Phenacyl linkers 
The Phenacyl group was introduced by Wang during the early exploration of photolabile linkers 
[63].  The resin 1 was subjected to Friedel-Crafts acylation and subsequently the first amino acid 
was coupled leading to the construct 111, cf. scheme 24. Then standard SPPS followed and upon 
final photolysis the peptide 113 was released in 70% yield.  
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Scheme 24. Synthesis of phenacyl photolabile handle and its use in peptide synthesis. 
A phenacyl linker was also used by Tam in multi detachable resins cleavable both under 
photolytic conditions and by base or nucleophiles [11, 12]. 
In 1982 Tjoeng developed a phenacyl linker system [64] which this time was a non-
integral linker that could be coupled to the resin instead of direct derivatization of the resin as 
described by Wang. Initial esterification of phenylacetic acid (114) and subsequent Friedel-
Crafts acylation led to the methyl ester 115 which upon simple ester hydrolysis led to the 
phenacyl linker 116, cf. scheme 25. With 116 in hand, coupling of the first amino acid followed 
by standard SPPS led to the peptide 120 in 78% yield after photolytic cleavage [64].  
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Scheme 25. Synthesis of phenacyl photolabile linker 116 and its use for the synthesis of 
thymopoietin II fragments. 
2.6 p-alkoxyphenacyl linkers 
Introduced by Mutter in 1985 [65], the p-alkoxyphenacyl linker is very similar to the phenacyl 
linker, but has an electron-releasing alkoxy substituent in the para-position making photolysis at 
350 nm much more efficient. The synthesis started from methyl phenoxyacetate (121) which 
after Friedel-Crafts acylation and ester hydrolysis provided the bromide 122, cf. scheme 26. 
Coupling to the resin followed by attachment of the first amino acid either in the presence of KF 
or as its cesium salt led to 124. Standard SPPS followed and final photolysis and deprotection led 
to the peptide 125 in 71% yield.  
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Scheme 26. Synthesis of p-alkoxyphenacyl photolabile linker and its use in peptide synthesis. 
Gauthier used the same linker for the synthesis of octapeptides in good yield (>85%) in 
his synthesis of mammalian glucagon [66]. 
 Belshaw developed a safety-catch photolabile linker based on the p-alkoxyphenacyl 
moiety [67]. The idea was to mask the photolability of the linker thus making the linker 
photostable and enabling the use of photolabile protecting groups in a light directed synthesis of 
oligonucleotides. The linker synthsis started from acetophenone 126, cf. scheme 27. A 
Mitsunobu reaction led to 127 which after acetal formation and methyl oxidation provided the 
alcohol 128. Protection with the photolabile NPPOC group followed by alcohol deprotection 
gave 129, which was then prepared for attachment to the solid support by treatment with 2-
cyanoethyl diisopropylchlorophosporamidite resulting in the linker 130. 130 was then attached to 
the solid support and iterative cycles of photolytic deprotection and coupling of nucleotides 
bearing a photolabile protecting group furnished construct 132. Mild acidic hydrolysis then 
activated the linker for photolytic cleavage and final photolysis provided the DNA chain 134. 
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Scheme 27. Synthesis and use of safety-catch photolabile linker for light directed synthesis and 
release of oligonucleotides (NNNx = DNA chain). 
Sucholeiki introduced a traceless thioether p-methoxyphenacyl linker for use in Stille 
cross-couplings [68, 69]. Methylation of 135 and subsequent Friedel-Crafts acylation and 
halogen exchange led to the chloride 138, cf. scheme 28. 
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Scheme 28. Synthesis and use of traceless thioether p-methoxyphenacyl linker in Stille 
couplings. 
Substitution and disulfide formation then furnished the linker 139 which after attachment to the 
solid support and disulfide cleavage was reacted with 4-iodobenzyl bromide providing the 
construct 141 set up for Stille coupling. Stille coupling and subsequent photolysis finally led to 
the biaryl 142 in a yield of 27% with a C-H bond at the former attachment point. 
2.7 Benzoin linkers 
The benzoin safety-catch linker was first developed by Chan for the purpose of binding two 
molecules together in solution [70]. It was later exploited for solid phase synthesis by 
Balasubramanian [71, 72]. The synthesis started from 3-hydroxybenzaldehyde (143) which was 
coupled to the resin and then reacted with 2-phenyl-1,3-dithiane to form a dithioacetal that acted 
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as a masked ketone and the safety-catch trigger upon hydrolysis, cf. scheme 29. Fmoc-β-Ala-OH 
was then coupled to the resin providing 146 which after hydrolysis of the dithioacetal and 
subsequent photolysis released the amino acid 148 in excellent yield. Good to excellent yields 
(75–97%) were obtained using this strategy with other carboxylic acids. 
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Scheme 29. Use of photolabile benzoin safety-catch linker in solid-phase synthesis. 
Later Balasubramanian developed a second generation benzoin linker, this time as a non-
integral linker system where the linker was prepared in solution and then coupled to the solid 
support [73]. The linker was prepared with a carboxylic acid as anchoring point to exploit the 
wide range of amine functionalized resins available and with a longer tether as this had been 
shown to be advantageous (cf. o-nitroveratryl linkers). The synthesis started from aldehyde 149 
and a six step sequence led to the linker 155, cf. scheme 30. 
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Scheme 30. Synthesis of photolabile benzoin linker with a carboxylic acid anchor. 
To address the sometimes tricky dithioacetal removal Copley developed a new benzoin linker in 
which the carbonyl group is protected as a dimethyl ketal instead [74]. The dimethyl ketal 
protection is stable towards common solid phase esterification and amide bond formation 
techniques and can be easily removed with 3% TFA in under five minutes. The synthesis of the 
linker started from 3-formylbenzoic acid (156) and a four step sequence provided the dithioacetal 
160, cf. scheme 31. Finally the dithioacetal functionality was replaced with a dimethyl ketal 
leading to the linker 161. Attachment to the solid support and subsequent standard SPPS 
followed by photolysis released the tetradecapeptide 162. 
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Scheme 31. Synthesis and use of photolabile dimethyl ketal benzoin linker for peptide synthesis. 
2.8 Pivaloyl linkers 
A new photolabile linker was developed by Giese based on the pivaloyl group [75]. The 
synthesis started from 1,3-dihydroxyacetone dimer (163) and a six step sequence gave the linker 
168 in an overall yield of 40%, cf. scheme 32.  The linker was then coupled to the solid support 
and after attachment of the first amino acid and then standard SPPS provided construct 171, 
which finally upon photolysis, released the peptide 172, in a yield of 86%. 
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Scheme 32. Synthesis and use of pivaloyl-based photolabile linker. 
The linker 168 also proved useful for the synthesis and release of compounds arising from Stille, 
Suzuki or epoxidation reactions [75]. Later a modified version able to release alcohols upon 
photolysis was proposed by Giese [76]. 
 Bochet exploitet the fact that the pivaloyl linker used in his synthesis of Leu-Enkephalin 
is stable at longer wavelengths thus enabling the use of photolabile protection groups with a 
different chromatic lability [77].  The synthesis started with the coupling of NVOC-Leu-OH to 
the linker resin 173 under standard conditions, cf. scheme 33. Then four cycles of photolytic 
deprotection (at 360 nm) and amino acid coupling furnished construct 175. Final deprotection 
and photolytic cleavage from the resin (at 305 nm) released Leu-enkephalin in a yield of 55%. 
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Scheme 33. Synthesis of Leu-Enkephalin utilizing both a photolabile linker and photolabile 
protection groups. 
2.9 Other photolabile linkers 
Routledge introduced a traceless photolabile linker based on thiohydroxamic acid [78]. Starting 
with the attachment of trityl protected 4-hydroxymercaptophenol 177 to the solid support, the 
linker construct 181 was prepared in four steps, cf. scheme 34.  
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Scheme 34. Synthesis and use of traceless photolabile linker. 
Then N-methylindole-3-acetic acid was attached and photolysis yielded 1,3-dimethylindole 183 
in a yield of 55% with a C-H bond at the former attachment point to the solid support. This 
method does however haw a drawback in form of the need of a hydrogen donor, in this case a 
toxic tin species, to facilitate the release from the solid support whereas photolysis in other cases 
normally can be achieved under mild and neutral conditions. 
 Nicolaou introduced a photolabile linker exploiting the photochemical properties of the 
5-bromo-7-nitroindoline group [79]. Photolytic release in the presence of amines provided 
amides and intramolecular trapping of an amine was also possible with this linker leading to 
heterocycles. The synthesis started from the indole 184, cf. scheme 35. 
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Scheme 35. Photolabile linker for the synthesis of heterocycles. 
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Reduction, acylation and methylation led to the methyl ester 186. Nitration followed by ester 
hydrolysis and amide formation provided the amide 189, which after photolytic removal of the 
acetyl group and ester hydrolysis furnished the linker 191. Attachment to the solid support and 
further synthetic elaboration led to the costruct 194, which upon photolytic cyclorelease provided 
the heterocycle 195 in a yield of 50%. 
 A triazene-based photolabile linker was developed by Enders [80]. 3-hydroxyaniline 
(196) was attached to Merrifiled resin and diazotation and reaction with a secondary amine (in 
this case piperazine) led to the triazene construct 199, cf. scheme 36.  
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Scheme 36. Synthesis and use of triazene-based photolabile linker developed by Enders. 
Acylation and photolytic release provided the tertiary amide 201. Generally moderate yields and 
excellent purities were achieved. 
3 Conclusions 
Since the first photolabile linker was published more than 40 years ago a wide range of 
photolabile linkers have been developed providing an extensive toolkit for the synthesis of 
peptides, oligosaccharides, oligonucleotides and small molecules. Photolabile linkers provide an 
orthogonal method of cleavage compared to traditional linkers and even systems utilising groups 
with different chromatic lability thus enabling the simultaneous use of both photolabile 
protection groups and photolabile linkers that are completely orthogonal to each other have been 
developed. Furthermore photolabile linkers can commonly be cleaved under very mild 
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conditions a fact that among others have made them attractive for and widely used in chemical 
biology [81]. 
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